CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 1 of 100  PROTOCOL 
Protocol Amendment 4.0  
 
TITLE PAGE  
Study Title:  A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study 
to Evaluate the Safety and Efficacy of Avacopan ( CCX168) in 
Patients with C3 Glomerulopathy  
Protocol Number:  CL011_168 
Investigational P roduct:  Avacopan  (formerly CCX168) 
Indication:  Treatment of patients with C3 glomerulopathy 
Sponsor:  ChemoCentryx, Inc.  
Development Phase:  [ADDRESS_1095024] number  2017-001821-42 
Sponsor's Responsible 
Medical Officer:  Chemo Centryx, Inc.  
Mountain View, [LOCATION_004] [ZIP_CODE], [LOCATION_003] 
Sponsor Signatory: 
Approval Date: 29 June 2017 
13 September  2017 – Protocol Amendment 1.0 
16 April 2018 – Protocol Amendment 2.0  
10 September 2018 – Protocol Amendment 3.0 
20 March  2019 – Protocol Amendment 4.0  
 
Confidential  
The information contained herein is the property of the Sponsor and may not be reproduced, 
published, or disclosed to others without written authorization of the Sponsor. 
This study will be conducted according to the principles of Good Clinical Practice as described 
in International Conference on Harmonisation guidelines, including the archiving of essential documents. 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 2 of 100  INVESTIGATOR SIGNATORY PAGE  
Protocol Number:  CL0 11_168 
Protocol Title:  A Randomized, Double-Blind, P lacebo -Controlled Phase 2 Study to Evaluate the 
Safety and Efficacy of Avacopan ( CCX168) in Patients with C3 Glomerulopathy  
I agree:  
• To assume responsibility for the proper conduct of the study at this site. 
• To conduct the study in compliance with this pro tocol, any future amendments, and with any 
other study conduct procedures provided by [CONTACT_596792], Inc. 
• Not to implement any deviations from or changes to the protocol without agreement from the 
Sponsor and prior review and written approval from the Institutional Review Board 
(IRB)/Ethics Committee (EC), except where necessary to eliminate an immediate hazard  to 
the patients, or for administrative aspects of the study (where permitted by [CONTACT_87465]). 
• That I am thoroughly familia r with the appropriate use of the investigational drug(s), as 
described in this protocol, and any other information provided by [CONTACT_150222], but not limited to the following: the current version of the Investigator’s Brochure prepared by [CONTACT_794124], Inc. and approved product label, if applicable. 
• That I am aware of and will comply with current International Conference on Harmonisation 
ICH/  Food and Drug Administration  (FDA ) good clinical practices guidelines (GCP) and all 
regulatory requirements. 
• To ensure that all persons assisting me with the study are adequately informed about the investigational drug(s) and their study -related duties and function as described in the 
protocol. 
__________________________________     ___________________ 
Principa l Investigator            Date  
 __________________________________ Printed Name  
[CONTACT_2761]*_____________________________________________________________ 
____________________________________________________________________ 
Phone Number* ___________________________________________ 
* If the address or phone number needs to be changed during the course of the study, this will be 
done by [CONTACT_737], with written notification to the Sponsor, and will not require (a) protocol amendment(s). 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095025] INFORMATION 
Protocol Number:  CL0 11_168 
Protocol Title:  A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the 
Safety and Efficacy of Avacopan ( CCX168) in Patients with C3 Glomerulopathy  
 
Medical Officer  
Vice President , Clin ical Development and Translational Medicine  
ChemoCentryx, Inc.  
[ADDRESS_1095026] 
Mountain View, CA [ZIP_CODE] [LOCATION_003] 
Tel:Fax: +
Email:
 
Cl
inical Operations Manager  
Director of Clinical Op era tions, 
Che
moCentryx, Inc.  
[ADDRESS_1095027] 
Mountain View, CA [ZIP_CODE] [LOCATION_003] 
Mobile telephone number:Fax number: 
Email:
 
  
CCX168 (avacopan)   Protocol CL011_168 
  Amendment 4.0 
 ChemoCentryx, Inc.  CONFIDENTIAL  Page 5 of 100 SUMMARY OF CHANGES: PROTOCOL AMENDMENT [ADDRESS_1095028](s) to patient(s) throughout the document for consistency. 
3. Protocol updated to specify that the study drug or study medication is blinded throughout 
the document, where applicable.  
4. Details on the  study drug or medication updated to be avacopan or placebo throughout 
the document. 
5. SYNOPSIS: study period increased from [ADDRESS_1095029] previous increase of sample size and slower than expected enrollment.  
6. SYNOPSIS – Methodology , Section 3.[ADDRESS_1095030] timepoint for the primary efficacy analysis and to clarify that the primary analysis of the primary population (elevated C5b -9 stratum) 
can occur at a timepoint independent of the secondary population. 
7. SYNOPSIS – Methodology has been updated:  
a. To increase the frequency of hematology testing based on the recommendation of the DMC . 
b. To clarify the time allowed to differentiate between common fluctuations of renal function and true deterioration of renal function and to prevent unnecessary discontinuation. 
8. SYNOPSIS – Test Product has been updated to clarify that the medication will be administered orally and that placebo contain s no active ingredient. 
9. Hematology testing was added to study weeks 23, 35, [ADDRESS_1095031] been updated: Time & Events Table , Section 6.10. Study Week 23, Section 6.14. Study Week 
35, 6.16. Study Week 41 and Section 6.18. Study Week 48. 
10. Study Schema simplified  for better overview and to present duration of individual 
treatments  and to eliminate redundancies (Visit days, Study procedures) and to align with  
the Time and Events Table.  
11. LIST OF ABBREVIATIONS AND ACRONYMS has been updated to include missing acronyms . 
12. Section 1.2 Previous Clinical Studies has been updated to include current status of clinical studies and additional details on the review of safety data. 
13. Section 3.3.2. Adolescent Patients – Study Treatments , added a statement to clarify the 
procedure to keep study team blinded. 
14. Section 3.4 Study Flow has been updated: 
a. To increase the frequency of hematology testing based on the recommendation of the 
DMC.  
CCX168 (avacopan)   Protocol CL011_168 
  Amendment 4.0 
 ChemoCentryx, Inc.  CONFIDENTIAL  Page 6 of 100 b. To make statement more concise and reduce redundancies within the protocol; the 
reader is directed to “Section 4.4 Removal of Patients from Therapy” where important lab observations are presented that would cause pausing or discontinuation of study drug (avacopan or placebo). 
15. Section 4.[ADDRESS_1095032] been updated: 
a. To ensure that li ver function tests are repeated in a timely manner, that study drug 
(avacopan or placebo) dosing is paused during investigation into the causality of 
abnormal liver tests and to permanently discontinue study drug when applicable. 
b. To ensure that study drug (avacopan or placebo) dosing is paused during investigation into the causality of abnormal hematology and serum chemistry tests.  
c. To relocate paragraph from Section 3.4 to Section 4.4 to ensure that study drug (avacopan or placebo) dosing is permanently dis continued if a patient experiences 
deteriorating renal function; for clarification of time allowed to differentiate between common fluctuations of renal function and true deterioration of renal function, and to prevent unnecessary discontinuation. 
d. To reloc ate text for laboratory abnormalities from [IP_ADDRESS]. Laboratory Abnormalities  
and consolidate in “Section 4.4 Removal of Patients from Therapy” 
16. Section 5.6 Blinding has been updated to clarify that the actual value, if within normal range, will be blinded and reported as “normal” but that values outside the normal range will be made available for safety monitoring.  
17. Section 5.9 Concomitant Medications and Restrictions has been updated relocate text to “Section 4.4 Removal of Patients from Therapy” where its presentation is more appropriate. 
18. Section 7.2.1. Physical Examinations, Vital Signs and 12- lead ECGs has been updated to 
clarify that only clinically significant changes will be recorded as Adverse Events.  
19. Section 7.2.2 Clinical Safety Laboratory Assessments has been updated: 
a. To clarify that safety laboratory assessments are performed through a central 
laboratory for safety monitoring of lab thresholds. 
b. To specify the components of the bilirubin test 
c. To add coagulation test in the case of elevated ALT and A SN 
20. Section [IP_ADDRESS]. Laboratory Abnormalities has been update to make statement more 
concise and reduce redundancies within the protocol. The reader is directed to Section 4.4 Removal of Patients from Therapy where important lab observations are presented t hat 
would cause pausing or discontinuation of study drug. 
21. Section 12.3.2 Clinical Evaluation has been updated to include current clinical status, clarify patient safety information and to include the clinical safety information based on DMC review of safet y data from all completed and ongoing studies of avacopan. 
 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095033] INFORMATION  .......................................................................................3  
SPONSOR SIGNATURE [CONTACT_794187]  .................................................................................4  
SUMMARY OF CHANGES: PROTOCOL AMENDMENT [ADDRESS_1095034] OF ABBREVIAT IONS AND ACRONYMS  ......................................................................30  
1. INTRODUCTION  ......................................................................................................33  
1.1. Complement and Avacopan ........................................................................................33  
1.2. Previous Clinical Studies  ............................................................................................34  
1.3. Rationale for the Study ...............................................................................................36  
2. OBJECTIVES  .............................................................................................................37  
2.1. Primary Objective  .......................................................................................................37  
2.2. Secondary Objectives  .................................................................................................37  
2.3. Exploratory Objectives ...............................................................................................38  
3. STUDY DESIGN  .......................................................................................................38  
3.1. Stratification  ...............................................................................................................38  
3.2. Randomization ............................................................................................................39  
3.3. Study Treatments  ........................................................................................................39  
3.3.1.  Adult Patients - Study Treatments  ..............................................................................39  
3.3.2.  Adolescent Patients - Study Treatments  .....................................................................40  
3.4. Study Flow  ..................................................................................................................41  
4. STUDY POPULATION  .............................................................................................43  
4.1. Size of the Population .................................................................................................43  
4.2. Inclusion Criteria  ........................................................................................................43  
4.3. Exclusion Criteria  .......................................................................................................44  
4.4. Removal of Patients from Therapy  .............................................................................45  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
 ChemoCentryx, Inc.  CONFIDENTIAL  Page 8 of 100  5. STUDY MEDICATION/TREATMENT  ...................................................................[ADDRESS_1095035] Characteristics  ...............................................................................................47  
5.2. Randomization and Method of Treatment Assignment  ..............................................47  
5.3. Doses and Regimens ...................................................................................................47  
5.4. Rationale for Dose Selection  ......................................................................................48  
5.5. Drug Supply ................................................................................................................49  
5.5.1.  Packaging and Labeling  ..............................................................................................49  
5.5.2.  Storage  ........................................................................................................................49  
5.6. Blinding ......................................................................................................................49  
5.7. Drug Accountability ...................................................................................................50  
5.8. Treatment Compliance  ................................................................................................50  
5.9. Concomitant Medications and Restrictions ................................................................50  
6. STUDY PROCEDURES  ............................................................................................51  
6.1. Screening and Enrollment  ...........................................................................................51  
6.2. Study Day 1  ................................................................................................................52  
6.3. Study Week 1 (Day 8) ................................................................................................53  
6.4. Study Week 2 (Day 15) ..............................................................................................54  
6.5. Study Week 4 (Day 29) ..............................................................................................55  
6.6. Study Week 8 (Day 57) ..............................................................................................56  
6.7. Study Week 12 (Day 85) ............................................................................................57  
6.8. Study Week 16 (Day 113) ..........................................................................................57  
6.9. Study Week 20 (Day 141) ..........................................................................................58  
6.10.  Study Week 23 (Day 162) ..........................................................................................59  
6.11.  Study Week 26 (Day 183) ..........................................................................................60  
6.12.  Study Week 28 (Day 197) ..........................................................................................61  
6.13.  Study Week 32 (Day 225) ..........................................................................................62  
6.14.  Study Week 35 (Day 246) ..........................................................................................62  
6.15.  Study Week 38 (Day 267) ..........................................................................................63  
6.16.  Study Week 41 (Day 288) ..........................................................................................64  
6.17.  Study Week 44 (Day 309) ..........................................................................................64  
6.18.  Study Week 48 (Day 337) ..........................................................................................65  
6.19.  Study Week 52 (Day 365) ..........................................................................................65  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
 ChemoCentryx, Inc.  CONFIDENTIAL  Page 9 of 100  6.20.  Study Week 54 (Day 379) ..........................................................................................66  
6.21.  Study Week 57 (Day 400) ..........................................................................................67  
6.22.  Study Week 60 (Day 421) ..........................................................................................67  
6.23.  Early Termination Visit ..............................................................................................68  
7. STUDY ASSESSMENTS  ..........................................................................................69  
7.1. Efficacy Assessments  .................................................................................................69  
7.1.1.  Renal Histology  ..........................................................................................................69  
7.1.2.  Urinary Measurements  ................................................................................................70  
7.1.3.  Estimated Glomerular Filtration Rate  .........................................................................71  
7.1.4.  Health -Related Quality of Life Assessments  ..............................................................72  
7.2. Safety Assessments  .....................................................................................................72  
7.2.1.  Physical Examinations, Vital Signs and 12 -lead ECGs ..............................................72  
7.2.2.  Clinical Safety Laboratory Assessments  ....................................................................72  
7.2.3.  Complement Panel  ......................................................................................................73  
7.2.4.  Adverse Events  ...........................................................................................................73  
[IP_ADDRESS].  Adverse Event Severity Assessment  ..........................................................................74  
[IP_ADDRESS].  Causality Assessment  .................................................................................................74  
[IP_ADDRESS].  Serious Adverse Events ..............................................................................................74  
[IP_ADDRESS].  Infections  ....................................................................................................................75  
[IP_ADDRESS].  SARs and S[LOCATION_003]Rs  .....................................................................................................75  
[IP_ADDRESS].  Laboratory Abnormalities  ...........................................................................................76  
[IP_ADDRESS].  Pregnancies  .................................................................................................................76  
7.2.5.  Special Situation Reporting ........................................................................................76  
7.2.6.  Serious Adverse Event Reporting ...............................................................................77  
7.3. Pharmacokinetic Assessments  ....................................................................................78  
7.4. Pharmacodynamic Assessments .................................................................................78  
7.5. Study Completion and Withdrawal ............................................................................79  
7.6. Data Monitoring Committee  .......................................................................................79  
8. STATISTICAL METHODS  .......................................................................................79  
8.1. Patient Populations .....................................................................................................80  
8.1.1.  Intent-to-Treat Population ..........................................................................................80  
8.1.2.  Per Protocol Population ..............................................................................................80  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095036] or Ethics Committee  .......................................................88  
10.3.  Informed Consent/Assent ...........................................................................................88  
10.4.  Protocol Modifications ...............................................................................................88  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095037] Retention  ........................................................................................................89  
10.8.  Case Report Form Completion  ...................................................................................90  
10.9.  Monitoring ..................................................................................................................90  
10.10.  On-site Visits and Audits  ............................................................................................90  
10.11.  Study Registration, Use of Information and Publication ............................................90  
11. REFERENCES  ...........................................................................................................92  
12. APPENDICES  ............................................................................................................93  
12.1.  Statement of Obligations of Sponsor, Monitor, and Clinical Investigator .................93  
12.2.  Informed Consent/Assent Form ..................................................................................[ADDRESS_1095038] OF TABLES  
Table 1:  Dosing Groups in the First and Last 26 Weeks of Treatment in Adults .....................40  
Table 2:  Avacopan/Placebo Starting Dose and Dose Adjustments Based on Avacopan 
Plasma Exposure in Adolescent Patients  ....................................................................41  
Table 3:  CKD-EPI [INVESTIGATOR_794094] .........................................................71  
 
 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
 ChemoCentryx, Inc.  CONFIDENTIAL  Page 12 of 100  PROTOCOL SYNOPSIS  
Name [CONTACT_794188], Inc.  Name [CONTACT_596848] ( CCX168)  Study number:  
CL011_168 
Title  
A Randomized, Double-Blind, Placebo- Controlled Phase 2 Study to Evaluate the Safety and 
Efficacy of Avacopan ( CCX168) in Patients with C3 Glomerulopathy  
Investigators Several  
Study centers  
Multi- center  
Study period  
32 months (first patient enrolled 
to last patient last study visit)  Phase of development  
Phase [ADDRESS_1095039] of avacopan  treatment on renal disease activity in 
patients with complement component 3 glomerulopathy  (C3G). 
Objectives  
The primary objective is to evaluate the efficacy of avacopan compared to placebo based on 
histologic changes in kidney biopsies taken before and during treatment. 
The secondary objectives of this study include evaluation of: 
1. The safety of avacopan compared to placebo based on the incidence of adverse events, 
chang es in clinical laboratory measurements and changes in vital signs;  
2. Changes in laboratory parameters of renal disease including estimated glomerular filtration rate (eGFR) , proteinuria, and urinary excretion of monocyte che moattractant 
protein- 1 (MCP -1) wit h avacopan compared to placebo; 
3. Health -related quality -of-life changes based on Short Form-36 version 2 (SF-36 v2) and 
EuroQOL-5D- 5L (EQ -5D-5L) with avacopan compared to placebo ; 
4. The pharmacokinetic profile of avacopan  in patien ts with C3G. 
Additionally, c hanges from baseline in markers of alternative complement pathway 
involvement and other markers of inflammation may be assessed in plasma/serum or urine over 
the course of the treatment period. 
Rationale 
C3G is characterized by [CONTACT_794125] C3 deposition 
in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, formerly 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
 ChemoCentryx, Inc.  CONFIDENTIAL  Page 13 of 100  called membranoproliferative glomerulonephritis [MPGN] Type II) and C3 glomerulonephritis 
(C3GN, formerly called idiopathic MPGN). Genetic mutations leading to defective complement 
regulation, including reduced -function mutations of complement factor H (CFH) , have been 
described in some of these patients. Patients with C3 G often have progressive deterioration in 
renal function , ultimately leading to end -stage renal disease. 
There is no approved treatment for patients with C3G. Immunosuppressive drugs such as 
cyclophosphamide, mycophenolate mofetil, and glucocorticoids, as well as biologics such as rituximab have been used with limited success. The anti -C5 antibody eculizumab previously 
showed evidence of improvement in some patients with C3G. Eculizumab blocks the formation of C5a and C5b- 9 (membrane attack complex) from C5. Evidence from animal models suggests 
that inhibition o f C5a may  be more important than inhibition of C5b-9 in C3G, because deletion 
of C6 (which is part of the C5b-9 complex) in CFH knockout mice failed to protect the mice from developi[INVESTIGATOR_424785] C3G ( Pi[INVESTIGATOR_116281] ., 2006). This provides support for tes ting 
drugs that target C5aR, such as avacopan. 
Avacopan is an orally administered, selective inhibitor of the complement 5a receptor (C5aR) 
which is in Phase 3 clinical development for treatment of patients with anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis (AAV). Phase 2 study data with avacopan  
in patients with AAV indicate efficacy with 30 mg avacopan given twice daily based on improvement in disease activity  (Birmingham Vasculitis Activity Score) , a significant anti-
proteinuric effect, and improvement in quality of life among other improved disease parameters 
(Jayne et al ., 2017) . This treatment effect was observed in patients  receiving avacopan  plus 
cyclophosphamide or rituximab, but with out oral glucocorticoids. 
One patient with treatment refractory C3GN , one of the subtypes of C3G, has been treated 
successfully with [ADDRESS_1095040] to F ollow up in 
December 2016 under a “Special Needs” program in the [LOCATION_006]. This patient had progressive 
decline i n renal function despi[INVESTIGATOR_794095], rituximab, and 
glucocorticoids, as well as a kidney transplant. 
Kidney histology prior to treatment with avacopan showed endocapi[INVESTIGATOR_794096]68 -positive cell s (macrophages) in the glomeruli. After 2 months of treatment 
with avacopan, histology showed no evidence of endocapi[INVESTIGATOR_794097] a 
small number of CD68 -positive cells in the glomeruli. A renal biopsy conducted approximately 
6 months after starting avacopan treatment showed no hypercellularity and no crescents, and 
very few CD68 -positive cells in the glomeruli. There was attenuation of eGFR decline. The 
patient’s quality of life showed a significant improvement since starting avacopan tre atment  
until the patient was lost for follow up. 
Based on the results in the patient with C3GN and the Phase 2 study in AAV, testing avacopan 
more broadly in patients with C3G is indicated.  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095041] the efficacy, safety , and tolerability of avacopan in patients with 
C3G, including both C3GN and DDD. Patients with biopsy -proven C3G (biopsy has  occurred  within 12 weeks prior to signing 
informed consent or is to occur after consenting during the screening  period ), with or without a 
renal transplant, will be stratified by [CONTACT_794126] C5b -9 and then will be 
randomized 1:1 using a minimization algorithm to receive 30  mg avacopan BID or placebo BID  
for 26 weeks in a double-blind manner: 
 
Both strata, i.e., C5b-9 level  >244 ng/ml and ≤244 ng/mL , will include approximately 
44 patients each ; each level will have approximately 22 patients randomized to the avacopan or 
the placebo arm, respectively. E nrollment for the stratum with C5b- 9 level s ≤244 ng/ml could 
terminate early if patient en rollment in the other stratum (“ C5b-9 level >244 ng/mL ”) reach es 
target enrollment first.  
Eligible patients  within each of the C5b- 9 level strata will be further stratified based on two 
factors:  
1. C3GN or DDD, and  
2. Whether the patient has received a kidney tr ansplant or not. 
The earliest timepoint at which the  primary efficacy analysis can occur is when the last enrolled 
patient in the elevated stratum has completed the Week 26 visit. After the 26-week double-blind 
period, the avacopan group will continue receiving avacopan for another 26 weeks and the 
placebo group patients  will be switched over in a blinded manner to receive 30 mg avacopan 
twice daily treatment, instead of placebo, for another 26 weeks. 
Patients  will be screened for enrol lment based on biopsy-proven C3 G (i.e., ≥2 levels of 
magnitude greater staining of C3 than any combination of IgG, IgM, IgA, kappa and lambda 
light chains, and C1q) and evidence of proliferative glomerulonephriti s (mesangial 
hypercellularity and/or endocapi[INVESTIGATOR_794098]/Renal 
Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN; Sethi et al ., 2016).  

CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
 ChemoCentryx, Inc.  CONFIDENTIAL  Page 15 of 100  The screening period will be up to 42 days (6 weeks) . Screening procedures will include written 
Informed  Consent/ Assent , demographics, medical history, medication history  (medication given  
prior to Day 1 of dosing is considered medica tion history), physical examination and vital signs, 
12-lead ECGs, serum pregnancy test for women of childbearing potential, s erum ch emistry 
(including serum creatinine), hematology, urinalysis, urinary albumin  creatinine ratio (UACR) 
and protein: creatinine ratio (UPCR), viral and TB screening . If a patient did not have a renal 
biopsy in the past 12 weeks, a renal biopsy needs to be done prior to dosing. Prior to starting 
blinded study drug treatment (avacopan or placebo), blood samples will be collected for the following measurements to create a baseline profile for all patients : 
3. Plasma C3a, C5a, C5b-9, and C5; 
4. Serum C3 and C4; 
5. Serum C3 nephritic factor;  
6. Plasma complement factor H and factor B;  
7. Serum factor H autoantibody; 
8. Serum paraprotein detection; 
9. Complement factor H related protein 5 (CFHR5) mutation. 
Results obtained within 4 weeks prior to screening, or any time in the pas t for CFHR5 mutation , 
will be acceptable for the study.  Patients  who do not provide consent for genetic evaluation are 
allowed to participate in the study without the collection of genetic information.  
Patients  meeting eligibility  criteria will start blinded study drug treatment on Day 1. Patients  
will take avacopan  30 mg or matching placebo orally twice daily . The placebo-controlled 
treatment period  is 26 weeks  (182 days). This placebo- controlled treatment period will be 
followed by [CONTACT_3440]- label 26- week treatment period during which all patients  will receive 
avacopan. Thereafter, all patients  will be followed for 8 weeks (56 days) without study drug 
treatment.  
At post-Day [ADDRESS_1095042] every 4  weeks throughout the study. Health -
related quali ty of life using the EQ-5D-5L and SF-36 v2 surveys will be assessed periodically 
over the course of the study. Blinded study drug will be dispensed and drug accountability will 
be done. Concomitant medication and adverse event assessments will be made at every study 
visit. A follow-up renal biopsy will be performed at the following time points: 
1. Within  2 weeks of the Week 26 visit, and completed before dosing with open- label 
treatment; 
2. If a patient is withdrawn early from the study, and 
3. After the 52 -week treatment period.  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
 ChemoCentryx, Inc.  CONFIDENTIAL  Page 16 of 100  The Week 52 biopsy is optional in a dolescent patients.  
If a patient is on other immunosuppressive treatment at the start of dosing, the dose (s) of 
concomitant immunosuppressive treatment may not be increased during the study. Treatment 
with these other drugs may be reduced or stopped during the study at the discretion of the Investigator, if the patient’s condition justifies it. Adjustments of tacrolimus and cyclosporine 
doses to ensure these medications are at goal trough levels for maintenance of immunosuppression in transplant patients will be allowed during the study. No new treatments for C3G , except for renin -angiotensin -aldosterone system (RAAS) blockers,  may be added 
during the study period (52- week  treatment period or 8- week follow up), unless the patient’s 
condition deteriorates to the extent that the investigator deems it in the best interest of the 
patient to do so. Addition of new treatments for C3G during the treatment period will be considered a treatment failure.  
Patients  who experience deteriorating renal function based on an increase in serum creatinine of 
at least 50% (confirmed by a repeat measurement after  at least  2 weeks) which is otherwise not 
explained (e.g., dehydration, new medication), or an increase in proteinuria of > 3 g/g creatinine 
(confirmed by a repeat measurement after  at least  2 weeks)  from Screening or baseline during 
the 52- week treatment period, will exit the treatment phase of the study and be treated at the 
discretion of their physician . The increase of serum creatinine or proteinuria will be calculated 
from the higher value that is measured either at Screening or baseline. They will remain in the 
study and complete the remaining study visits and procedures. If a patient refuses further study 
participation, the Early Termination visit procedures will be performed, if possible. These patients  will be considered treatment failures.  
Dose strengths given to study patients will differ for adult and adolescents. Adolescent patients 
(12 to 17 years old) are allowed to be enrolled only in countries and at study centers for which 
approval by [CONTACT_794127]/ECs was granted. 
All adults will receive an avacopan dose of 30 mg twice daily or matching placebo twice daily 
in the initial 26 -week, placebo -controlled treatment period. When they enter the open- label 
26-week treatment period , all study patients regardless of their prior treatment will receive 
avacopan 30 mg twice daily.  
For study centers where enrollment of adolescent patients (12 to 17 years old) is approved, the 
dose of avacopan or placebo dose will be given based on the ir body weight and avacopan 
plasma exposure ( AUC
0-6hr) or avacopan trough concentrations. This is further specified in the 
main protocol. 
Patients  will visit the study center  for Screening and on Day  1 (baseline) and on Weeks 1, 2, 4, 
8, 12, 16, 20, [ADDRESS_1095043] been 
completed. The patient ’s condition will be evaluated by [CONTACT_794128] t he 
clinical trial ( Week 60 ) and appropriate standard of care medical treatment will be prov ided to 
all patients  as needed.  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
 ChemoCentryx, Inc.  CONFIDENTIAL  Page 17 of 100  Number of Patients  
Approximately 88 male or female patients  with C3 G will be enrolled in this study  with 
approximately 44 patients in each of the two C5b- 9 level  strata . Patients who drop out early will 
not be replaced . 
Main Criteria for Inclusion  
1. Biopsy-proven C3G, either DDD or C3GN, with or without a renal transplant, and with 
the following observations upon renal biopsy taken within 12 weeks prior to screening or during screening: 
a. ≥2 levels of magnitude greater staining of C3 than any combination of IgG, IgM, 
IgA, kappa and lambda light chains, and C1q by [CONTACT_9064], and 
b. Evidence of proliferative glomerulonephritis (mesangial hypercellularity of greater than 3 mesangial cells per mesangial area and/or endocapi[INVESTIGATOR_794099], causing luminal narrowing) based on light microscopy, and  
c. Confirma tion of the presence of electron dense deposits in the glomeruli on 
electron microscopy corresponding with the C3 immunofluorescence positivity. 
The site will use their site -specific standard technique for taking the biopsy, which can 
include ultrasound guidance.  
2. Male or female patients , aged  at least 18 years; where approved, adolescents (12  to 
17 years old) m ay be enrolled; female patients  of childbearing potential (i.e., those who 
have experienced menarche and who are  not permanently sterile or postmenopausal, 
defined as at least 12 consecutive months with no menses without an alternative medical cause) may participate if adequate contraception is used during and for at least the three months after study completion; m ale patients  with partners of childbea ring potential 
may participate in the study if they had a vasectomy at least [ADDRESS_1095044] the 3 months after study completion; male patients  with partners of childbearing potential must be 
excluded if they plan to father a child during the study. Adequate contraception is defined as resulting in a failure rate of less than 1% per year (combined est rogen and 
progestogen [oral, intravaginal, or transdermal], or progestogen-only hormonal contraception (oral, injectable, or implantable), intra-uterine device, intra- uterine 
hormone releasing system, bilateral tubal occlusion, vasectomized partner, or true sexual abstinence, i.e., in line with the preferred and usual lifestyle of the patient ); In addition, 
a barrier method (i.e. , cervical cap, diaphragm or condom) must be used during 
intercourse between a male patient  and a female of child -bearing potential.  
3. Willing and able to give written Informed Consent and to comply with the requir ements 
of the study protocol; written Assent and Informed Consent must be obtained from the legal guardian in accordance with regional laws or regulations for patients  12 to 17 years 
of age; and  
4. Judged to be otherwise fit for the study  by [CONTACT_737],  based on medical history, 
physical examination, and clinical laboratory assessments. Patients  with clinical 
laboratory values that are outside of normal limits (other than those specified in the Exclusion Criteria) and/or with other abnormal clinical find ings that are judged by [CONTACT_794129], may be entered into the study. 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
 ChemoCentryx, Inc.  CONFIDENTIAL  Page 18 of 100  Main Criteria for Exclusion  
1. Pregnant or nursing; 
2. Tubulointerstitial fibrosis appears to be more than 50% based on standard assessment 
using trichrome staining of the renal biopsy; 
3. Use of eculizumab or another anti-C5 antibody within 26 weeks prior to dosing; 
4. Secondary C3 disease, e.g., infection- associated disease, or associated with another 
systemic or autoimmune disease; presence of a monoclonal sp ike on serum or urine 
protein electrophoresis or immunofixation assay; 
5. Currently on dialysis or likely will require dialysis within 7 days after screening;  
6. History or presence of any form of cancer within the [ADDRESS_1095045] carcinoma in situ  that has been excised or resected 
completely and is without evidence of local recurrence or metastasis;  
7. Positive HBV, HCV, or HI V viral screening test  indicative of acute or chronic infection; 
8. Evidence of tuberculosis based on interferon γ release assay (IGRA), tuberculin purified protein derivative ([COMPANY_003]) skin test, or chest radiography done at screening or within 6 weeks prior to screening; a CT  scan or chest X -ray are  not mandatory if evidence of 
tuberculosis was excluded by [CONTACT_794130]; 
9. Active uncontrolled infection; 
10. WBC count less than 3500/ µL, or neutrophil count less than 1500/ µL, or lymphocyte 
count less than 500/ µL before start of dosing ; 
11. Evidence of hepatic d isease; AST, ALT, alkaline phosphatase, or bilirubin >3x the 
upper limit of normal before start of dosing; 
12. Currently using a strong inducer of the cytochrome P450 3A4 (CYP3A4) enzyme, such as carbamazepi[INVESTIGATOR_050], phenobarbital, phenytoin, rifampin, or St. John’s wort;  
13. Known hypersensitivity to ava
 opan o  inactive ingredients of the avacopan  capsules 
(including ) 
or inability to swallow the 
capsu
les; 
14. Par
ticipated in any clinical study of an investigational product within [ADDRESS_1095046] dose; and  
15. History or presence of any medical condition (for example , contraindication to local 
anesthesia required for renal biopsy, or recurring serious infections) or disease which, in the opi[INVESTIGATOR_689], may place the patient  at unacceptable risk for study 
participation.  
Test Product  
Avacopan  will be administered orally as  hard gelatin capsules containing [ADDRESS_1095047] gelatin capsules containing no 
avacopan but inactive ingredients . The placebo  capsules will be supplied to the study centers in 
plastic bottles containing 180 capsules. 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
 ChemoCentryx, Inc.  CONFIDENTIAL  Page 19 of 100  Patients  will receive one bottle of avacopan or placebo capsules on Day 1 and Weeks 4, 8, 12, 
and 16, and two bottles at Weeks 20, 26, 32, 38, and 44. 
Patients  will be asked to take 3 capsules every morning and 3 capsules ever y evening  orally 
with water , approximately 12 hours after the morning dose, as instructed. Study medication 
(avacopan or placebo) should be taken preferably with food. If a patient  misses a dose, the next 
dose should be taken as soon as possible. If it is close to the time for their next dose (within 3 
hours), the missed dose should not be taken and the next dose should be taken at the regular time. 
Duration of Treatment and Observation  
Patients  will be screened within a period not to exceed 42 days prior to Day 1. The total 
treatment period is 52 weeks (364 days) and all patients  will be followed for 8 weeks (56 days ) 
after the dosing period. 
To the extent possible, any adverse events that are deemed study drug -related and are ongoing 
at discharge will be followed-up to resolution or until a determination is made that the 
unresolved event is stable. The patient ’s condition will be evaluated by [CONTACT_794131].  
Safety Assessments  
Safety assessments include adverse events, physical examination abnormalities, vital signs, 12-lead ECG, and clinical laboratory tests (including blood chemistry, hematology, and urinalysis).  
Efficacy Asse ssments  
Efficacy assessments include:  
1. Renal biopsy to perform light microscopy, immunohistochemistry, and electron 
microscopy; light microscopy and immunohistochemistry will be used to determine the C3G Histologic Index for disease activity and chronicity; 
2. eGFR calculated from serum creatinine using the Chronic Kidney Disease-Epi[INVESTIGATOR_794100] (CKD -EPI) equation ( Levey et al ., 2009) in adult patients  and the 
modified Schwartz equation  in adolescents ( Schwartz et al ., 2009); 
3. Urinary protein:cr eatinine ratio (UPCR); 
4. Urinary MCP -1:creatinine ratio ; 
5. Health -related quality of life based on the EQ-5D-5L and SF-36 v2. 
Pharmacokinetic Assessments  
Concentrations of avacopan and its metabolite CCX168 -M1 will be determined in plasma 
according to the Tim e and Events Table, using a validated analytical method.  
Exploratory Pharmacodynamic Markers  
Plasma/serum samples will be collected according to the Time and Events Table  for 
pharmacodynamic marker measurements, which may include, for example, complement 
fragments, and inflammatory cytokine and chemokine levels. Urine samples will also be collected according to the Time and Events Table  for biomarker assessments including, for 
example, complement fragments, sCD163, and inflammatory cytokine and chemokine l evels.  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095048]’s evaluation . Patients  must have biopsy-proven C3G, either DDD or C3GN, with 
≥2 levels of magnitude greater staining of C3 than an y combination of IgG, IgM, IgA, kappa 
and lambda light chains, and C1q, and with evidence of proliferative glomerulonephritis (mesangial hypercellularity and/ or endocapi[INVESTIGATOR_567464] ). 
All renal biopsies will be analyzed with the routine panel of stains which includes hematoxylin -
eosin (H&E), periodic acid–Schiff ( PAS), trichrome, and Jones methenamine silver. A 
minimum of 4 (preferably 6) unstained slides from paraffin- embedded renal tissue will be 
provided by [CONTACT_794132] (e.g., CD45, CD68, MPO , C5a, C5aR, etc. ). 
Renal biopsies will be evaluated by a central reader, an expert in C3G renal pathology, who will be blinded to treatment assignment from either slides or digitized h igh-resolution images . 
The central reader will determine the degree of disease activity and chronicity based on the C3G Histologic Index. A semi -quantitative scale of 0 to 3 will be used, indicating either the 
proportion (%) of glomeruli involved or the proportion of cortex involved (for tubular atrophy and interstitial fibrosis).  
The C3G Histologic Index for disease a ctivity will consider 7 lesions: 
1. Mesangial hypercellularity, defined as >3 mesangial cells per mesangial area; 
2. Endocapi[INVESTIGATOR_567464] /proliferation , defined as an increased number of cells 
within glomerular capi[INVESTIGATOR_794101], causing luminal narrowing ; 
3. Membranoproliferative morphology ; 
4. Leukocyte infiltration;  
5. Crescent formation, defined as extracapi[INVESTIGATOR_794102] >50% of the lesion occupi[INVESTIGATOR_794103]; 
6. Fibrinoid necrosis; 
7. Interstitial inflammation . 
Definitions are based on the Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN ( Sethi et al ., 2016) and the activity 
index score uses the glomerulopathy histologic score as described by [CONTACT_794133] . (Bomback 
et al., 2018). 
For endocapi[INVESTIGATOR_567464] /proliferation , mesangial hypercellularity , 
membranoproliferative morphology , and leukoc yte infiltration  the following scale will be used: 
0 = none, 1 = 1-25%, 2 = 26-50%, 3 = >50% involvement. For crescent formation  and fibrinoid 
necrosis , the following scale will be used: 0  = none, 1 = 1-10%, 2  = 11-25 %, and 3 = >25% 
involvement.  For inters titial inflammation, a score  according to percentage of cortical 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
 ChemoCentryx, Inc.  CONFIDENTIAL  Page 21 of 100  tubulointerstitial area involved will be used: 0 = <10% , 1 = 1 0-25%, 2 = 26 -50%, 3 = >50% 
involvement.  
The C3G Histologic  Index for disease activity can assume a score from 0 -21. 
The C3G His tologic Index for disease c hronicity w ill consider 4 lesions ( Bomback et al ., 2018): 
1. Glomerulosclerosis  (% glomeruli with global and segmental sclerosis) , 
2. Tubular atrophy, and  
3. Interstitial fibrosis  
4. Arterio - and arteriolosclerosis  
Glomerulosclerosis (global plus segmental), tubular atrophy, and interstitial fibrosis will be  
assigned a score of 0 to 3 based on the percentage of glomeruli or cortical tubulointerstitial area 
involved. The following scale will be used for the chronicity index: 0 = <10%, 1 = 10-25%, 
2 = 26-50%, 3 = >50% involvement. For vascular disease, a score of 0 will be  assigned if 
intimal thickening i s < thickness of media and 1 if intimal thickening i s ≥ thickness of media. 
The C3G Histologic  Index for disease chronicity can assume a score from [ADDRESS_1095049] of avacopan on specific immune cell populations, such as total leukocytes, macrophages, and neutrophils.  
Statistical Methods  
This study will enroll and treat two  patient populations: patients in the elevated stratum of 
C5b- 9 levels (i .e., >244 ng/mL) and patients in the non- elevated stratum of C5b -9 levels (i .e., 
≤244 ng/mL). Data summaries and statistical analyses will be presented for each of the two 
strata as well as combine d. The elevated stratum will be considered  as the primary po pulation, 
the non- elevated stratum will be considered  as the secondary population, and the two strata 
combined will be considered the exploratory population. E nrollment for the stratum with C5b -9 
levels ≤244 ng/m L could terminate early, if patient enrollme nt in the other stratum (C5b- 9 level 
>244 ng/mL) reaches target enrollment first.  Further, both strata can be analyzed separately and 
independently. The stratum with elevated levels (primary population) will be analyzed first should the stratum with C5b-9 ≤ 244 ng/m L (secondary population) continue a blinded follow 
up – further details will be provided in the statistical analysis plan (SAP).  
For efficacy analysis, t o control for the T ype I error rate, a gate- keepi[INVESTIGATOR_794104] (percent change in C3G Histologic 
Index for disease activity ). The primary endpoint will be tested in the elevated stratum first with 
a two -sided α  = 0.05. If this test reaches statistical significance, then the primary en dpoint will 
be tested in the non- elevated stratum with a two -sided α  = 0.05. If the test in the elevated 
stratum fails to reach statistical significance, then the test in the non -elevated stratum will only 
be performed  as an exploratory analysis . 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
 ChemoCentryx, Inc.  CONFIDENTIAL  Page 22 of 100  The stati stical analysis for the secondary endpoint (C3G Histologic Index for disease 
chronicity ) will be tested at a 0.05 α -level only if the primary endpoint in the same stratum 
reaches statistical significance.  
Demographics and Baseline Characteristics  
All patient  baseline characteristics and demographic data (age, sex, race, ethnicity, weight, 
height, body mass index, viral test results, C3G disease type and duration [ from time of first 
diagnosis based on renal biopsy], eGFR, proteinuria [ UPCR ], complement mark er levels, 
urinary MCP- 1:creatinine ratio, physical examination abnormalities, medical history, previous 
[within 6 months of screening] and concomitant medications [including other treatments for 
C3G] at study entry ) will be listed  by [CONTACT_794134], and will also be 
summarized.  
Efficacy Analysis  
The primary efficacy endpoint is the percent change from baseline to Week 26 in the C3G 
Histologic Index for disease activity . 
The avacopan and placebo groups will be compared by [CONTACT_794135] C3G Histologic Index for disease activity as covariate. A point estimate and 
corresponding 95% confidence interval will be estimated for the treatment main effect. The heterogeneity of the treatment effect across disease diagnos es and renal transplant strata will be 
investigated through subgroup analyses. The treatment effect based on the baseline complement 
profile of patients  will also be investigated.  If data are not normally distributed, in addition to 
the ANCOVA for the  percent change in C3G Histologic Index for disease activity and 
chronicity, the Cochran- Mantel -Haenszel (CMH) test will be applied to the percent change 
results and ANCOVA will be applied to the change in C3G Histologic Index disease activity 
and chronici ty scores.  
Data from patients  who are treatment failures, i.e., requiring treatment rescue measures such as 
high dose glucocorticoids during the treatment period, will be excluded from efficacy analysis after the point of rescue treatment.  Missing data will be imputed with the last observation 
carried forward (LOCF). Multiple -imputation using Markov Chain Monte Carlo (MCMC) or 
other statistical method may also be performed.  
Since the placebo group will receive avacopan during the second [ADDRESS_1095050]. Point estimates and corresponding 95% con fidence intervals will be 
estimated for the difference between the second 26 weeks (avacopan treatment) and the first 26 weeks (placebo treatment).  
The change from baseline to Week 52 in the C3G Histologic Index in the avacopan group will also be compared to the change from baseline to Week 26 in placebo control group using similar methodology as described for the primary efficacy endpoint. 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
 ChemoCentryx, Inc.  CONFIDENTIAL  Page 23 of 100  Other efficacy endpoints include:  
1. The proportion of patients  who have a histologic response, defined as a decrease 
(improvement) in the C3G Histologic Index for disease activity of at least 3 5% from 
baseline to Week 26; 
2. The percent change from baseline in the C3G Histologic Index for disease chronicity 
over the placebo-controlled 26-week treatment period; 
3. The change and percent change from baseline in eGFR over the placebo -controlled  
26-week treatment period;  
4. The percent change from baseline in U PCR over the placebo -controlled 26- week 
treatment period;  
5. The percent change from baseline in urinary MCP -1:creatinine ratio ove r the 
placebo -controlled 26- week treatment period;  
6. Change from baseline in EQ -5D-5L (visual analogue scale and index) and SF-36 v2 
(domains and component scores) over the placebo -controlled 26- week treatment period . 
Continuous variables, including eGFR, UPCR, urinary MCP-1: creatinine  ratio, EQ-5D- 5L, and 
SF-36 v2 will be analyzed using a mixed effects model for repeated measures (MMRM) with 
treatment group, visit, and treatment- by-visit interaction as factors, and baseline as covariate. 
Patients  will be co nsidered as repeated measure units over visits. The interaction term may be 
dropped if it is not significant at α  = 0.25 level. Point estimates and corresponding 95% 
confidence intervals will be estimated for the difference between the avacopan  group and t he 
control group at Week  [ADDRESS_1095051] errors, and 95% confidence intervals will be calculated. Geometric means will be calculated for UPCR and MCP -1: creatinine , and other measurements that are not normally 
distributed. For the categorical variable of histologic response, the number and percentage of patients , as well as the 95% confidence intervals will be calculated.  
The primary efficacy analysis will be based on the intent- to-treat (ITT)  population, defined as 
all patients  who are randomized. If data are still missing after all efforts made to collect post -
baseline C3G Hist ologic Index  data, missing data  will be imputed using the last observation 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095052] method. This method may im pute Week 26 missing data with the baseline value 
if there are  no unscheduled data from visits prior to the missing time point.  
Safety Analysis  
Safety endpoints include: 
1. Patient  incidence of treatment -emergent serious adverse events, adverse events, and 
study withdrawals due to adverse events;  
2. Change from baseline and shifts from baseline in all safety laboratory parameters;  
3. Change from baseline in vital signs. 
All patients  who are randomized and received at least one dose of study medication will be 
included in the safety population. 
All clinical safety and tolerability data will be listed by [CONTACT_794136] , and will 
be summarized by [CONTACT_1570].  
All reported adverse events will be coded using MedDRA and listed by [CONTACT_1196], 
preferred term, and verbatim term.  
Treatment -emergent adverse events will be listed and summarized by [CONTACT_794137], by [CONTACT_596827].  
Treatment -emergent serious adverse events and adverse event s leading to study withdrawal will 
be summarized by  [CONTACT_1570].  
Individual vital signs and change from baseline in vital signs will be listed by [CONTACT_1570], patient , and study visit, and summarized by [CONTACT_1570] . 
Laboratory data (actual valu es and change from baseline) will be listed by [CONTACT_1570], 
patient , and study visit. Abnormal laboratory values will be flagged. Laboratory data will also 
be summarized by [CONTACT_67486]. Shift tables will be generated for shifts in labor atory parameters by [CONTACT_15449].  
Sample Size Assumptions  
A sample size of 22 patients  per treatment group (a vacopan and  placebo, respectively) in each 
of the C5b- 9 level strata is based on the between -treatment difference  of -35% in the C3G 
Histologic Index for disease activity  at Week [ADDRESS_1095053] deviation (SD) 34%, power 90%, and 
2-sided α  = 0.05. The sample size also provides approximately 90% power to detect a delta 
of -35% in the C3G Histologic Index for disease activity between the percent change from 
baseline in the first 26 weeks and in the second 26 weeks, assuming an SD of 34% for each change.  
Pharmacokinetic and Exploratory Pharmacodynamic Marker A nalysis  
Individual plasma concentrations of avacopan (and metabolite CCX168- M1) will be listed, 
plotted, and summarized descriptively and graphically. When possible, the mean steady state trough concentrations and the terminal elimination half -life will be calculated.  
The following parameters will be determined, where possible, in 12- 17 year -old pati ents: 
C
max Maximum plasma concentration  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095054]- Day 1 visits  
Plasma and urinary PD markers will be summarized and may be analyzed using methods 
analogous to the efficacy parameters.  
The relationship between PK parameters and renal function based on eGFR will be evaluated. 
The data may also be used to evaluate the PK/PD relations hip of avacopan  treatment  for both 
C5b- 9 level strata separately as well as combined . To this end, the change and/or percent 
change from baseline in the C3G Histologic Index, UPCR, eGFR, urinary MCP-1: creatinine 
ratio, and other biomarkers may be used as PD markers.  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
 ChemoCentryx, Inc.  CONFIDENTIAL  Page 26 of 100  STUDY SCHEMA  
 

CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 27 of 100  TIME AND EVENTS  TABLE 
 Screening  Double -Blind Treatment   Active Treatment  Follow -up 
Study Daya ≤42 days  1 8 15 29 57 85 113 141 162 183 197 225 246 267 288 309 337 365    
Study Week1 ≤6  1 2 4 8 12 16 20 23 26  28 32 35 38 41 44 48 52 54 57 60 
Informed 
Consent/Assent  X                      
Demographics, 
medical history, 
prior medications  X                      
Physical 
examinationb X Xc X X X X X X X  X X X  X  X  X X X X 
Vital signs X Xc X X X X X X X  X X X  X  X  X X X X 
12-lead ECG  X Xc X        X X X      X X X X 
Serum pregnancy 
test for women of 
childbearing 
potential  X Xc   X X X X X  X X X  X  X  X X X X 
HIV, HBV, HCV 
testing  X                      
Screening for 
tuberculosisd X                      
Serum chemistry X Xc  X X X X X X X X X X X X X X X X X X X 
Hematology  X Xc X X X X X X X X X X X X X X X X X X X X 
Urinalysis  X Xc X X X X X X X  X X X  X  X  X X X X 
Urine albumin, 
protein and 
creatinine  X Xc X X X X X X X  X X X  X  X  X X X X 
Renal biopsy  for 
light and electron microscopy, immunostaining, morphometry,  and 
C3G Histologic Index 
calculatione,f Xe          Xe        X    
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 28 of 100   Screening  Double -Blind Treatment   Active Treatment  Follow -up 
Study Daya ≤42 days  1 8 15 29 57 85 113 141 162 183 197 225 246 267 288 309 337 365    
Study Week1 ≤6  1 2 4 8 12 16 20 23 26  28 32 35 38 41 44 48 52 54 57 60 
Complement 
profilingg X                      
Stratification and 
randomization   X                     
Urine MCP -1 and 
creatinine   Xc X X  X  X  X  X X X  X    X   X 
EQ-5D-5L and 
SF-36 v2   Xc   X  X  X  X  X  X    X   X 
Avacopan/Placebo  
dispensing   Xc   X X X X X              
Avacopan 
dispensing            X  X  X  X      
Avacopan/Placebo  
double -blind 
dosing   X→ → → → → → → →  →X            
Avacopan dosing            Xh → → → → → → → Xi    
Avacopan/Placebo  
accountability      X X X X X  X  X  X  X  X   X 
PD plasma /serum 
sample collectionj  Xc X X X  X  X  X X X  X    X X X X 
Blood sample for 
lymphocyte subset 
analysisk  Xc X X X  X    X    X    X   X 
PD urine sample 
collect ion  Xc X X X  X  X  X X X  X    X   X 
PK plasma sample 
collection   Xc X X X  X  X  X X X  X    X X X X 
Concomitant 
medications  X X X X  X X X X X X X X X X X X X X X X X X 
Adverse event 
assessment   X X X X X X X X X X X X X X X X X X X X X 
a Week 1 through 20 visits may occur within a ± 2 day window. Week 26 through 60 vis its may occur within a ± [ADDRESS_1095055] dose of avacopan.  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 29 of 100  d Any one of the following may be done for TB screening: Inte rferon γ release assay (IGRA), tuberculin purified protein derivative ([COMPANY_003]) skin test, or chest 
radiography (done within 6 weeks prior to Screening or done during Screening).  
e Renal biopsy required for eligibility if not performed within 12 w eeks prior to screening; renal biopsy - 2 weeks prior to the Week 26 visit, and should be 
completed before open -label medication is started.  
f In ad olescents, only the baseline and one follow -up renal biopsy (at Week 26) are required; the 52 -week biopsy is optional.  
g Plasma C3a, C5, C5a, and C5b -9; serum C3, C4, and C3 nephritic factor; pla sma complement Factor H and factor B; serum factor H auto -antibody; serum 
paraprotein detection; CFHR5 mutation. Results obtained within [ADDRESS_1095056] for CFHR5 m utation will be acceptable for 
the study.  
h Only in adolescent p atients, plasma samples for avacopan measurements will be taken at pre- dose, 0.5, 1, 2, 3, 4, and 6 hours after dosing on Day 1 and on Day 
183 (Week 26). For all other visits, single time point samples approximately [ADDRESS_1095057] dose of study drug prior to the PK sample collection will be recorded. Note: For adolescents only  - it is 
important that on Day 183 (Week 26) the adolescent patients take the dose when instructed at the study center, NOT at home, and they should be reminded 
through a telephone call two days before the Day 183 (Week 26) visit.  
i For both adults and adolescents , the final dose of avacopan should NOT be taken on the morning of the scheduled Week 52 visit. Note: Patients should be 
reminded through a telephone call two days before the scheduled We ek 52 visit.  
j Blood samples will be put in wet ice immediately after collection, centrifuged in a refrigerated centrifuge and plasma or serum stored at ≤ -70 °C.  
k For T cell, B cell, and natural killer T cell counts.  
 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095058]  Aspartate aminotran sferase  
ATC  Anatomic Therapeutic Chemistry  
AUC  Area under the plasma concentration -time curve  
AUC 0-6hr Area under the plasma concentration -time curve for 0 to 6 hours after dosing  
b.i.d. or BID  Twice daily  
BVAS  Birmingham Vasculitis Activity Score  
C1q Complement component C1q  
C3 Complement component 3  
C3G  C3 glomerulopathy  
C3GN  C3 glomerulonephritis  
C3NeF  C3 nephritic factor  
C4 Complement component 4  
C5a Complement component 5a fragment  
C5aR  Receptor for C5a  
C5b-9 Membrane attack complex or te rminal complement complex  
C6 Complement 6  
CA Competent Authority  
CBC  Complete Blood C ount 
CD11b  Cluster of differentiation 11b  
CD45  Cluster of differentiation 45  
CD60  Cluster of differentiation 60  
CD68  Cluster of differentiation 68  
CD163  A protein that in humans is encoded by [CONTACT_8671]163  gene 
CFH  Complement factor H  
CFR  Code of Federal Regulations  
CFHR5  Complement factor H related protein 5  
Cmax Maximum (maximal) plasma concentration  
Cmin Minimum plasma concentration  
CKD -EPI [INVESTIGATOR_794105] -Mantel -Haenszel  
CPK  Creatine phosphokinase  
CRA  Clinical Research Associate  
CRF/eCRF  Case Report File  
CRO  Clinical Research Organization  
CSR  Clinical Study Report   
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095059] Computerized Tomography  
CTCAE  Common Ter minology Criteria for Adverse Events  
CYP3A4  Cytochrome P450 3A4 enzyme  
DDD  Dense Deposit Disease  
DMC  Data Monitoring Committee  
EC Ethics Committee  
ECG  Electrocardiogram  
EDC  Electronic Data Capture  
eGFR  estimated Glomerular Filtration Rate  
EQ-5D-5L EuroQuality of Life -5 Domains -5 Levels  
EU European Union  
FDA  Food and Drug Administration  
g gram  
GCP  Good Clinical Practices  
GMP  Good Manufacturing Practices  
GFR  Glomerular Filtration Rate  
H or hr  Hour  
H&E  Hematoxylin -eosin  
HBV  Hepatitis B virus  
HCV  Hepatitis C virus  
HDPE  High Density Polyethylene  
hERG  Potassium channel encoded by [CONTACT_596802] -à-gogo related gene  
HIV Human Immunodeficiency Virus  
ICH International Conference on Harmonisation  
IHC Immunohistochemistry  
IC50 Concentration a ssociated with 50% inhibition  
Ig Immunoglobulin  
IgA Immunoglobulin A  
IgG Immunoglobulin G  
IgM Immunoglobulin M  
IgAN  Immunoglobulin A Nephropathy  
IGRA  Interferon γ Release Assay  
IND Investigational New Drug  
INR International normalized ratio  
IRB Institutional Review Board  
IRT Interactive Response Technology  
ITT Intent -To-Treat  
IV Intravenous(ly)  
kD kilodalton  
kg kilogram  
lbs. Pound (weight)  
LOC F Last observation carried forward  
LVFS  Swedish Medical Products Agency’s Code of Statues  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 32 of 100  MAC  Membrane Attack Complex  
MCMC  Markov Chain Monte Carlo (statistical method)  
MCP -1 Monocyte Chemoattractant Protein -1, also known as CCL2  
MedDRA  Medical Dictio nary for Regulatory Activities  
mg milligram  
mL milliliter  
MMRM  Mixed effects Model for Repeated Measures  
MPGN  Membranoproliferative Glomerulonephritis  
MPO  myeloperoxidase  
N Number  
PAS periodic acid Schiff  
PD Pharmacodynamics(s)  
PK Pharmacokinetic( s) 
PP Per Protocol  
[COMPANY_003] Purified Protein Derivative  
QT/QTc  Q-T interval on ECG; corrected Q -T interval  
RAAS  Renin -Angiotensin -Aldosterone System  
RBC  Red Blood Cell(s)  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SAR  Serious Adverse Reacti on 
SD Standard Deviation  
SEM  Standard Error of the Mean  
SF-[ADDRESS_1095060] Operating Procedure  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
TB Tuberculosis  
TCC  Terminal Complement Complex, also known as membrane a ttack complex  
Tmax Time of Maximal Concentration  
UACR  Urinary Albumin:Creatinine Ratio  
UPCR  Urinary Protein:Creatinine Ratio  
[LOCATION_006] [LOCATION_008]  
WBC  White Blood Cell  
WHODD  World Health Organization Drug Dictionary  
 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095061] generates biologically active fragments of 
complement proteins, e.g., C3a, C4a and C5a anaphylatoxins, and the C5b- 9 membrane attack 
complex (MAC) or terminal complement complex (TCC), all of which mediate inflamma tory 
responses by [CONTACT_596803], activating macrophages, neutrophils, platelets, mast cells and endothelial cells , and by [CONTACT_596804], cytolysis , and tissue 
injury. 
C5a is one of the most potent pro- inflammatory mediators of the complement system, being at 
least [ADDRESS_1095062] cell degranulation, and inducing release of lysosomal proteases and oxidative free radicals. The anaphylactic and chemotactic effects of C5a are mediated through its 
interaction with the C5aR, a G protein-coupled receptor expressed on human neutrophils, 
monocytes, basophils, eosinophils, renal glomerular tissues, and lung smooth muscle and endothelial cells.  
Avacopan  (formerly CCX168) is an orally administered, small molecule, selective inhibitor of 
the complement 5a receptor (C5aR).  
As measured in vitro , avacopan  functionally inhibits C5a -mediated chemotaxis, displaces 
[
125I]-C5a from human C5aR, and inhibits C5a- mediated increase in cytoplasmic calcium levels 
with a potency (IC 50) of 0.2 to 0.9 nM in buffer ( Bekker et al ., 2016). 
Avacopan  was also evaluated for  its ability to inhibit the C5a -mediated chemotaxis of 
neutrophils in freshly collected human whole blood. Avacopan  produced 50% inhibition (IC 50) 
of C5a- mediated  neutrophil migration at a concentration of 1.7 nM; 90% inhibition (A 10 value) 
occurred  at an avacopan  concentration of 15.4 nM. Avacopan  also inhibits C5aR in cynomolgus 
monkeys and hamsters at  potencies similar to that observed with human whole blood. However, 
avacopan  possesses moderate potency for rabbit C5aR (IC 50 ~ 1.4 µM) and lacks affinity for 
mouse, rat, or dog C5aR (IC 50 >10 µM). 
The efficacy of avacopan  was assessed u sing genetically  modified mice where the mouse C5aR 
coding region was substituted for the human C5aR coding region. In these studies, intravenous injection of mouse anti- myel operoxidase (anti-MPO) IgG into the human C5aR knock- in mice 
caused glomerulonephritis in a manner mimicking ANCA disease in humans. At daily oral doses of 30 mg/kg avacopan , a marked inhibition of anti-MPO induced glomerulonephritis was 
documented histologically, as assessed by [CONTACT_794138] -containing 
glomeruli. These results were consistent with reduced protein, leukocytes, and red blood cells in the urine, and reduced serum blood urea nitrogen and creat inine in mice receiving avacopan  
(Xiao et al, 2014).  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095063] that avacopan and its only major metabolite  CCX168- M1 are unlikely to 
pose a pro- arrhythmic risk in humans. Nonclinical toxicity studies of up to 26 weeks and 44 
weeks in duration (in rats and cynomolgus monkeys, respectively) involving exposures higher than those expected in the clinic did not identify any safety concerns with avacopan. No adverse effects upon fertility or embryo -fetal development were seen in reproductive toxicity studies 
conducted in hamsters and rabbits. No evidence of any immunotoxicity was noted as immunological, clinical, and anatomical pathological parameters were, with limited exceptions (e.g., minor clinical pathology changes in rats in the 26-week study), unaffected by [CONTACT_3148]. An 
in vitro study indicated that avacopan was not phototoxic. Thus, r esults from these nonclinical 
studies support chronic oral dosing of 30 mg avacopan  twice daily to humans. Refer to the 
Investigator’s Brochure for details of these studies.  
1.2. Previous Clinical Studies  
Five Phase [ADDRESS_1095064] previously been completed . A 
Phase 3 study in patients  with AAV previously completed enrollment but follow up is ongoing 
and the study remain s blinded. A total of 182 healthy volunteers participated in the five Phase 1 
studies; 153 of these pa tients  received avacopan at doses ranging from 1 mg up to 100 mg 
(CL001_168, CL004_168, CL007_168, and CL008_168, and Japanese Phase 1 study 
CCX1101). Avacopan was generally well tolerated in these studies. 
Following oral administration, avacopan was absor bed rapi[INVESTIGATOR_794106] a median time of approximately 2.[ADDRESS_1095065] a biphasic elimination profile (as observed from the log- linear concentration -
time profiles), with a r apid early phase followed by a long terminal phase, a moderate to high 
apparent clearance in humans, and a large apparent volume of distribution. Despi[INVESTIGATOR_794107] -life, repeat administration for [ADDRESS_1095066] 
accumul ation (~2-fold) at the higher dose levels. Co- administration with a high  fat, high calorie 
meal did not affect C
max but increased the plasma exposure (AUC) approximately 72% and 
delayed t max by [CONTACT_3450] 3 hours ( study CL007_168). 
Avacopan dose-dependently inhibited the C5a-induced upregulation of CD11b in patients ’ 
neutrophils in study CL001_168. At a mean avacopan plasma concentration of 150.9 ng/mL, C5a-induced upregulation of CD11b was inhibited by ~95% ( Bekker et al ., 2016). In Phase 2 
studies in patients with AAV, an average steady state plasma trough concentration of ~200 ng/mL was observed with the therapeutic dose of 30 mg avacopan given twice daily. 
Results from a mass balance study (CL004_168) showed that avacopan was mostly metabolized 
in the liver by [CONTACT_9058] P450 3A4 ( CYP3A4 ). 
Avacopan did not show evidence of a detrimental effect on QT/QTc based on results from an intensive ECG study (CL007_168). 
Co-administration of the strong CYP3A4 enzyme inducer, rifampi[INVESTIGATOR_2513], in study CL008_168 
resulte d in an approximately 93% reduction of systemic exposure of avacopan; this reduction 
may result in a loss of efficacy of avacopan. Therefore, the use of strong CYP3A4 enzyme 
inducers with avacopan is an exclusion criterion for the study. Co- administration of the strong 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc. CONFIDENTIAL Page 35 of 100  CYP3A4 enzyme inhibitor itraconazole resulted in a 119% increase of systemic exposure of 
avacopan. This approximate doubling of the avacopan  plasma concentrations indicates a modest 
interaction and should not pose a safety concern, given that the safety margins for [ADDRESS_1095067] 6 to 19-fold, respectively, 
based on the long-term cynomolgus monkey and ra t toxicology studies. Nevertheless, strong 
CYP3A4 enzyme inhibitors with avacopan should be used with caution. 
Two Phase 2 clinical trials in 109 patients w ith anti-neutrophil cytoplasmic antibody (ANCA)-
associated vasculitis (AAV) were conducte d. The first study in 67 patients (CL002_168) 
included three dose groups: 30 mg avacopan twice daily plus low dose prednisone (20 mg/day), 
30 mg avacopan twice daily plus no prednis one, and placebo plus full dose prednisone 
(60 mg/day). All patients received either IV cycl ophosphamide or rituximab as standard of care 
treatment. Avacopan, alone or with low dose prednisone, was associated with a rapid onset of 
action based on a global disease activity index, the Birmingham Vasculitis Activity Score 
(BVAS), renal parameters such as albuminuria, and health-related quality of life measurements 
over a 12-week treatment period ( Jayne et al., 2017 ). The steady state mean avacopan plasma 
concentration was approximately 204 ng/mL in th ese patients, corresponding to >95% projected 
inhibition of the C5aR in the circulation. Avac opan also showed a favorable safety profile. 
The second study in 42 patients (CL003_168) incl uded three dose groups: 10 mg avacopan twice 
daily plus full dose prednisone (60 mg), [ADDRESS_1095068] when avacopan treatment was stopped. Refer to the Investigator’s Brochure for more details. 
A Phase 3 clinical trial with patients with AAV previously completed enrollment of >300 
patients and follow up is  ongoing  (ADVOCATE, CL010_168). In this study in patients with 
AAV, avacopan (or placebo) is being compared with  standard of care gl ucocorticoids as added 
medications to background therapy of either cyclophosphamide followed by [CONTACT_596806], or of rituximab. The study remains blinded. 
The Data Monitoring Committee (DMC) for that study has commented on a 
. The DMC further 
commented on a potential risk of ter an unblinded review of safety data from 
enrolled patients because 
 
Specifically,  patients receiving bli nded study drug had Grade 2 (>3-5 times upper limit 
of normal [ULN]), and  patients receiving blinded study drug had Grade 3 transaminase 
elevations (>[ADDRESS_1095069]). In one patient, the transaminase elevation recurred when study 
drug was restarted. The interpretation was confounded by [CONTACT_794139] i rritants including Sulfam ethoxazole-Trimethoprim. 
The Reference Safety Information section of the Investigator’s Brochure has been updated to 
include the potential risk of , , and , and to state that general 
gastrointestinal adverse events (e.g., nausea, diarrhea) as previously  observed in Phase 2  AAV 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095070] been observed in the ongoing Phase 3 CL010_168 study at approximately the same 
frequency and severity . 
An open- label Phase 2 clinical trial in 7 patients with IgA nephropathy (IgAN) has been 
conducted (CL005_168). Results showed that avacopan was effective in improving proteinuria 
over a 12-week treatment period; 3 of 7 patients  showed approximately 50% decrease i n either 
urinary protein:creatinine ratio (UPCR) or albumin:creatinine ratio  (UACR) . An open- label 
Phase 2 clinical trial in 6 patients with atypi[INVESTIGATOR_151258] (aHUS) was conducted (CL006_168). R esults showed that serum collected from patie nts dosed with 
avacopan  caused  a mean percent reduction of  82% in thrombus size compared to baseline in an 
ex vivo assay. 
A benefit and risk assessment of avacopan is presented in  Section  12.3; detailed information 
about non- clinical and clinical trials with avacopan is presented in the Investigator’s Brochure. 
Results from nonclinical and clinical studies conducted to date showed a positive risk- benefit 
profile of avacopan in treatment of patients  with AAV ( Secti on 12.3.1 and  Section  12.3.2 ). 
1.3. Rationale for the Study  
C3 glomerulopathy (C3G) is characterized by [CONTACT_794140] C3 deposition in the glomeruli. There are two forms of the disease: dense deposit 
disease (DDD, formerly called membranoproliferative glomerulonephritis [MPGN] Type II) and 
C3 glomerulonephritis (C3GN, formerly called idiopathic MPGN). 
The major defect underlying C3G i s excessive activation of the alternative complement pathway, 
resulting in the deposition of multiple complement components in the glomerulus, including 
components of C3 and C5 ( Pi[INVESTIGATOR_116281] ., 2013), in the absence of antibody or immune 
complex deposition. The mechanism by [CONTACT_794141], but likely involves chemotaxis of leukocytes resulting from cleavage of C5 
to generate C5a, as well as the cytolytic effects of C5b -9 (Hou et al ., 2014).  
There i s no approve d treatment for patients with C3G . Immunosuppressive drugs such as 
cyclophosphamide, mycophenolate mofetil, and glucocorticoids, as well as biologics such as rituximab have been used with limited success. The anti-C5 antibody eculizumab has  shown 
evidence of improvement in some patients with C3G ( Bomback et al ., 2012; Herlitz et al., 2012). 
Eculizumab blocks the formation of C5a and C5b-9 (membrane attack complex) from C5. Evidence from animal models suggests that inhibition of C5a may  be more i mportant than 
inhibition of C5b-9 in C3G because deletion of C6 (which is part of the C5b-9 complex) in 
complement factor H ( CFH ) knockout mice failed to protect the mice from developi[INVESTIGATOR_794108] C3G ( Pi[INVESTIGATOR_116281] ., 2006). This provides support for testing drugs such as 
avacopan that target C5aR.  
We used mice deficient in complement factor H (CFH) which develop spontaneous 
glomerulonephritis resembling C3G in humans ( Pi[INVESTIGATOR_116281] ., 2002; Pi[INVESTIGATOR_116281] ., 2006 ) to 
evaluate the effect of avacopan . These CFH -deficient mice, carrying human C5aR , were treated 
with avacopan from [ADDRESS_1095071] been treated with vehicle showed elevated plasma 
creatinine comparing to CFH wild -type mice treated with vehicle (CFH deficient mice 1038 ± 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 37 of 100  15.48 µg/mL vs. CFH wild-type mice 863.5 ± 13.50 µg/mL; mean ± SEM; p  = 0.002 for 
comp arison of the two groups). The avacopan- treated CFH deficient mice had lower plasma 
creatinine compared  to vehicle -treated CFH deficient mice (avacopan 843.0 ± 23.43 µg/mL vs. 
vehicle 1038 ± 15.48 µg/mL mean ± SEM, p = 0.0003 for comparison of the two groups). These 
data indicate that administration of avacopan to CFH- deficient mice protects renal function and 
provides a strong rationale for blocking the C5a receptor with a drug such as avacopan as a novel 
therapeutic approach for patients with C3G. 
One pat ient with treatment refractory C3GN , one of the subtypes of C3G, has been treated with 
[ADDRESS_1095072] to Follow up in December 2016 
under  a “Special Needs” program in the [LOCATION_006]  (CL009_168). This patient had progress ive decline 
in renal function despi[INVESTIGATOR_794095], rituximab, and glucocorticoids, as well as a kidney transplant. Kidney histology prior to treatment with avacopan showed endocapi[INVESTIGATOR_794109]68- positive cells 
(macrophages) in the glomeruli. After 2 months of treatment with avacopan, histology showed no evidence of endocapi[INVESTIGATOR_794097] a small number of CD68- positive cells in 
the glomeruli. A renal biopsy conducted approximately 6 months after starting avacopan 
treatment showed no hypercellularity and no crescents, and very few CD68- positive cells in the 
glomeruli. There was attenuation of eGFR decline with avacopan treatment.  Refer to the 
Investigator’s Brochure for more detail. 
Based on the results in mice, the patient with C3GN , and  the Phase 2 studies  in AAV, IgAN, and 
aHUS, testing avacopan m ore broadly in patients with C3G is indicated.  
For more detail regarding the pharmacology and toxicology, and in-depth descriptions of c linical 
studies conducted with avacopan, please refer to the Investigator’s Brochure. This clinical trial will be conducted in compliance with the protocol, good clinical practice 
(GCP), and appl icable regulatory requirements.  
2. OBJECTIVES 
2.1. Primary Objective  
The primary objective is to evaluate the efficacy of avacopan compared to placebo based on histologic changes in kidney biopsies taken before and during treatment. 
2.2. Secondary Objectives  
The secondary objectives of this study include evaluation of: 
1. The safet y of avacopan compared to placebo based on the incidence of adverse events, 
changes in clinical laboratory measurements, and vital signs; 
2. Changes in laboratory parameters of renal disease including estimated glomerular 
filtration rate (eGFR), proteinuria, and urinary excretion of monocyte chemoattractant protein- 1 (MCP -1) with avacopan compared to placebo; 
3. Health -related quality -of-life changes based on Short Form-36 version 2 (SF-36 v2) and 
EuroQOL-5D- 5L (EQ -5D-5L) with avacopan compared to placebo; 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095073] 
involvement and other markers of inflammation may be assessed in plasma/serum or urine over 
the course of the treatment period. 
3. STUDY DESIGN 
There is no approved treatment for patients with C3G. Immunosuppressive drugs such as cyclophosphamide, mycophenolate mofetil, and glucocorticoids, as well as biologics such as 
rituximab have been used but w ith limited success. The anti-C5 antibody eculizumab has  shown 
evidence of improvement in some patients with C3G. 
Based on results both from preclinical s tudies and clinical results from treatment of a patient 
with C3GN in a “ Special Needs ” protocol, avacopan  has the potential to be an effective therapy 
for patients with C3G . The safety and efficacy of avacopan will be evaluated in this  randomized, 
double-blind, placebo -controlled clinical trial in approximately [ADDRESS_1095074] the efficacy, safety, and tolerability of avacopan  in patients with 
C3G, including both C3GN and DDD. Patients with biopsy -proven C3G (within 12 weeks prior to signing informed consent or after 
consenting during screening or during screening), with or without a renal transplant, will be 
stratified by [CONTACT_794126] C5b -9, and then will be randomized using a 
minimization algorithm to receive 30  mg avacopan twice daily or avacopan -matching  placebo 
twice daily for 26 weeks in a double-blind manner: 
 
Both strata , (i.e., C5b- 9 level s >244 ng/ml and ≤244 ng/mL ) will include approximately 
44 patients ; each level will have approximately 22 patients randomized (1:1) to the avacopan or 

CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 39 of 100  avacopan -matching  placebo arm, respectively. However, enrollment for the stratum with C5b-9 
level s ≤244 ng/ml could termi nate early if patient en rollment in the other stratum ( C5b- 9 level 
>244 ng/mL ) reach es target enrollment first.  
To obtain balance across treatment groups , eligible patients  within each of the C5 b-9 level strata 
will be further s tratified based on two factors:  
1. C3GN or DDD, and  
2. Whether the patient has received a kidney transplant or not. 
3.2. Randomization  
Patients  will be randomized  using an interactive response technology (IRT) system and a 
minimization algorithm, using the stratification factors, in a 1:1 ratio  to one of two treatment 
groups: 
Group A: avacopan -matching placebo  twice daily  
Group B: a vacopan  [ADDRESS_1095075] enrolled 
patient  in the primary population ( patient s in the elevated C5b-9 stratum, see  Section 8.2.1) has 
completed the Week 26 visit. After the 26-week double-blind period, the avacopan group will 
continue receiving avacopan for another 26 weeks, and the avacopan -matching  placebo group 
will be switched o ver in a blinded manner to receive 30 mg avacopan twice daily treatment, 
instead  of avacopan -matching placebo, for another 26 weeks. 
3.3. Study Treatments  
Treatments for each group are shown in  Table 1 and Table 2.  
The treatment period  is 52 weeks ( 364 days) .  
Study drug (avacopan or placebo) will be taken as described in S ection  5.3. 
Dose strengths given to study patients  will differ for  adults and adolescents. Adolescent patients 
(12 to 17 years old) are allowed to  be enrolled only in countries and at study centers for which 
approval by [CONTACT_794127]/ECs was granted. 
3.3.1. Adult P atients  - Study Treatments  
All adults will rec eive an avacopan dose of 30 mg twice daily or avacopan -matching  placebo 
twice daily in the initial 26 -week, placebo -controlled treatment period (Table 1). When they enter 
the open- label 26 -week treatment period , all study patients regardless of their prior treatment will 
receive avacopan 30 mg twice daily . 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 40 of 100  Table 1: Dosing Groups in the First and Last [ADDRESS_1095076] 26 Weeks  
(Placebo -controlled treatment pe riod)  Last 26 Weeks  
(Open -label treatment period)  
Group  Avacopan 
Active  Avacopan-M atching 
Placebo  Avacopan         Active  Avacopan- Matching 
Placebo  
A None 3 placebo capsules orally twice daily  3 x 10 mg avacopan 
capsules orally 
twice daily  None 
B 3 x 10 mg avacopan 
capsules orally 
twice daily  None 3 x 10 mg avacopan 
capsules orally 
twice daily  None 
3.3.2. Adolescent  Patients - Study Treatments  
For study centers where enrollment of adolescent patients (12 to 17 years old) is approved, the 
dose of avacopan or placebo on Day 1 of the placebo-controlled period will be given based on the body weight determined at screening. Depending on the avacopan plasma exposure 
(AUC
0-6hr) from Day 1 , the dose will be adjusted as shown in Table 2 . These dose adjustments 
will be made as soon as the plasma exposure results are available.  
When they enter the open- label 26 -week treatment period , all adolescent patients will receive 
avacopan twice daily. Starting on Day 183, their dose will be reset based on the body weight 
determined on that day according to Table 2.  Depending on the avacopan plasma exposure 
(AUC 0- 6hr) from Day [ADDRESS_1095077] 26 weeks, their dose adjustment in the open- label treatment 
period may be determined based on Day 183 trough concentration rather than exposure (AUC
0-6hr). 
In all adolescents, blood samples will be taken at pre-dose and at 0.5, 1, 2, 3, 4, and [ADDRESS_1095078] avacopan dose on Day 1 and Day 183, respectively, to determine the avacopan plasma 
exposure (AUC 0-6hr). Plasma samples will be sent to the central laboratory for expeditious 
measurement of avacopan and CCX168-M1 in these patients . 
These AUC 0-6hr thresholds are based on the mean avacopan plasma exposure (525 ng•hr/mL) and 
one standard deviation (174 ng•hr/mL) above or below the mean in adult patients  from Phase [ADDRESS_1095079] 26 weeks of the study, some patients  on placebo will 
also be instructed to modify the number of placebo capsules taken.  The laboratory personnel 
conducting the PK assays will communicate the dosage changes, without shar ing the PK results  
with the study site personnel or study team  (see Section 5.6). 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 41 of 100  Table 2: Avacopan /Placebo Starting Dose and Dose Adjustments Based on Avacopan 
Plasma Exposure in Adolescent Patients  
Body 
weight  Avacopan /Placebo Dose on 
Day 1 and Day 183, respectively  Avacopan  Plasma AUC
0-6hr 
(ng•hr/mL) on Day 1 (or Day [ADDRESS_1095080] 26 weeks)  Avacopan  Dose 
Adjustment  
<40 kg               
(88 lbs.) 10 mg (1 capsule) twice daily  ≥351  None  
  <351  Increase dose to 20  mg     
(2 capsules) twice daily  
40-55 kg   
(88-121 
lbs.) 20 mg (2 capsules) twice daily  351 to 699  None  
  <351  Increase dose to 30  mg     
(3 capsules) twice daily  
  >699  Decrease dose to 10  mg    
(1 capsule) twice daily  
>55 kg        (121 lbs.) 30 mg (3 capsules) twice daily  ≤699  None  
  >699  Decrease dose to 20  mg    
(2 capsules) twice daily  
3.4. Study Flow 
Patients  will be screened for enrollment based on biopsy-proven C3G (i.e., ≥2 levels of 
magnitude greater staining of C3 than any combination of IgG, IgM, IgA, kappa and lambda 
light chains, and C1q) and evidence of proliferative glomerulonephritis (mesangial 
hypercellularity and/or endocapi[INVESTIGATOR_794098]/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN; Sethi  et al ., 2016).  
The screening period will be up to 42 days  (6 weeks) . Screening procedures will include written 
Informed Consent /Assent , demographics, medical history, medication history (medication given 
prior to Day 1 of dosing is considered medication history) , physical examination , 12-lead ECG,  
and vital signs, serum pregnancy test for females  of childbearing potential, serum chemistry 
(including serum creatinine), hematology, urinalysis, urinary protein:creatinine ratio (UPCR) and 
albumin:creatinine ratio (UACR) , viral and tuberculosis ( TB) screening. If a patient  did not have 
a renal biopsy in the past 12 weeks, a renal biopsy is required  prior to Day 1 . Prior to starting 
blinded study drug treatment, blood samples will be collected for the following measurements to 
create a baseline profile for all patients : 
1. Plasma C3a, C5a, C5b-9 and C5; 
2. Serum C3 and C4; 
3. Serum C3 nephritic factor;  
4. Plasma complement f actor H and factor B;  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 42 of 100  5. Serum factor H autoantibody; 
6. Serum paraprotein detection; 
7. Complement factor H related protein 5 (CFHR5) mutation. 
Results obtained within [ADDRESS_1095081] for CFHR5 mutation , 
will be acceptable for the study.  Patients  who do not provide consent for genetic evaluation will 
not be excluded from the study. 
Patients  meeting eligibility  criteria will start blinded study d rug treatment on Day 1. Patients  will 
take avacopan 30 mg or matching placebo orally twice daily. The placebo- controlled treatment 
period is 26 weeks (182 days). This will be followed by 26 weeks during which all patient s will 
receive avacopan.  
Thereafter,  all patients  will be followed for 8 weeks (56 days) without study drug treatment. 
As specified in the Time and Events T able, blood and urine samples will be collected for safety, 
efficacy, and pharmacokinetic and biomarker measurements. A serum pregnancy test for women 
of childbearing potential will be done regularly during the 52-week treatment period and at the 
end of the 8- week follow -up period. Liver function and hematology including differential blood 
work  will be monitored at least every 4  weeks thro ughout the study. Physical examinations and 
vital signs assessments will be performed throughout the study. Health -related quality of life 
using the EQ-5D- 5L and SF -36 v2 surveys will be assessed periodically over the course of the 
study. Study drug (avaco pan or placebo) will be dispensed and drug accountability will be done. 
Concomitant medication and adverse event assessments will be made at every study visit. A follow- up renal biopsy will be performed at the following time points: 
1. Within 2 weeks prior to the Week 26 visit, and should be completed before open- label 
medication is started ; 
2. If a patient  is withdrawn early from the study, and 
3. After the 52- week treatment period.  
The Week 52 biopsy is optional in adolescent patients.  
If a patient  is on other immunosuppressive or glucocorticoid treatment at the start of dosing, the 
dose(s) of concomitant immunosuppressive or glucocorticoid treatment may not be increased 
during the study (see Section  5.9). Treatment with these other drugs may be reduced or stopped 
during the study at the discretion of the Investigator, if the patient ’s condition justifies it. 
Adjustments of tacrolimus and cyclosporine doses to ensure these medications are at goal trough levels for maintena nce of immunosuppression in transplant patients will be allowed during the 
study. No new treatments for C3G , except for renin -angiotensin -aldosterone system (RAAS) 
inhibitor s, may be added during the study period (52-week treatment period or 8-week follow 
up), unless the patient ’s condition deteriorates to the extent that the investigator deems it in the 
best interest of the patient  to do so. Addition of new treatments for C3G during the treatment 
period will be considered a treatment failure.  
Patients  who experience deteriorating renal function based on an increase in serum creatinine of 
at least 50%, or an increase in proteinuria of >3 g/g creatinine from Screening or baseline during 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 43 of 100  the 52- week treatment period , will be considered treatment failures  (see Section  4.4. Removal of 
Patients from Therapy ). 
Patients  will visit the study center for Screening and on Day 1 (baseline) and Weeks 1, 2, 4, 8, 
12, 16, 20, 23, 26, 28, 32, 35, 38, 41, 44, 48, 52, 54, 57, and 60 (follow -up visit) . 
Patients  will be discharg ed from the study when all the Week [ADDRESS_1095082] been 
completed. The patient ’s condition will be evaluated by [CONTACT_794142] (Week 60) and appropriate standard of care medical treatment will be provided to all 
patients  as needed.  
To the extent possible, any adverse events that are deemed study drug -related and are ongoing at 
discharge will be followed to resolution or until a determination is made that the unresolved event is stable.  
4. STUDY POPULATION  
4.1. Size of the Population  
The aim is to enroll approximately [ADDRESS_1095083] meet all of the following inclusion criteria in order to enter the study: 
1. Biopsy-proven C3G, either DDD or C3GN, with or without a renal transplant, and with the 
following observations upon renal biopsy taken within 12 weeks prior to screening or during screening:  
a. ≥2-levels of magnitude greater staining of C3 than any combination of IgG, IgM, 
IgA, kappa and lambda light chains, and C1q by [CONTACT_9064], and 
b. Evidence of proliferative glomerulonephritis (mesangial hypercellularity of greater than 3 mesangial cells per mesangial area and/or endocapi[INVESTIGATOR_794110], causing luminal narrowing) based on light microscopy, and  
c. Confirmation of the presence of electron dense deposits in the glomeruli on electron microscopy corresponding with the C3 immunofluorescence positivity. 
The site will use their site -specific standard technique for taking the biopsy, which can 
include ultrasound guidance. 
2. Male or female patients , aged at least 18 years; where approved, adolescents (12- 17 year s 
old) may be enrolled; female patients  of childbearing potential (i.e., those who have 
experienced menarche and who are not permanently sterile or postmenopausal, defined as at least 12 consecutive months with no menses without an alternative medical cause) may participate if adequate contraception is used during, and for at least the three months after study completion; Male patients  with partners of childbearing potential may participate in the 
study if they had a vasectomy at least [ADDRESS_1095084] the 3 months after study completion; male 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095085] be excluded if they plan to father a child 
during the study. Adequate contraception is defined as resulting in a failure rate of less than 
1% per year (combined estrogen and progestogen [oral, intravaginal, or transdermal], or progestogen-only hormonal contraception (oral, injectable, or implantable ), intra -uterine 
device, intra- uterine hormone releasing system, bilateral tubal occlusion, vasectomized 
partner, or true sexual abstinence, i.e., in line with the preferred and usual lifestyle of the patient ). In addition, a barrier method (i.e., cervical  cap, diaphragm or condom) must be used 
during intercourse between a male patient  and a female of child -bearing potential. 
3. Willing and able to give written Informed Consent and to comply with the requirements of the study protocol; written Assent and Informed Consent must be obtained from the legal guard ian in accordance with regional laws or regulations for patients  12 to 17 years of age; 
and 
4. Judged to be otherwise fit for the study by [CONTACT_737], based on medical history, physical examination, and c linical laboratory assessments. Patients  with clinical laboratory 
values that are outside of normal limits (other than those specified in the Exclusion Criteria) and/or with other abnormal clinical findings that are judged by [CONTACT_794143], may be entered into the study. At sites in which adolescents are allowed to be enrolled, the Investigator assures that the adolescent patient is willing and able to ingest the size “0” study drug.  
4.3. Exclusion Criteria  
1. Pregnant or nursi ng; 
2. Tubulointerstitial fibrosis appears to be more than 50% based on standard assessment using trichrome staining of the renal biopsy; 
3. Use of eculizumab or another anti-C5 antibody within 26 weeks prior to dosing; 
4. Secondary C3 disease, e.g., infection- associated disease, or associated with another 
systemic or autoimmune disease; presence of a monoclonal spi[INVESTIGATOR_794111]; 
5. Currently on dialysis or likely will require dialysis within 7 days after screening; 
6. History or presence of any form of cancer within the [ADDRESS_1095086] carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis;  
7. Positive hepatitis B virus (HBV), hepatitis C virus ( HCV), or human immunodeficiency 
virus ( HIV) viral screening test  indicative of acute or chronic infection ; 
8. Evidence of tuberc ulosis based on interferon γ release assay (IGRA), tuberculin purified 
protein derivative ([COMPANY_003]) skin test, or chest radiography done at screening or within 6 weeks prior to screening; a CT  scan or chest X -ray are not mandatory if evidence of 
tuberculosis was excluded by [CONTACT_794130]; 
9. Active uncontrolled infection; 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 45 of 100  10. WBC count less than 3500/μL, or neutrophil count less than 1500/μL, or lymphocyte 
count less than 500/μL before start of dosing;  
11. Evidence of hepatic disease; AST, ALT, alkaline phosphatase, or bilirubin >3x the upper limit of normal before start of dosing;  
12. Currently using a strong inducer of the CYP3A4  enzyme, such as carbamazepi[INVESTIGATOR_050], 
phenobarbital, phenytoin, rifampin, or St. John's wort; 
13. Known hypersensitivity to avacopa n o
 r inactive ingredients of the avacopan capsules 
(including ) 
or inability to swallow the 
capsu
les; 
14. Par
ticipated in any clinical study of an investigational product within [ADDRESS_1095087] dose; and  
15. History or presence of any medical condition  (for example: contraindication to local 
anesthesia required for renal biopsy, or recurring serious infections) or disease which, in the opi[INVESTIGATOR_689], may place the patient at unacceptable risk for study participation . 
4.4. Removal of Patients  from Therapy  
Investigators must clearly distinguish between discontinuation of study drug treatment (avacopan 
or placebo) and withdrawal from the study. Patients  who discontinue study drug treatment or 
who initiate medication changes (including those prohibited by [CONTACT_794144]) will not be automatically withdrawn from the study, but all efforts must be made to continue to follow the patients  for all regularly scheduled visits. 
Investigators must take appropriate measures to make sure that patients  are motivated to comply 
with all requirements of the protocol in order to minimize the amount of missing data. Patients  
who discontinue study treatment early or initiate medication changes (including those prohibited by [CONTACT_760]) should continue to be followed for all regularly scheduled visits for safety and efficacy assessments.  Investigators and their staff must take measures to actively maintain 
contact [CONTACT_794145], such as telephone calls , texts,  or emails between visits, 
and offers for transportation support to visit the study site.  
Patients  may be w ithdrawn from the study for only one of the following two reasons: 
1. Patient  withdrawal of consent to contribute additional outcome information; 
2. Loss to follow-up.  
Patients  may discontinue study drug treatment for any of the following reasons: 
1. Patient  withdraw al of consent ; 
2. The Investigator may discontinue study drug treatment if, in his/her clinical judgment, it 
is in the best interest of the patient ; 
3. The Sponsor may request discontinuation of study drug treatment for safety reasons . If a 
patient develops any of the following lab abnormali ties: 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095088] >3x ULN, additional testing should be performed immediately 
and repeated in one week to assay for total and fractionated serum bilirubin concentration, serum 
albumin concentration, and prothrombin time or INR, in addition to repeat transaminase (ALT, AST) te sting. In addition, i f a patient develops Grade 3 or greater increased hepatic 
transaminases (>5 times the upper limit of normal), or if a patient  develops Grade 2 or greater 
increased transaminases (>3 times the upper limit of normal) with elevation of bilirubin to >[ADDRESS_1095089] be permanently discontinued ( FDA Guidance 2009) if any of the 
following markers of hepatic injury and/or impaired liver synthetic fu nction are observed, and 
cannot be attributed to a reversible etiology unrelated to study medication (e.g., cholelithiasis) : 
• ALT or AST >8x  ULN  
• ALT or AST >5x  ULN for more than 2 weeks 
• ALT or AST >3x  ULN and (Total Bilirubin >2x ULN or INR >1.5) 
• ALT or AST >3x  ULN with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%) 
If a patient develops Grade 3 or greater leukopenia (WBC count <2 x 10
9/L) or neutropenia 
(<1 x 109/L), or Grade 4 lymphopenia (<0.2 x 109/L), then study drug (avacopan or placebo) 
must be paused in this patient. In addition, if a patient develops Grade 2 leukopenia (WBC count 
<3 x 109/L, but ≥ 2 x 109/L), the patient must be followed closely for infection and for further 
significant reduction (reduction by [CONTACT_33018] 0.5 x 109/L or more , or to <2 x 109/L) in WBC 
count; if either occurs, then study drug must be paused in this patient. Study drug may be 
resumed only if the abnormal value returns to normal and the Investigator deems resumption to 
be appropriate. 
If a patient develops Grade 3 or worse CPK increase (>5 times the upper limit of normal), dosing 
with study drug must be paused in this patient. Study drug may be resumed only if the CPK 
returns to normal l evels.  
Patients  who experience deteriorating renal function based on an increase in serum creatinine of 
at least 50% (confirmed by a repeat measurement after at least 2 weeks) which is otherwise not 
explained (e.g., dehydration, new medication), or an increase in proteinuria of > 3 g/g creatinine 
(confirmed by a repeat measurement after at least 2 weeks)  from Screening or baseline during 
the 52- week treatment period, will exit the treatment phase of the study and be treated at the 
discretion of their physici an. The increase of serum creatinine or proteinuria will be calculated 
from the higher value that is measured either at Screening or baseline. They will remain in the 
study for follow up and complete the remaining study visits and procedures. If a patient refuses 
further study participation, the Early Termination visit procedures will be performed, if possible. These patients will be considered treatment failures.  
In the event of early withdrawal from the study , the tests and evaluations listed for the Earl y 
Termination visit in  Section 6.23 will be performed , whenever possible. Data collected at this 
visit will be designated as an “Early Termination” visit in the EDC. The Sponsor should be notified of all study dr ug treatment and study withdrawals in a timely manner.  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 47 of 100  5. STUDY MEDICATION/TREATMENT  
5.1. Product Characteristics  
Avacopan  will be administered orally as hard gelatin capsules containing [ADDRESS_1095090] gelatin capsules 
containing no avacopan  but inactive ingredients. The capsules are manufactured under current 
good manufacturing practices . All doses of study medication will be administered or ally. The 
placebo  capsules will be supplied to the study centers in plastic bottles containing 180 capsules. 
This is sufficient for 30 days of twice daily  dosing. 
5.2. Randomization and Method of Treatment Assignment  
Eligible patients  with biopsy-proven C3G (within 12 weeks prior to signing Informed Consent or 
after consenting during screening or during screening), with or without a renal transplant, will be 
stratified by [CONTACT_794146] C5b-9 and then further stratified based on t wo 
stratification factors ( C3GN or DDD and renal transplant or no renal transplant), and eventually 
randomized to one of the two treatment groups in a ratio of 1 pla cebo: avacopan . 
Randomization will be performed centrally via an interactive response techno logy (IRT)  system 
and minimization algorithm, using the stratification factors . In order to protect the blinding, the 
randomization schedule will not be accessible to study personnel who have contact [CONTACT_794147]. 
5.3. Doses and Regimens 
Treatments for each group are shown in  Table 1. Adult patients  will receive 30 mg avacopan  or 
avacopan -matching placebo  twice daily. For patients  who are 12 to 17 years old, i nitial avacopan  
or avacopan -matching placebo doses will be selected based on body weight and further refined 
based on avacopan  plasma exposure according  to Table 2.  
The treatment period  is 52 weeks ( 364 days), followed by [CONTACT_1629] 8- week (56 days) follow-up period. 
Study drug (avacopan or placebo) within each of the C5b- 9 level strata will be taken as follows 
by [CONTACT_27457] : 
Group A ( placebo ): 
• Three avacopan -matching  placebo capsules in the morning, preferably with food, and three in 
the evening, preferably with food, approximately 12 hours after the morning dose, daily for 26 weeks ( 182 days).  
• This will be followed by [CONTACT_794148], preferably with food, and 
three in the evening, preferably with food, approximately 12 hours after the morning dose, daily for the next 26 weeks (182 days). 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 48 of 100  Group B ( avacopan ): 
• Three 10 mg avacopan  capsules in the morning, preferably with food, and three 10 mg 
avacopan  capsules  in the evening, preferably with food, approximately 12 hours after the 
morning dose, daily for 52 weeks (364 days). 
The placebo capsules will be identical in appearance to the avacopan  capsules . 
Patients  in Group A will receive one bottle of avacopan- matching  placebo  capsules on Day 1 and 
Weeks 4, 8, 12, and 16, and two bottles at the Week 20  visit. These patients  will then receive 2 
bottles of avacopan capsules at the Week  26, 32, 38, and 44 visits . Patients  will be asked to take 
3 capsules every morning , preferably with food, and 3 capsules every evening , preferably with 
food, as instructed. Patients  will be asked to bring all bottles, whether empty or not, to the study 
center at each study visit. Capsules will be taken with water.  
Patients  in Group B will receive one bottle of avacopan capsules on Day 1 and Weeks 4, 8, 12, 
and 16, and two bottles of avacopan capsules at the  Week 20, 26, 32, 38, and 44 visits. Patients  
will be asked to take 3 capsules every morning, preferably with food, and 3 capsules every 
evening , preferably with food, as instructed. Patients will be asked to bring all bottles, whether 
empty or not, to the study center at each study visit. Capsules will be taken with water.  
If a patient misses a dose, the next dose should be taken as soon as possible. If it is close to the time for their next dose (within 3 hours), the missed dose should not be taken and the next dose 
should be taken at the regular time. 
5.4. Rationale for Dose Selection  
Single doses of 1 mg up to 100 mg avacopan  were studied in a Phase 1 study (CL001_168) in 48 
healthy volunteers; once daily doses of 1, 3, and 10 mg avacopan  and twice daily doses of 30 mg 
and 50 mg for up to 7 days were studied in the multiple dose period of this  study. Doses from 
3 mg up to 100 mg twice daily for 7 days were tested in 16 healthy volunteers in Phas e 1 study 
CL007_168; 30 mg single doses and 30 mg twice daily doses were tested for 17 days in 32 
healthy volunteers in Phase 1 study CL008_168. The various avacopan  doses given in these 
studies were found to be safe.  
A dose of 30 mg avacopan twice daily g iven for 12 weeks was studied in clinical trial 
CL002_168 in patients with AAV. This dose regimen was shown to be effective and well 
tolerated in study CL002_168. Doses of 10 mg and 30 mg avacopan  twice daily given for 12 
weeks were studied in clinical trial CL00 3_168 in patients with AAV  and found to be well 
tolerated . Refer to the Investigator’s Brochure for detail s. 
An avacopan dose regimen of 30 mg twice daily w as well tolerated in  a patient with C3G N in a 
“Special Needs ” study (CL009_168) ; this patient  had been dosed continuously from September 
[ADDRESS_1095091] to Follow -up in December 2016. 
A dose of 30 mg avacopan twice daily has been selected for adults in this study, which is lower 
than the maximum dose of 100 mg twic e daily tested  in study CL007_168. Adolescent patients 
may receive a lower starting dose, depending on their body weight ( see Table  2). A dose regimen  
of 30 mg avacopan  twice daily provides steady state trough (C min) a plasma avacopan  
concentration  of approximately 200 ng/mL . This concentration was shown to provide at least 
95% C5aR blockade of blood neutrophils continuously throughout the day ; the blockade level is  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 49 of 100  based on ex vivo C5a-induced CD11b upregulation assays conducted in whole blood samples 
obtained from patients  in Phase 1 clinical trial  CL001_168. This level of C5aR coverage is 
deemed appropriate to achieve optimal pharmacology. 
Based on the favorable safety profile observed in the long- term toxicology studies  (26 weeks in 
rats and 44 weeks in cynomolgus monkeys ; see Investigator’s Brochure), and on the safety and 
tolerability results from the clinical trials conducted to date, [ADDRESS_1095092] in adults in this study. 
5.5. Drug Supply  
5.5.1. Packa ging and Labeling 
Avacopan  capsules containing 10 mg avacopan  and identical appearing placebo capsules will be 
packaged in high density polyethylene (HDPE) bottles with child -resistant screw caps and 
provided to the study sites for dispensing . Each bottle will contain 180 capsules.  
5.5.2. Storage 
Avacopan  and avacopan -matching  placebo capsules will be stored according to label 
instructions. Access should be restricted to pharmacy staff or to the designated responsible member of the Investigator’s staff, and to the study monitor. The Investigator agrees that neither 
s/he nor any of the study staff will supply study medication to any persons other than those 
enrolled in the study. 
5.6. Blinding  
This study is double-blinded . Blinding of the study will be achieved by [CONTACT_70731]:  
1. The blinded study drug bottles and capsule appearance for avacopan  and its matching 
placebo wi ll be identical;  
2. Limited access to the randomization code; Sponsor personnel, study site personnel, study 
patients , personnel responsible for study monitoring, and biostatisticians and data 
managers involved in data analysis of the study will remain blinded to treatment assignment for the duration of the study; 
3. While laboratory personnel conducting the PK assays will not be blinded to treatment assignment, unblinded avacopan  plasma concentration results will not be shared with the 
study site personnel or study staff who have direct contact [CONTACT_596810];  
4. Data that could potentially be unblinding, i.e., UP CR, UACR, and WBC and neutrophil 
count data within the normal range  (i.e., values outside the normal range will be made 
available for safety monitoring) , histology results from the central pathologist analysis , 
and urinary MCP- 1:creatinine ratio  will not be made available to stud y site personnel, 
study patients , personnel responsible for study monitoring, biostatisticians and data 
managers during the study unless required for safety monitoring. Investigators, however, will be provided with safety laboratory data reports, flagging abnormally high and low values in order to make informed decisions regarding patient  care.  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 50 of 100  Treatment assignments for individual patients  will remain blinded to the study team,  
investigators, and patients  until after the study database has been cleaned and locked. Designated 
study staff will be provided with instructions regarding how to unblind an individua l patient 
treatment assignment. An individual patient  treatment assignment may be unblinded only in the 
case of an adverse event that requires knowledge of the study medication received by [CONTACT_794149]. The study monitor 
and Sponsor should be notified as soon as possible in the event that unblinding of an individual patient ’s treat ment assignment occurs prior to study completion. 
An external data monitoring committee (DMC) will be constituted prior to start of the study (see Section  7.6). The DMC members will review data periodically over the course of the study in an 
unblinded manner. The DMC will provide recommendations to the Sponsor regarding further conduct of the study. The DMC will operate according to a charter developed prior to study initiation.  
5.7. Drug Accountability 
The study pharm acist and Investigator must maintain accurate records of dates and quantities of 
product(s) received, to whom dispensed ( patient -by-patient  accounting), and accounts of any 
product accidentally or deliberately destroyed. The Investigator must retain all un used and/or 
expi[INVESTIGATOR_794112]. All remaining study medication will be returned to the central depots for destruction. 
5.8. Treatment Compliance  
The avacopan  and avacopan -matching  placebo capsule s will be self -administered by 
[CONTACT_794150] . The morning dose of blinded study drug on Day 1 will be taken in 
the presence of study site personnel. Patients  will be provided with dosing instructions at the start 
of the study and will be encouraged by [CONTACT_794151] g to the instructions for the duration of the study. Patients  will be instructed to bring the 
assigned bottles of study medication to the site staff at each study visit, whether empty or not. The study drug dispensed will be checked and a capsule count will be done from Week 4 through Week 52 of any remaining avacopan  or placebo capsules. This information will be recorded and 
entered into  the EDC system . 
Avacopan  plasma concentration measu rements over the course of the study may also be used to 
assess patient  compliance. Any events of non-compliance to the protocol will be documented in 
the study records. 
5.9. Concomitant Medications and Restrictions  
In order not to disrupt patient care, the pro tocol will allow initial continuation of treatment with 
glucocorticoids, immunosuppressants, calcineurin inhibitors, or RAAS  inhibitors at the start of 
the study, at the same or lower dose than what was given prior to the study. Treatment with these other drugs may be reduced or stopped during the study if, in the opi[INVESTIGATOR_021], t he patient’s condition justifies  it. Adjustments of tacrolimus and cyclosporine doses 
to ensure these medications are at goal trough levels for maintenance of i mmunosuppression in 
transplant patients will be allowed during the study.  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 51 of 100  With the exception of RAAS inhibitors, dose increases of these concomitant treatments, or 
introduction of new treatments for C3G , will not be allowed during the study period (active 
treatment period) unless the patient ’s condition deteriorates to the extent that the Investigator 
deem s it in the best interest of the patient  to do so. This w ill be considered a treatment failure.  
Eculizumab (and other anti-C5 antibodies) and investigational drugs will not be allowed during 
the study. The rationale for excluding anti-C5 antibodies is that these drugs act on the same branch  of the complement pathway (C5), even though avacopan is selective for the C5aR. 
Therefore, eculizumab  may interfere w ith the safety and efficacy assessment of avacopan. 
Investigational drugs have unknown effects and will therefore be excluded from the study. 
Plasma exchange or infusion during the study will also not be allowed, since these may interfere 
with the efficacy  and safety evaluation of avacopan.  
Drugs that are  strong inducers of the CYP3A4  enzyme, such as carbamazepi[INVESTIGATOR_050], phenobarbital, 
and phenytoin, rifampin, or St. John’s wort are prohibited  during the study because these drugs 
may substantially reduce the plas ma concentrations of avacopan  and reduce its effectiveness. If a 
patient requires one of these drugs, the Medical Monitor needs to be contact[CONTACT_794152].  
Substances that are strong inhibitors of CYP3A4, such as boceprevir, clarithromycin, c onivaptan, 
indinavir, itraconazole, ketoconazole, lopi[INVESTIGATOR_054]/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, and voriconazole, and grapefruit 
juice should be avoided during the study because the se may modestly increase (~2 -fold) the 
plasma concentrations of avacopan . However, these substances are not absolutely 
contraindicated.  In case it is unavoidable that these substances are used concomitantly with 
avacopan , patients  should be monitored carefully for any untoward side effects. 
All concomitant medications taken during the course of the study must be recorded meticulously 
on the concomitant medication pages of the CRF. 
6. STUDY PROCEDURES  
6.1. Screening and Enrollment  
Informed Consent (and Assent , if re levant) must be obtained prior to performance of any study-
specific tests or evaluations. Within a period not t o exceed 42 days prior to randomization, 
patients  will undergo the following evaluations to determine their eligibility for study 
participation: 
• Recording of demographic data and relevant medical history  in the EDC; 
• Recording of all prior medications for C3G for the 12-month period prior to screening in the 
EDC;  
• Recording of all  other prior medications for the  6-month period prior to screening in t he 
EDC ; 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 52 of 100  • Recording of all other concomitant medications on the screening day(s) in the EDC, 
including alcohol intake, recreational drug use, non-prescription medications, herbal preparations or special diets ; 
• A physical examination will be performed; body w eight  and height will be measured ; 
• Vital signs (temperature, sitting blood pressure, heart rate) will be measured after at least [ADDRESS_1095093]; 
• A [ADDRESS_1095094] in  a supi[INVESTIGATOR_2547]; 
• Serum pregnancy test (in women of childbearing potential); 
• Virology assessments as detailed in Section  7.2.2, unless done within 6 weeks prior to 
screening;  
• At least one of the following tests to exclude tuberculosis: interferon γ re lease assay (IGRA), 
tuberculin purified protein derivative ([COMPANY_003]) skin test, or chest radiography (X rays or CT scan); tests performed within 6 weeks prior to screening ar e allowed to assess eligibility ; 
• Serum chemistry and hematology tests (results from te sts done within 72 hours prior to 
screening may be used for eligibility assessment);  
• A clean catch, midstream urine sample will be collected for urinalysis , and urine protein, 
urine albumin and urine creatinine measurement  for UPCR  and UACR ; 
• A renal biopsy will be taken if renal histology has not been performed within 12 weeks prior to screening;  
• Complement profiling as detailed in  Section  7.2.3. Results obtained within [ADDRESS_1095095] for CFHR5 mutation, w ill be acceptable for the study . Also, 
the results from these tests do not need to be available before start of dosing on Day 1, except for the C5b- 9 levels that are needed for eligibility assessment.  
Results from tests that ha ve been performed prior to screening may  be used to determine study 
eligibility if thes e tests were performed as part of the practice of medicine and were done 
whether or not study entry was contemplated, such as for diagnosis or treatment of the patient’s  
condition. Results from the prior tests must be recorded in the EDC. 
After all screening procedures have been completed, and the patient  satisfies all eligibility 
criteria, the study schedule will be discussed with the patient  and the schedule will be pro vided 
to the patient  to ensure compliance with the study visits . 
6.2. Study Day [ADDRESS_1095096] dose of avacopan  or placebo : 
• Stratification and randomization in the I RT system ; 
• A physical examination  including body weight; height will also be measured in 12 to 17 
year-old patients ; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_1095097] ; 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 53 of 100  • A [ADDRESS_1095098] in  a supi[INVESTIGATOR_2547]; 
• Blood samples will be collected for shipment to the central laboratory for serum chemistry, 
hematology, serum pregnancy test (in women of childbearing potentia l), lymphocyte subset 
analysis, and PK  and PD baseline measurements ; 
• A clean catch, midstream urine sample will be collected , aliquoted, and sent to the central 
laboratory for urinalysis (including blood, protein, and nitrites; if positive for blood, protein, or nitrites, a  microscopic assessment for RBC count will be performed), albumin, protein, 
MCP -1, and creatinine measurement (for  UACR, UP CR and MCP -1:creatinine  ratio ), and 
urinary PD markers related to inflamm ation and the complement system; 
• Patients  will be asked to c omplete the SF -36 v2 and EQ-5D- 5L; 
• Any pre -treatment adverse events (from time of the screening visit) will be recorded;  
The patient will be stratified and randomized, and  the following procedures will be performed: 
• Blinded study medication (1 bottle  of avacopan  or avacopan -matching  placebo ) will be 
provided to the patient  with dosing instructions (see Section  5.3); 
• The patient  will be asked to take the first dose of blinded study medication while at the study 
center;  
• The time of the dosing of avacopan  or avacopan -matching  placebo  will be recorded;  
• If the patient is [ADDRESS_1095099] dose of avacopan  or avacopan -matching placebo ; plasma 
samples will be frozen and sent to the central laboratory for expeditious measurement of 
avacopan  and metabolite plasma concentration s. Precise dosing and sampling times need to 
be recorded;  
• Any changes in concomitant medication use will be  recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any post-dosing adverse events will be recorded; 
• After all study procedures have been completed, the patient  will be reminded to : 
− Come to the study center for the Week 1  study visit;  
− Store the blinded study medications  in a cool and dry place according to label instructions 
for the duration of the study;  
− Take the avacopan  or avacopan -matching  placebo , as instructed , and 
− Continue t aking all their other c oncomitant medications as usual. 
6.3. Study Week 1  (Day 8)  
The Study Week [ADDRESS_1095100] occur within ± 2 day s of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination  including body weight; height will also be measured in 12 to 17 
year-old patients ; 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 54 of 100  • Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_1095101] ; 
• A [ADDRESS_1095102] in  a supi[INVESTIGATOR_2547]; 
• Bloo d samples will be collected for shipment to the central laboratory  for hematology,  
lymphocyte subset analysis, and  for PK  and PD measurements. Record the date and time of 
blood draw; 
• The date and time of the last dose of avacopan / avacopan -matching placebo  prior to 
collection of the PK sample will be recorded;   
• If the patient has not yet taken the morning dose of avacopan /placebo for this day, the patient 
will be asked to take the dose; 
• A clean catch, midstream urine sample will be collected  for urinalysis,  for PD assessment, 
and for urine protein, urine albumin, urinary MCP-1 and urine creatinine measurement for 
calculation of UPCR, UACR and urinary MCP- 1:creatinine  ratio; the sample will be  sent to 
the central laboratory ; 
• The bottle of blinded study medica tion will be checked to make sure the patient is taking the 
blinded study medication as instructed; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets ; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient  will be reminded to: 
− Come to the study center for the Week 2 study visit;  
− Store the blinded study medications  in a cool and dry place acco rding to label instructions 
for the duration of the study; 
− Take the avacopan  or avacopan -matching placebo as instructed , and 
− Continue taking all their other c oncomitant medications as usual.  
6.4. Study Week 2  (Day 15)  
The Study Week [ADDRESS_1095103] occur within ± 2 day s of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination  including body weight ; height will also be measured in 12  to 17 
year-old patients ; 
• Vital signs (temperature, sitting blood pressure, heart rate)  after at least [ADDRESS_1095104] ; 
• Blood samples will be collected for shipment to the central laboratory for serum chemistry , 
hematology, lymphocyte subset analysis, and for PK  and PD measurements. Record the date 
and time of blood draw; 
• The date and time of the last dose of avacopan / avacopan -matching placebo prior to 
collection of the PK sample will be recorded;  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 55 of 100  • If the patient  has not yet taken the morning dose of avacopan / avacopan -matching  placebo 
for this day, the patient  will be asked to ta ke the dose;  
• A clean catch, midstream urine sample will be collected  for urinalysis, for PD assessment, 
and for urine protein, urine albumin, urinary MCP-1 and urine creatinine measurement for 
calculation of UPCR, UACR and urinary MCP- 1:creatinine ratio; the sample will be sent to 
the central laboratory;  
• The bottle of blinded study medication will be checked to make sure the patient is taking the 
blinded study medication as instructed; 
• Any changes in concomitant medication use will be recorded , including al cohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special  diets ; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient  will be reminded to: 
− Come to the study center for the Week 4 study visit;  
− Store the blinded study medications  in a cool and dry place according to label instructions 
for the duration of the study; 
− Take the avacopan  or avacopan -matching  placebo as instructed , and 
− Continue taking all their other c oncomitant med ications as usual. 
6.5. Study Week  4 (Day 29)  
The Study Week [ADDRESS_1095105] occur within ± 2 day s of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination  including body weight ; height will also be measure d in 12 to 17 
year-old patients ; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_1095106] ; 
• Blood samples will be collected for shipment to the central laboratory for serum chemistry, 
hematology, serum pregnancy test (i n women of childbearing potential), lymphocyte subset 
analysis, and PK and PD measurements . Record the date and time of blood draw; 
• The date and time of the last dose of avacopan / avacopan -matching placebo prior to 
collection of the PK sample will be recor ded; 
• If the patient  has not yet taken the morning dose of avacopan /avacopan -matching placebo for 
this day, the patient  will be asked to take the dose; 
• A clean catch, midstream urine sample will be collected  for urinalysis, for PD assessment, 
and for urine protein, urine albumin, urinary MCP-1 and urine creatinine measurement for 
calculation of UPCR, UACR and urinary MCP- 1:creatinine ratio; the sample will be sent to 
the central laboratory ; 
• Patients  will be asked to complete the SF -36 v2 and EQ-5D- 5L; 
• Drug a ccountability will be performed on the returned avacopan /placebo bott le; 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 56 of 100  • A new bottle of avacopan /avacopan -matching placebo will be dispensed; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient  will be reminded to: 
− Come to the study center for the Week 8 study visit;  
− Store the blinded stu dy medications  in a cool and dry place according to label instructions 
for the duration of the study; 
− Take the avacopan  or avacopan -matchi ng placebo as instructed , and 
− Continue taking all their other concomitant medications as usual. 
6.6. Study Week 8 (Day 57) 
The Study Week [ADDRESS_1095107] occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight ; height will also be measured in 12  to 17 
year-old patients ; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_1095108] ; 
• Blood samples will be collected for shipment to the central laboratory for serum chemistry, 
hematology, and serum pregnancy test (in women of childbearing potential). R ecord the date 
and time of blood draw; 
• If the patient  has not yet taken the morning dose of avacopan /avacopan -matching placebo for 
this day, the patient  will be asked to take the dose; 
• A clean catch, midstream urine sample will be collected  for urinalysis  and for urine protein, 
urine albumin, and urine creatinine measurement for calculation of UPCR and UACR; the sample will be sent to the central laboratory ; 
• Drug accountability will be performed on the returned avacopan /avacopan -matching placebo 
bottle ; 
• A new bottle of avacopan /placebo will be dispensed; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient  will be reminded to: 
− Come to the study center for the Week 1 2 study visit;  
− Store the blinded study medications  in a cool and dry place according to label instructions 
for the duration of t he study;  
− Take the avacopan  or avacopan -matching placebo as instructed , and 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 57 of 100  − Continue taking all their other concomitant medications as usual. 
6.7. Study Week 1 2 (Day 85) 
The Study Week [ADDRESS_1095109] occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; height will also be measured in 12 to 17 
year-old patients ; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_1095110] ; 
• Blood samples will be collected for shipment to the central laboratory for a serum pregnancy 
test (in women of childbearing potential), serum chemistry, hematology, lymphocyte subset analysis, and PK and PD measurements . Record the date and time of blood dr aw; 
• The date and time of the last dose of avacopan / avacopan -matching placebo prior to 
collection of the PK sample will be recorded;  
• If the patient  has not yet taken the morning dose of avacopan / avacopan -matching  placebo 
for this day, the patient  will be asked to take the dose;  
• A clean catch, midstream urine sample will be collected  for urinalysis, for PD assessment, 
and for urine protein, urine albumin, urinary MCP-1 and urine creatinine measurement for 
calculation of UPCR, UACR and urinary MCP- 1:creatini ne ratio; the sample will be sent to 
the central laboratory ; 
• Patients  will be asked to complete the SF -36 v2 and EQ-5D- 5L; 
• Drug accountability will be performed on the returned avacopan / avacopan -matching placebo 
bottle ; 
• A new bottle of avacopan / avacopan -matching placebo will be dispensed; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient  will be reminded to: 
− Come to the study center for the Week 16 study visit;  
− Store the blinded study medications  in a cool and dry place according to label instructions 
for the duration of the study; 
− Take the avacopan / avacopan- matching  placebo  as instructed, and 
− Continue taking all their other concomitant medications as usual. 
6.8. Study Week 16 (Day 113)  
The Study Week [ADDRESS_1095111] occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 58 of 100  • A physical examination including body weight ; height will also be measured in 12  to 17 
year-old patients ; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_1095112] ; 
• Blood samples wil l be collected for shipment to the central laboratory for serum chemistry, 
hematology, and serum pregnancy test (in women of childbearing potential) . Record the date 
and time of blood draw; 
• If the patient  has not yet taken the morning dose of avacopan / avacopan -matching  placebo 
for this day, the patient  will be asked to take the dose;  
• A clean catch, midstream urine sample will be collected  for urinalysis and for urine protein, 
urine albumin, and urine creatinine measurement for calculation of UPCR and  UACR;  the 
sample will be sent to the central laboratory ; 
• Drug accountability will be performed on the returned avacopan / avacopan -matching placebo 
bottle ; 
• One new bottle of avacopan / avacopan -matching placebo will be dispensed; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the patient  will be reminde d to: 
− Come to the study center for the Week 20 study visit;  
− Store the blinded study medications  in a cool and dry place according to label instructions 
for the duration of the study; 
− Take the avacopan / avacopan- matching  placebo  as instructed, and 
− Continue taking all their other c oncomitant medications as usual. 
6.9. Study Week 20 (Day 141)  
The Study Week [ADDRESS_1095113] occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including  body weight; height will also be measured in 12 to 17 
year-old patients ; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_1095114] ; 
• Blood samples will be collected for shipment to the central laboratory for a serum pre gnancy 
test (in women of childbearing potential), serum chemistry, hematology, and PK and PD 
measurements . Record the date and time of blood draw; 
• The date and time of the last dose of avacopan/ avacopan -matching placebo prior to 
collection of the PK sampl e will be recorded;  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 59 of 100  • If the patient  has not yet taken the morning dose of avacopan / avacopan -matching  placebo 
for this day, the patient  will be asked to take the dose;  
• A clean catch, midstream urine sample will be collected  for urinalysis, for PD assessment , 
and for urine protein, urine albumin, urinary MCP-1 and urine creatinine measurement for 
calculation of UPCR, UACR and urinary MCP- 1:creatinine ratio; the sample will be sent to 
the central laboratory ; 
• Patients  will be asked to complete the SF -36 v2 and EQ -5D- 5L; 
• Drug accountability will be performed on the returned avacopan/ avacopan -matching placebo 
bottle; 
• Two new bottles of avacopan/ avacopan -matching placebo will be dispensed; 
• Any changes in concomitant medication use will be recorded , including alco hol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded ; 
• After all study procedures have been completed, the patient  will be reminded to: 
• Come to the study center for the We ek 23 study visit;  
− Store the blinded study medication  in a cool and dry place according to label instructions 
for the duration of the study; 
− Take the avacopan/avacopan -matching  placebo  as instructed, and 
− Remember not to take the morning dose of avacopan or /avacopan -matching placebo at 
home on the morning of the next visit at the study center, and 
− Continue taking all their other concomitant medications as usual. 
6.10. Study Week 23 (Day 162)  
The Study Week [ADDRESS_1095115] occur within ± 7 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A blood sample will be collected for measurement of serum chemistry and hematology. 
Record the date and time of blood draw. 
• Any changes in concomitant medication use will be recorded, i ncluding alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or changes to a 
special diet ; 
• Any adverse events will be recorded ; 
• After all study procedures have been completed, the patient will be reminded to: 
− Come to th e study center for the Week 26 study visit 
− Take the avacopan/ avacopan -matching placebo as instructed, and 
− Remember not to take the morning dose of avacopan or avacopan- matching placebo at 
home on the morning of the next visit at the study center, and 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 60 of 100  − Continue taking all their other concomitant medications as usual. 
6.11. Study Week 26  (Day 183)  
The Study Week [ADDRESS_1095116] occur within ± 7 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; height will also be measured in 12 to 17 
year-old patients ; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_1095117] ; 
• A [ADDRESS_1095118] in a supi[INVESTIGATOR_92627]; 
• Blood samples will be collected before the morning dose for shipment to the central laboratory for a serum pregnancy test (in women of childbearing potential), serum chemistry, 
hematol ogy, lymphocyte subset analysis, and P K and PD measurements . Record the date and 
time of blood draw; 
• The date and time of the last dose of avacopan/ avacopan -matching  placebo prior to 
collection of the PK sample will be recorded;  
• The patient  will be asked to take the morning dose of avacopan  while at the study center;  
• The time of the dosing of avacopan  will be recorded;  
• If the patient  is 12 to 17 years old, blood samples will be taken before dosing and at Hour 
0.5, 1, 2, 3, 4, and 6 after the morning dose of avacopan; plasma samples will be frozen and 
sent to the central laboratory for expeditious measurement of avacopan and metabolite 
plasma concentrations . Note: it is important that on Day 183 the adolescent patients take the 
dose when instructed at the study center, NOT at home, and they should be reminded through 
a telephone call two days before the Day 183 visit. 
• A clean catch, midstream urine sample will be collected  for urinalysis, for PD assessment, 
and for urine protein, urine albumin, urinary MCP-1 and urine creatinine measurement for calculation of UPCR, UACR and urinary MCP- 1:creatinine ratio; the sample will be sent to 
the central laboratory ; 
• Renal biopsy, performed within  -2 weeks prior to  the Week 26 visit and BEFORE patient  is 
started on open- label treatment; 
• Patients  will be asked to complete the SF -36 v2 and EQ -5D- 5L; 
• Drug accountability will be performed on the returned avacopan/ avacopan -matching  placebo 
bottles;  
• Two new bottles of avacopan will be dispensed; 
• For adolescents , two new bottles of avacopan will be provided to the patient  with dosing 
instructions according to body weight (see Section  5.3); 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets ; 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 61 of 100  • Any adverse events will be recorded ;  
• After all study procedures have been completed, the patient  will be reminded to: 
− Come to the study center for the Week 28 study visit;  
− Store the study medication  in a cool and dry place according to label instructions for the 
duration of the study;  
− Take the avacopan  as instructed, and 
− Continue taking all their other concomitant medications as usual. 
6.12. Study Week 28  (Day 197)  
The Study Week [ADDRESS_1095119] occur within ± 2 days of the scheduled date. During thi s visit, the 
following study procedures will be performed: 
• A physical examination including body weight; height will also be measured in 12 to 17 
year-old patients ; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_1095120]; 
• A [ADDRESS_1095121] in a supi[INVESTIGATOR_2547];  
• Blood samples will be collected for shipment to the central laboratory for a serum pregnancy 
test (in women of childbearing potential), serum chemistry, hematology, and PK and PD 
measurements . Record the date and time of blood draw; 
• If the patient  has not yet taken the morning dose of avacopan  for this day, the patient  will be 
asked to take the dose; 
• The date and time of the last dosing of avacopan  prior to the colle ction of the PK sample will 
be recorded ; 
• A clean catch, midstream urine sample will be collected  for urinalysis, for PD assessment, 
and for urine protein, urine albumin, urinary MCP-1 and urine creatinine measurement for calculation of UPCR, UACR and urina ry MCP -1:creatinine ratio; the sample will be sent to 
the central laboratory;  
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets;  
• Any adverse events will be recorded;  
• The dose for this visit and doses forward for adolescent patients may be adjusted based on the PK result of Day 183, per directions from the Sponsor; 
• After all study procedures have been completed, the patient  will be re minded to: 
− Come to the study center for the Week 32  study visit;  
− Store the study medication  in a cool and dry place according to label instructions for the 
duration of the study;  
− Take the avacopan  as instructed, and 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 62 of 100  − Continue taking all their other concomitant medications as usual. 
6.13. Study Week 32 (Day 225 ) 
The Study Week [ADDRESS_1095122] occur within ± 7 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; height will also  be measured in 12 to 17 year 
old patients ; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_1095123] ; 
• A [ADDRESS_1095124] in a supi[INVESTIGATOR_2547] ; 
• Blood samples will be collected for shipment to the central laboratory for a serum pregnancy 
test (in women of childbearing potential), serum chemistry, hematology, and PK and PD 
measurements . Record the date and time of blood draw; 
• If the patient  has not yet taken the morning dose of avacopan  for this day, the patient  will be 
asked to take the dose; 
• The date and time of the last dose of avacopan  prior to collection of the PK sample will be 
recorded;  
• A clean catch, midstream urine sample will be collected  for urinalysis, for PD assessm ent, 
and for urine protein, urine albumin, urinary MCP-1 and urine creatinine measurement for 
calculation of UPCR, UACR and urinary MCP- 1:creatinine ratio; the sample will be sent to 
the central laboratory ; 
• Patients  will be asked to complete the SF -36 v2 and EQ-5D- 5L; 
• Drug accountability will be performed on the returned avacopan bottles; 
• Two new bottles of avacopan will be dispensed; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescriptio n medications, herbal preparations or special diets; 
• Any adverse events will be recorded ; 
• After all study procedures have been completed, the patient  will be reminded to: 
− Come to the study center for the Week 3 5 study visit;  
− Store the study medication  in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the avacopan  as instructed, and 
− Continue taking all their other concomitant medications as usual. 
6.14. Study Week 35 (Day 246)  
The Study Week [ADDRESS_1095125] occur within ± 7 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 63 of 100  • A blood sample will be collected for measurement of serum chemistry  and hematology . 
Record  the date and time of blood draw.  
• Any changes in concomitant medicati on use will be recorded, including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or changes to a 
special diet;  
• Any adverse events will be recorded ; 
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week 38 study visit  
− Take the avacopan/ avacopan -matching placebo as instructed, and 
− Remember not to take the morning dose of avacopan or avacopan- matching placebo at 
home on the morning of the next visit at the study center, and  
− Continue taking all their other concomitant medications as usual. 
6.15. Study Week 38 (Day 267) 
The Study Week [ADDRESS_1095126] occur within ± 7 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; height will also be measured in 12 to 17 year 
old patients ; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_1095127] ; 
• Blood samples will be collected for shipment to the cen tral laboratory for a serum pregnancy 
test (in women of childbearing potential), serum chemistry, hemat ology, lymphocyte subset 
analysis, and PK and PD measurements . Record the date and time of blood draw; 
• If the patient  has not yet taken the morning dose of avacopan  for this day, the patient  will be 
asked to take the dose; 
• The date and time of the last dose of avacopan prior to collection of the PK sample will be 
recorded;  
• A clean catch, midstream urine sample will be collected  for urinalysis, for PD asses sment, 
and for urine protein, urine albumin, urinary MCP-1 and urine creatinine measurement for calculation of UPCR, UACR and urinary MCP- 1:creatinine ratio; the sample will be sent to 
the central laboratory ; 
• Patients  will be asked to complete the SF -36 v2 and EQ-5D- 5L; 
• Drug accountability will be performed on the returned avacopan bottles; 
• Two new bottles of avacopan will be dispensed; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescript ion medications, herbal preparations or special diets; 
• Any adverse events will be recorded ;  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 64 of 100  • After all study procedures have been completed, the patient  will be reminded to: 
− Come to the study center for the Week 4 1 study visit;  
− Store the study medication  in a cool and dry place according to label instructions for the 
duration of the study;  
− Take the avacopan  as instructed, and  
− Continue taking all their other concomitant medications as usual. 
6.16. Study Week 41  (Day 288) 
The Study Week [ADDRESS_1095128] occur within  ± 7 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A blood sample will be collected for measurement of serum chemistry  and hematology . 
Record the date and time of blood draw. 
• Any changes in concomitant med ication use will be recorded, including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or changes to a 
special diet;  
• Any adverse events will be recorded ; 
• After all study procedures have been completed, the patient will be reminded to: 
− Come to the study center for the Week 44 study visit  
− Take the avacopan as instructed, and  
− Remember not to take the morning dose of avacopan at home on the morning of the next 
visit at the study center, and  
− Continue taking all their oth er concomitant medications as usual. 
6.17. Study Week 44 (Day 309) 
The Study Week [ADDRESS_1095129] occur within ± 7 days of the scheduled date. During this visit, the following study procedures will be performed: 
• A physical examination including body weight; height will also be measured in 12 to 
17 year-old patients ; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_1095130] ; 
• Blood samples will be collected for shipment to the central laboratory for a serum pregnancy 
test (in wome n of childbearing potential), serum chemistry, and hematology . Record the date 
and time of blood draw; 
• If the patient  has not yet taken the morning dose of avacopan  for this day, the patient  will be 
asked to take the dose; 
• The date and time of the last dos e of avacopan prior to collection of the PK sample will be 
recorded;  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 65 of 100  • A clean catch, midstream urine sample will be collected  for urinalysis  and for urine protein, 
urine albumin, and urine creatinine measurement for calculation of UPCR and UACR; the 
sample will be sent to the central laboratory ; 
• Drug accountability will be performed on the returned avacopan bottles; 
• Two new bottles of avacopan will be dispensed; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non-prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded ;  
• After all study procedures have been completed, the patient  will be reminded to: 
− Come to the study center for the Week 48 study visit;  
− Store the study medication  in a cool and dry place according to label instructions for the 
duration of the study;  
− Take the avacopan  as instructed  
− Continue taking all their other concomitant medications as usual. 
6.18. Study Week 48 (Day 337)  
The Study Week [ADDRESS_1095131] occur within ± 7 days of the scheduled date. During this visit, the following study procedures will be performed: 
• A blood sample will be collected for measurement of serum chemistry  and hematology . 
Record the date and time of blood draw . 
• Any changes  in concomitant medication use will be recorded, including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or changes to a 
special diet;  
• Any adverse events will be recorded ; 
• After all study procedures have been completed, the patient will be reminded to: − Come to the study center for the Week 52 study visit  
− NOT  take any study medication the morning of the Week 52 visit 
6.19. Study Week 52  (Day 365)  
The Study Week [ADDRESS_1095132] occur within ± [ADDRESS_1095133] telephone the patient (this applies to both adults and 
adolescents) to remind him or her to NOT take any avacopan in the morning of this visit. The dose will also NOT be taken at the study center on this day. During this visit, the following  study 
procedures will be performed: 
• A physical examination including body weight; height will also be measured in 12 to 
17 year-old patients ; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at  least [ADDRESS_1095134]; 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 66 of 100  • A [ADDRESS_1095135] in a supi[INVESTIGATOR_2547] ; 
• Blood samples will be collected for shipment to the central laboratory for a serum pregnancy 
test (in women of childbearing potential), serum c hemistry, hematology, lymphocyte subset 
analysis, and PK and PD measurements . Record the date and time of blood draw; 
• The date and time of the last dose of avacopan prior to collection of the PK sample will be 
recorded;  
• A clean catch, midstream urine sample will be collected  for urinalysis, for PD assessment, 
and for urine protein, urine albumin, urinary MCP-1 and urine creatinine measurement for calculation of UPCR, UACR and urinary MCP- 1:creatinine ratio; the sample will be sent to 
the central laboratory ; 
• Renal biopsy, performed within  ± 2 weeks of the Week 52 visit; this procedure is optional for 
adolescent patients ; 
• Patients  will be asked to complete the SF -36 v2 and EQ-5D- 5L; 
• Drug accountability will be performed on the returned avacopan bottles; 
• Any ch anges in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded ;  
• After all study procedures have been completed, the patient  will be reminded to: 
− Come to the study center for the Week 54 study visit, and 
− Continue taking all their other concomitant medications as usual. 
6.20. Study Week 54 (Day 379)  
The Study Week [ADDRESS_1095136] occur within ± 7 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; height will also be measured in 12 to 17 
year-old patients ; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_1095137]; 
• A [ADDRESS_1095138] in a supi[INVESTIGATOR_2547];  
• Blood samples will be collected for shipment to the central laboratory for a serum pregnancy 
test (in women of childbearing potential), serum chemistry, hematology, and PK and PD measurements. Record the date and time of blood draw; 
• A clean catch, midstream urine sample will be collected  for urinalysis and for urine protein, 
urine albumin, and urine creatinine measurement for calculation of UPCR and UACR; t he 
sample will be sent to the central laboratory ; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 67 of 100  • Any adverse events will be recorded ; 
• After all study procedures have been completed, the patient  will be reminded to: 
− Come to the study center for the Week 57 study visit, and 
− Continue taking all their other concomitant medications as usual. 
6.21. Study Week 57 (Day 400)  
The Study Week [ADDRESS_1095139] occur within ± 7 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; height will also be measured in 12 to 17 
year-old patients ; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_1095140] ; 
• A [ADDRESS_1095141] in a supi[INVESTIGATOR_2547];  
• Blood samples will be collected for shipment to the central laboratory for a serum pregnancy 
test ( in women of childbearing potential), serum chemistry, hematology, and PK and PD 
measurements. Record the date and time of blood draw; 
• A clean catch, midstream urine sample will be collected  for urinalysis and for urine protein, 
urine albumin, and urine creatinine measurement for calculation of UPCR and UACR; the sample will be sent to the central laboratory ; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal prepa rations or special diets ; 
• Any adverse events will be recorded ; 
• After all study procedures have been completed, the patient  will be reminded to: 
− Come to the study center for the Week 60 study visit, and 
− Continue taking all their other c oncomitant medication s as usual.  
6.22. Study Week 60 (Day 421 ) 
The Study Week 60 visit (follow -up visit) must occur within ± 7 days of the scheduled date. 
During this visit, the following  study procedures will be performed: 
• A physical examination including body weight; height will a lso be measured in 12 to 17 
year-old patients ; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_1095142] ; 
• A [ADDRESS_1095143] in a supi[INVESTIGATOR_2547] ; 
• Blood samples will be collected for shipment to the central laboratory for a serum pregnancy 
test (in women of childbearing potential), serum chemistry, hematology, lymphocyte subset analysis, and PK and PD measurements . Record the date and time of blood draw; 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 68 of 100  • A clean catch, midstream urine sample will be collected  for urinalysis, for PD assessment, 
and for urine protein, urine albumin, urinary MCP-1 and urine creatinine measurement for 
calculation of UPCR, UACR and urinary MCP- 1:creatinine ratio; the sample will be sent to 
the central laboratory ; 
• Patients  will be asked to complete the SF -36 v2 and EQ-5D- 5L; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded ; 
• After all study procedures have been completed, the patient  will be discharged from the 
study. The patient ’s condition will be evaluated by [CONTACT_794142] ( Week 60) and appropriate standard of care medical treatment will be provided to all 
patients  as needed.  
6.23. Early Termination Visit  
If a patient is  withdrawn early from the study, the following termination procedures must be 
completed whenever possible: 
• A physical examination  including body weight ; height will also be measured in 12  to 17 
year-old patients ; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_1095144] ; 
• A [ADDRESS_1095145] in a supi[INVESTIGATOR_2547] ; 
• Blood samples will be collected for shipment to the central laboratory for serum chemistry, 
hematology, lymphocyte subset analysis and serum pregnancy test (in women of ch ildbearing 
potential) measuremen t. Record the date and time of blood draw; 
• A clean catch, midstream urine sample will be collected  for urinalysis at the central 
laboratory; 
• Drug accountability will be performed on the returned avacopan /avacopan -matching placebo 
bottles;  
• Any changes in concomitant medication use will be recorded , including al cohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded.  If an adverse event remains unresolved at the 
conclusion of the study, a clinical assessment will be made by [CONTACT_941] I nvestigator and the 
Sponsor’s Medical Monitor to determine whether continued follow-up of the adverse event is 
warranted.  
• A follow-up renal biopsy will be performed if a patient is withdrawn early from the study. 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095146]’s evaluation. 
Patients  must have biopsy- proven C3G, either DDD or C3GN, with ≥2- levels of magnitude 
greater staining of C3 than any combinatio n of IgG, IgM, IgA, kappa and lambda light chains, 
and C1q, and with evidence of proliferative glomerulonephritis (mesangial hypercellularity and/or endocapi[INVESTIGATOR_567464]). 
All renal biopsies will be analyzed with the routine panel of stains which includes hematoxylin -
eosin (H&E), periodic acid–Schiff (PAS), trichrome, and Jones methenamine silver. A minimum 
of 4 (preferably 6) unstained slides from paraffin-embedded renal tissue will be provided by 
[CONTACT_794132] (e.g., CD45, 
CD68, MPO, C5a, C5aR, etc.). 
Renal biopsies will be evaluated by a central reader, an expert in C3G renal pathology, who will 
be blinded to treatment assignment from either slides or digitized high -resolutio n images.  
The central reader will determine the degree of disease activity and chronicity based on the C3G Histologic Index. A semi- quantitative scale of 0 to 3 will be used, indicating either the 
proportion (%) of glomeruli involved or the proportion of cortex involved (for tubular atrophy and interstitial fibrosis).  
The C3G Histologic Index for disease activity will consider 7 lesions: 
1. Mesangial hypercellularity, defined as >3 mesangial cells per mesangial area; 
2. Endocapi[INVESTIGATOR_567464]/proliferation , defined as an increased number of cells 
within glomerular capi[INVESTIGATOR_794101], causing luminal narrowing;  
3. Membranoproliferative morphology ; 
4. Leukocyte infiltration;  
5. Crescent formation, defined as extracapi[INVESTIGATOR_794113] >50% of the lesion occupi[INVESTIGATOR_794103]; 
6. Fibrinoid necrosis; 
7. Interstitial inflammation . 
Definitions are based on the Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN (Sethi et al ., 2016)  and the activity 
index score uses the glomerulopathy histologic score as described by [CONTACT_794153] (Bomback et al ., 2018).  
For endocapi[INVESTIGATOR_567464]/proliferation, mesangial hypercellularity, membranoproliferative morphology, and leukocyte infiltration the following scale will be used: 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 70 of 100  0 = none, 1 = 1-25%, 2 = 26-50%, 3 = >50% involvement. For crescent formation and fibrinoid 
necrosis, the following scale will be used: 0 = none, 1 = 1-10%, 2 = 11-25%, and 3 = >25% 
involvement. For interstit ial inflammation, a score according to percentage of cortical 
tubulointerstitial area involved will be used: 0 = <10%, 1 = 10-25%, 2 = 26-50%, 3 = >50% involvement. 
The C3G Histologic  Index for disease activity can assume a score from 0 -21. 
The C3G Histologic Index for disease chronicity will consider 4 lesions ( Bomback et al ., 2018) : 
1. Glomerulosclerosis (% glomeruli with global and segmental sclerosis),  
2. Tubular atrophy, 
3. Interstitial fibrosis , and 
4. Arterio - and arteriolosclerosis  
Glomerulosclerosis (global plus segmental), tubular atrophy, and interstitial fibrosis will be 
assigned a score of 0 to 3 based on the percentage of glomeruli or cortical tubulointerstitial area 
involved. The following scale will be used for the chronicity index: 0 = <10%, 1 = 10-25%, 
2 = 26-50%, 3 = >50% involvement. For vascular disease, a score of 0 will be  assigned if intimal 
thickening is  < thickness of media and 1 if intimal thickening is  ≥ thickness of media. The C3G 
Histologic  Index for disease chronicity can assume a score from [ADDRESS_1095147] of avacopan on specific immune cell populations such as total leukocytes, macrophages, neutrophils , etc. 
7.1.2. Urinary Measurements  
A clean catch midstream urine sample needs to be collected at the clinic according to instructions provided separately. T he urine samples will be sent to the central laboratory for analysis. The 
following analyses will be performed according to the  Time and Events Table : 
• Urinalysis including blood, protein, and nitrites; if positive for blood, protein, or nitrites, a microscopic assessment for RBC casts and RBC count will be performed; 
• Quantitative albumin, protein and creatinine measurements to calculate the urinary 
albumin:creatinine ratio (UACR) and protein:c reatinine ratio  (UPCR ); 
• Quantitative MCP -1 measurements to calculate the MCP -1:creatinine ratio; 
• Other urinary markers related to inflammation and the complement system may also be 
measured . 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095148] is pos itive for blood, nitrite , or protein. 
When microscopy is performed, hematuria will be categorized as follows: None, Occasional 
(Occ), 1 - 2, 3 - 5, 6 - 9, 10 - 15, 16 - 29, 30 - 49, 50 - 75, and >75 RBCs per high power field.  
Proteinuria will be assessed by [CONTACT_794154]. Results will be expressed as mg protein/g creatinine.  
Albuminuria will be assessed by [CONTACT_794155]. Results will be expressed as mg albumin/g creatinine.  
Urine MCP -1 will be measured by [CONTACT_794156] . Urine MCP -1 levels will be 
standardized to urine creatinine and expressed as pg MCP- 1/mg creatinine.  
Other inflammation and complement markers will be measured using validated assay 
methodology. 
7.1.3. Estimated Glomerular Filtration Rate  
For adults (aged 18 years or older), e stimated glomerular filtration rate (eGFR) will be calculated 
from serum creatinine measurements at all app licable study visits using the Chronic Kidney 
Disease-Epi[INVESTIGATOR_794114] (CKD- EPI) equation according to Table 3 ( Levey et 
al., 2009).  
Table 3: CKD -EPI [INVESTIGATOR_794115], 
µmol/L (mg/dL)  Equation  
Black    
Female  ≤62 (≤0.7)  GFR = 166 x (serum creatinine/0.7)-0.329 x (0.993)Age 
 >62 (>0.7) GFR = 166 x (serum creatinine /0.7)-1.209 x (0.993)Age 
Male  ≤80 (≤0.9)  GFR = 163 x (serum creatinine /0.9)-0.411 x (0.993)Age 
 >80 (>0.9)  GFR = 163 x (serum creatinine /0.9)-1.209 x (0.993)Age 
White or Other    
Female  ≤62 (≤0.7)  GFR = 144 x (serum creatinine /0.7)-0.329 x (0.993)Age 
 >62 (>0.7) GFR = 144 x (serum creatinine /0.7)-1.209 x (0.993)Age 
Male  ≤80 (≤0.9)  GFR =  141 x (serum creatinine /0.9)-0.411 x (0.993)Age 
 >80 (>0.9)  GFR = 141 x (serum creatinine /0.9)-1.209 x (0.993)Age 
Source: Levey et al ., 2009  
The CKD -EPI [INVESTIGATOR_794116] ( Selistre et al ., 
2016). The modified Schwartz equation has been developed to calculate the eGFR in children 
(Schwartz  et al ., 2009). The equation is as follows: 
eGFR = (0.413 x Height [in cm]) / Serum creatinine (in mg/dL) 
The revised Schwartz equation will be used to calculate eGFR in ado lescents (12 to 17 years old) 
enrolled in this study. 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 72 of 100  Serum creatinine (and eGFR) measurements will be made according to  the Time and Events 
Table. Change and percent change from baseline in eGFR will be calculated and will be assessed 
as a secondary endpo int in the study.  
7.1.4. Health -Related Quality of Life Assessments  
The SF -36 v2 and EQ -5D-5L will be completed by [CONTACT_794157] -related quality of life. Proven 
translations will be used for non-English speaking patients  whe never possible. An administrator 
will facilitate completion of the questionnaires by [CONTACT_13935], but will not complete the forms 
for the patients. The administrator will establish a rapport with the patient, emphasize the 
importance of completing the form, and serve to answer questions and address concerns. The questionnaires should be completed by [CONTACT_794158]. 
7.2. Safety Assessments  
7.2.1. Physical Examinations, Vital Sig ns and 12- lead ECGs 
A complete physical examination (including evaluation of general appearance/mental status, head, eyes, ears, nose, throat, and the following body systems: dermatologic, cardiovascular, respi[INVESTIGATOR_696], gastrointestinal, musculoskeletal and neurologic) will be performed at visits indicated in the Ti me and Events Table. Findings must be recorded in the source documents. 
Any new or worsening findings upon physical examination need to be recorded as adverse events.  
Body weight will be measured as part of the physical examinations. Height needs to be recorded at screening only , except for adolescents (12  to 17 years  old) in whom height will also be 
included as part of all physical examinations. BMI will be calculated in the EDC from the body weigh t and height measurements.  
Vital signs will be measured during s creening and on each scheduled study day as indicated in 
the Time and Events Table. Sitting b lood pressure, pulse rate, and body temperature will be 
measured. All vital signs assessments will be performed after the patient  has rested for at least 
three minutes.  
12-lead EC Gs will be performed  at visits indicated in  the Ti me and Events Table . Findings must 
be recorded in the source documents. The ECG will be performed after the patient has rested  for 
three minutes  in a supi[INVESTIGATOR_2547]. Abnormal and clinically significant changes in EC G per 
Investigator’s assessment compared to baseline screening  need to be recorded as adverse events.  
7.2.2. Clinical Safety Laboratory Assessments 
The following tes ts will be performed via Central Laboratory at the visits identified in the Time 
and Events Table . 
• Hematology: hemoglobin, hematocrit, RBC  count, WBC  count with differential, platelet 
count, mean cell hemoglobin, mean cell  hemoglobin concentration, mean corpuscula r 
volume; 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 73 of 100  • Serum Chemistry: liver panel (total and fractionated  biliru bin, lactate dehydrogenase, 
aspartate aminotransferase, alanine aminotransferase), renal panel ( blood urea nitrogen, 
creatinine), creatine phosphokinase (CPK), albumin, sodium, potassium, magnesium, 
bicarbonate, chloride, calcium, inorganic phosphorus, glucose, total protein , alkaline 
phosphatase, total cholesterol, uric acid, serum amylase, and serum lipase; 
• Coagulation: PT and INR if retest is per formed because of ALT and /or AST > 3x ULN;  
• Urinalysis: a t the central laboratory, nitrite, blood, and protein, will be tested. If positive, 
microscopy will be performed; 
• Virology (measured only at s creening  and may be measured  at the local laboratory): hepatitis 
B surface antigen, hepatitis C anti bodies, HIV 1 and 2 antibodies; virology tests done within 
[ADDRESS_1095149] be recorded in the EDC system ; 
• TB screen: only one of the following is needed: interferon γ release assay (IGRA), tuberculin purified protein derivative ([COMPANY_003]) skin test, or c hest radiograms (X rays or CT scan); chest 
radiography done within 6 weeks prior to screening is allowed for eligibility assessment.  
7.2.3. Complement P anel 
The following panel will be measured in all patients  based on recommendations from a 
consensus panel ( Pi[INVESTIGATOR_116281] ., 2013):  
• Plasma C3a, C5a, C5b-9, and C5; 
• Serum C3 and C4; 
• Serum C3 nephritic factor ; 
• Plasma  complement factor H and factor B ; 
• Serum factor H auto -antibody; 
• Serum  paraprotein detection ; 
• CFHR5 mutation  
Results from tests performed within [ADDRESS_1095150] not been performed previously in a patient , samples need to be collected prior to Day 1 for 
measurement either at the local laboratory (if capabilities exist) or at the central laboratory. Results from these tests do not need to be available prior to start of dosing on Day 1, except for 
C5b-9 which is needed for eligibility assessment . Results from tests performed at the local 
laboratories need to be recorded in the EDC. 
7.2.4. Adverse Events  
An adverse event (AE) is defined as any untoward medical occurrence associated with the use of 
a drug in humans, whether or not considered drug related. An adverse event could therefore be any unfavorable and/or unintended sign (including abnormal laboratory findings), symptom, or 
disease temporally associated with  the use of the drug, whether or not considered related to the 
drug. This definition includes intercurrent illnesses or injuries, and exacerbation of pre- existing 
conditions. 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 74 of 100  An unexpected adverse event is an adverse event that is not identified in nature, severity, or 
frequency in the current Investigator’s Brochure, or that is of greater severity than expected 
based on the information in the Reference Safety Information listing within the Investigator’s 
Brochure.  
All adverse events occurring in patients  who have been randomized to treatment will be recorded 
in the EDC system and will be reported in accordance with regulatory requirements. Adverse events reported prior to commencement of administration of blinded study medication will be considered pre- treatment events  and will also be captured. 
All adverse events will be monitored until resolution or, if the adverse event  is determined to be 
chronic, until a cause is identified. If an adverse event remains unresolved at the conclusion of 
the study, a clinic al assessment will be made by [CONTACT_2725]’s Medical 
Monitor to determine whether continued follow- up of the adverse event is warranted.  
[IP_ADDRESS]. Adverse Event Severity Assessment  
The severity of each adverse event will be determined by [CONTACT_596820]:  
• Mild (Grade 1): no limitation of usual activities  
• Moderate (Grade 2): some limitation of usual activities  
• Severe (Grade 3): inability to carry out usual activities  
• Life-threatening (Grade 4): an immediate risk of death  
• Death (Grade 5)  
It is not necessary to utilize Common Terminology Criteria for Adverse Events ( CTCAE ) 
grading for clinical events. However, in terms of lab values, the lab CTCAE criteria may be used 
for severity assessment. If there is a clinical AE that is related to a lab abnormality, the AE should be reported as the clinical event, where possible. 
[IP_ADDRESS]. Causality Assessment  
The relationship of avacopan /placebo to an adverse event will be determined by [CONTACT_794159]: 
• Probably Not Related: the adverse event was more likely explained by [CONTACT_794160]/placebo.  
• Possibly Related: there is evidence for a reasonable possibility that avacopan/placebo 
administration caused the adverse event . 
[IP_ADDRESS]. Serious Adverse Events  
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose:  
• Results in death ; 
• Is life -threatening (i.e., the patient  was, in the opi[INVESTIGATOR_689], at immediate risk 
of death from the event as it occurred); 
• Requires or prolongs hospi[INVESTIGATOR_059]; 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 75 of 100  • Results in persistent or significant disability or incapacity ; 
• Is a congenital anomaly or birth defect ; 
• Is an important and significant medical event that, based on appropriate medical judgment, 
may jeopardize the pat ient and/or may require medical or surgical intervention to prevent one 
of the other outcomes defining serious. 
Elective surgery already known during screening to occur in the course of the study, and elective 
hospi[INVESTIGATOR_794117] t which are clearly unrelated to any medical 
condition and agreed upon between the Investigator and the patient  prior to randomization, will 
not have to be reported as SAEs. 
[IP_ADDRESS]. Infections  
For medically important infections, the organism(s) involved in the infection needs to be 
determined whenever possible. As a selective C5aR antagonist, avacopan  does not appear to 
affect formation of the C5b- [ADDRESS_1095151] infection 
by [CONTACT_794161] . Nevertheless, any such events need  to 
be clearly  documented  in the EDC  and all local and national vaccination recommendations 
should be followed. 
[IP_ADDRESS]. SARs and S[LOCATION_003]Rs  
A serious adverse reaction (SAR) is defined as an SAE for which there is at least a reasonable 
possibility that the study drug (avacopan or placebo) caused the event . 
A suspected  unexpected serious adverse reaction (S[LOCATION_003]R) is defined as an SAE for which there 
is at least a reasonable possibility that the study drug caused the event, and the SAE is 
”unexpected”, i.e., not described in terms of nature, severity, or frequency in the Reference Safety Information within the current Investigator ’s Brochure.  
“Reasonable possibility” means that there is evidence to suggest a causal relationship between 
the study drug and the adverse event. Within the reporting requirements, the following examples illustrate the types of evidence that would suggest a causal relationship:  
• A single occurrence of an event that is uncommon and known to be strongly associated with drug exposure (e.g., angioedema, hepatic injury, Stevens-Johnson Syndrome); 
• One or more occurrences of an event that is not commonly associated with drug 
exposure, but is otherwise uncommon in the population exposed to the drug (e.g., tendon 
rupture); 
• An aggregate analysis of specific events observed in a clinical trial (such as known consequences of the underlying disease or condition under investigation or other events that commonly occur in the study population independent of drug therapy) that indic ates 
those events occur more frequently in the drug treatment group than in a concurrent or historical control group. 
Events related to the underlying disease , such as relapses  or worsening of disease will not be 
considered as S[LOCATION_003]Rs, unless there is a reasonable possibility that avacopan  use was associated 
with the se event s. 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 76 of 100  [IP_ADDRESS]. Laboratory Abnormalities 
Safety laboratory tests are performed frequently over the course of the study. Laboratory reports 
with abnormal findings will be reviewed by [CONTACT_737] . The Medical Monitor will review 
notably abnormal laboratory results according to the Safety Monitoring Plan. 
Please see Section 4.4 for guidance on laboratory abnormalities (white blood cell count, 
neutrophil count, lymphocyte count, AST or ALT and other l ab abnormalities of impaired liver 
function or hepatic toxicity, CPK increase, creatinine or proteinuria increases) that would prompt 
pausing or permanently discontinuing study drug (avacopan or placebo). 
[IP_ADDRESS]. Pregnancies  
If a patient  becomes pregnant during the study or within the safety follow up period defined in 
the protocol, the investigator is to stop dosing with study drug(s) (avacopan or placebo) 
immediately and the patient  should be withdrawn from the study. Early termination procedures 
should be implem ented at that time.  
A pregnancy is not considered to be an AE or SAE; however, i must be reported to Clinical Safety within 24 hours of knowledge of the event. Clinical Safety wil  then 
provide
 the investigator/site the Exposure In Utero ( EIU) form for compl etion. The 
investigator/site must complete the EIU form and fax/email it back to Clinical Safety.  
If the female partner of a male patient  becomes pregnant while the patient  is receiving study drug 
or within the safety follow up period defined in the protocol, the investigator should notify 
Clinical Safety as described above.  
The pr
egnancy should be followed until the outcome of the pregnancy, whenever possible. Once 
the outcome of the pregnancy is known, the EIU form should be complete follow-up form and faxed/emailed to
Cl
inical Safety. If the outcome of the pregnancy meets the criteria for 
imm
ediate classifica on as an SAE, (i.e. postpartum complication, spontaneous abortion, 
stillbirth, neonatal death, or congenital anomaly) the investigator should follow the procedures for reporting an SAE.  
7.2.5. Speci
al Situation Reporting  
Special situation reports include reports of overdose, misuse and abuse of the IMP: 
• Overdose: Refers to the administration of a quantity of a medicinal product given per 
administration or cumulatively (accidentally or intentionally), which is above the 
maximum recommended dose according to the protocol. Clinical judgment should always be applied. In cases of a discrepancy in the drug accountability, overdose will be 
established only when it is clear that the patient has taken excess dose(s) or the 
Investigator has reason to suspect that the patient has taken additional dose(s). 
• Misuse: Refers to situations where the medicinal product is intentionally and inappropriately used in a way that is not in accordance with the protocol instructions or local prescribing information and may be accompanied by [CONTACT_239640]/or psychological effects.  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 77 of 100  • Abuse: Is defined as persistent or sporadic, intentional e xcessive use of a medicinal 
product which is accompanied by [CONTACT_3584]. 
• Medication Error: Medication error is any unintentional error in the prescribing, 
dispensing or administration of a medicinal product by a healthcare professional, patient 
or consumer, respectively. The administration or consumption of the unassigned 
treatment and administration of an expi[INVESTIGATOR_239610], cases of patients  missing doses of investigational product are not considered 
reportable as medication error.  
All spec al situation reports must be reported on the special situations report form and forwarded to Cl
inical Safety within 24 hours. 
All ad
verse events (AEs) associated with these special situation r eports should be reported as 
AEs or SAEs at the same time using the AE eCRF and/or the SAE report form. Details of the symptoms and signs, clinical management and outcome will be reported, when available. 
7.2.6. Serious Adverse Event  Reporting  
Any serious adverse event  occur
 ring from screening through the end of the follow-up period, 
whe her or not considered study related, will be reported immediately (within 24 hours) to the 
 C
linical Safety team. Patie nts who terminate early from the trial will have SAEs  
reco ded at follow -up visits or at least [ADDRESS_1095152] study drug (avacopan or placebo) 
administration. Reporting is done by [CONTACT_596822] . If it is not 
possible to access the EDC system, the Investigator will send an emai l to the  clinical 
safety mailbox (see information below) or call their regional SAE hotline and fa he completed 
SAE report form within [ADDRESS_1095153] details are as follows:  
SAE hotline – [LOCATION_003]:  
Tel
eph
one:
Facsimile: 
e-mail: 
 
SAE hotline – Europe: 
Tele
phone:  
Fax: 
e-mail: 
 Any
 medication or other therapeutic measures used to treat the event, in addition to the outcome 
of the adverse event , will be recorded in the EDC system. 
 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095154] continue to follow the patient  until the SAE has subsided or until the 
condition becomes chronic in nature, stabilizes (in the case of persistent impairment) , or the 
patient  dies.  
Within [ADDRESS_1095155] update the SAE form 
ele
ctronically in the EDC system for the  study and submit any supporting documentation (e.g., 
patient  discharge summary or autopsy reports) to Clinical Safety via fax or e- mail.  If it 
is not possible to access the EDC system, refer to th  pr cedures outlined above for initial reporting of SAEs.  
The 
Sponsor or its representatives will report all S[LOCATION_003]Rs to national health authorities and 
central ethics committees in an expedited manner in accordance with Clinical Trial Directive, Articles [ADDRESS_1095156] any safety communication as applicable to their local ethics 
committees.  
7.3. Pharmacokinetic Assessments  
Concentrations of avacopan  (and  its metabolite  CCX168- M1) will be determined in plasma 
according to the schedule in the Time and Events Table, using a validated analytical method.  The 
samples on Day [ADDRESS_1095157] dose of avacopan /placebo on that day. Only 
for patients  [ADDRESS_1095158] dose of avacopan /placebo on Day 1 and following the morning dose of 
avacopan on Day 183 (Week 26). The Day 183 morning dose for these adolescent patients  
should be taken in the clinic, not at home. The blood samples collected on the other study days 
will be single time point samples and do not need to be collected prior to the avacopan /placebo 
dose on those days. However, t he date and time of the last dose of avacopan/placebo  (or 
avacopan in the open-label portion of the st udy) prior to the sample collections must be recorded 
in the EDC system .  
On the day of the Week [ADDRESS_1095159] (four samples total collected on Week 52, Week 54, Week 57, and on the 
follow-up visit, Week 60) is for terminal PK evaluation.  
Total plasma concentrations of avacopan  (and its metabolite  CCX168- M1) will be determined 
using validated analytical methods. P lasma samples collected for PK analysis  may also be used 
to measure cytokines, complement fragments, or other markers associated with AAV. 
7.4. Pharmacodynamic Assessments  
Blood samples will be collected according to the schedule in the Time and Events Table f or PD  
marker measurements  in plasma  and serum, which may include , for example, cystatin C, 
complement components, and inflammatory cytokine and chemokine levels. Blood samples 
collected will be used  for lymphocyte subset counts including B cells, T cell s, and natural killer 
cells. The complete blood cell (CBC) count results from the hematology samples will also be 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095160] Study Day for all patients . Procedures for this day will be 
completed per the Time and Events Table . Each  patient ’s condition will b e evaluated by [CONTACT_794162]. For early withdrawals from the study, the procedures for 
the Early Termination visit will be performed , when possible (s ee Section  6.23) . 
The clinical trial will be terminated early if there is a safety concern that cannot be addressed by a modification of the protocol. 
7.6. Data Monitoring Committee  
In addition to continuous safety mo nitoring by [CONTACT_67806] c linical staff, an external 
Data Monitoring Committee (DMC) will monitor the safety of patients  over the course of the 
study . The DMC will consist of external  physicians and a biostatistician. At least one of the 
DMC mem bers will be a pediatric nephrologist. A DMC charter will be developed before start of 
the study and the DMC will function according to the charter. 
It is anticipated that the DMC will have regular meetings, once every [ADDRESS_1095161] of the study. 
8. STA TISTICAL METHODS  
Details of the statistical analysis will be  provided in a separate statistical analysis plan (SAP), 
which will be written, finalized, and approved prior to database lock and will be included in the 
Clinical Study R eport (CSR) for this protocol. The SAP will supersede the statistical analysis 
methods described in this clinical protocol. Any major deviations from the protocol will be 
documented and described in the final report. If changes to principal features stated in the 
protocol are required, the se will be documented in a protocol amendment. The final SAP will 
take into account any amendment to the protocol. Data analysis and writing of a CSR for all 
study data will be performed by [CONTACT_794163]. Analysis of 
PK and PD data, and writing of PK  and PD reports will be performed by [CONTACT_794164] s in accordance with their  standard operating procedures. 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095162] provided 
written Informe d Consent/ Assent and are randomized  in the study. 
8.1.2. Per Protocol Population  
The Per Protocol (PP) population will consist of all randomized patients  who receive at least one 
dose of study drug and do not have protocol deviations that could significantly affe ct the 
interp retation of the results for the primary endpoints. Patients ’ inclusion/exclusion from the PP 
population will be determined and documented prior to the database lock and unblinding. 
8.1.3. Safety Population 
The safety population will include all patie nts who are randomized and have received at least one 
dose of study drug. 
8.2. Target Patient Population  
8.2.1. C5b-9 Elevated Stratum 
This population includes all patients  enrolled under the C5b- 9 elevated stratum , and is the 
primary target population for analysis. 8.2.2. C5b-9 Non- Elevated Stratum  
This population includes all patients  enrolled under the C5b-9 non- elevated stratum. This is the 
secondary target population for analysis. 
8.2.3. Exploratory Population 
The two strata combined will be considered the exploratory population. 
8.3. Efficacy Endpoints  
8.3.1. Primary Endpoint  
The primary efficacy endpoint is the percent change from baseline to Week 26 in the C3G 
Histologic Index for disease activity . 
8.3.2. Secondary and Other Endpoints  
Secondary efficacy endpoints include: 
1. The proportion of patients  who have a histologic response, defined as a decrease 
(improvement) in the C3G Histologic Index for disease activity of at least 35% from 
baseline to Week 26  (see Section  8.8 for basis of selection of 35% threshold); 
2. The percent change from baseline in the C3G Histologic Index for disease chronicity over the placebo-controlled 26- week treatment period . 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 81 of 100  Other efficacy endpoints include: 
1. The change and percent change from baseline in eGFR over the placebo- contr olled 
26-week treatment period;  
2. The percent change from baseline in UPCR over the placebo -controlled 26- week 
treatment period;  
3. The percent change from baseline in urinary MCP -1:creatinine ratio over the placebo -
controlled 26-week treatment period; 
4. Change f rom baseline in EQ-5D-5L (visual analogue scale and index) and SF-36 v2 
(domains and component scores) over the placebo-controlled 26- week treatment period . 
8.4. Safety Endpoints  
Safety endpoint s include: 
1. Patient incidence of treatment -emergent serious adverse events, adverse events, and 
withdrawals due to adverse events;  
2. Change from baseline and shifts from baseline in all safety laboratory parameters;  
3. Change fr om baseline in vital signs . 
8.5. Pharmacokinetic Endpoints  
Avacopan  (and its metabolite  CCX168- M1) plasma concentration results for both C5 b-9 level 
strata combined will be used to calculate trough plasma concentrations (C min) over the course of 
the clinical trial. When possible, the terminal elimination half -life will also be calculated.  
The C max, Tmax, and A UC 0-6hr will be determined for patients  12 to 17 years old based on 
avacopan  and metabolite plasma concentration data on Day 1 and on Day 183 (Week 26). 
8.6. Exploratory Pharmacodynamic Endpoints  
The following PD endpoints may be assessed: 
1. Change and percent ch ange  from baseline in plasma biomarkers such as inflammatory 
cytokine and chemokine levels ; 
2. Change and percent change from baseline in urine biomarkers such as urinary 
sCD163:creatinine ratio, inflammatory cytokine and c hemokine levels ; 
3. Change from baseline in CBC count (especially WBCs, neutrophils, and lymphocytes) 
and lymphocyte subset counts including B cells, T cell s, and natural killer cells ; 
4. The relationship between PK parameters and renal function based on eGFR will be evaluated. The data may also b e used to evaluate the PK/PD relationship of avacopan  
treatment  for both C5b- 9 level strata separately as well as combined . To this end, the 
change and/or percent change from baseline in the C3G Histologic Index, UPCR, eGFR, urinary MCP- 1:creatinine ratio,  and other biomarkers may be used as PD markers. 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 82 of 100  8.7. Statistical Analysis Methodology  
A statistical analysis plan (SAP). with specific details of all the planned analyses and sensitivity 
analyses will be generated and approved before unblinding the data for ana lysis.  
All statistical testing will be two -sided, with the T ype I error rate at α = 0.05. 
The efficacy analyses for the efficacy endpoints will be performed in the ITT and PP 
populations, with the ITT analysis being the primary analysis. 
The earliest timepoint at which the primary analysis  of the efficacy endpoints can  be conducted  
is when all patients  in the elevated stratum have completed at least the Week 26 study visit. 
Additionally, enrollment for the stratum with C5b -9 levels ≤ 244 ng/ml could terminate early, if 
patient enrollment in the other stratum (C5b -9 level >244 ng/mL) reaches  target enrollment first. 
Further, both strata can be analyzed separately and independently. The stratum with elevated 
levels (primary population) will be analyzed first should the stratum with C5b- 9 ≤244ng/ml 
(secondary population) continue a blinded follow up – further details will be provided in the 
SAP.  
For efficacy analysis, to control for the T ype I error rate, a gate- keepi[INVESTIGATOR_794104] (percent change in C3G Histologic Index for disease activity ). The primary endpoint will be tested in the elevated C5b-[ADDRESS_1095163] with a two -sided α  = 0.05. If this test reaches statistical significance, then the primary 
endpoint will be tested in the non- elevated C5b-9 stratum with a two -sided α  = 0.05. If the test in 
the elevated stratum fails to reach statistical sig nificance, then the test in the non- elevated C5b-9 
stratum will not be performed  and only performed as an exploratory analysis . The statistical 
analysis for the secondary endpoint (C3G Histologic Index for disease chronicity ) will be tested 
at a 0.[ADDRESS_1095164] value prior to start of dosing with study medication (typi[INVESTIGATOR_596787] 1 pre- dose value).  
8.7.1. Patient Disposition  
The number of patients  who were screened, who screen failed (by [CONTACT_48933]), who were 
randomized, who completed Week 26, Week 52, and Week 60 of the study, who withdrew early 
from the study, along with the reasons for withdrawal , will be presented by [CONTACT_63300]. 
8.7.2. Demographics and Baseline Characteristics  
All patient  baseline characteristics and demographic data (age, sex, race, ethnicity, weight, 
height, body mass index, viral test results, C3G disease type and duration [ from time of first 
diagnosis based on renal biopsy], eGFR, proteinuria [ UPCR ], complement marker levels, urinary 
MCP -1:creatinine ratio, physical examination abnormalities, medical history, previous [within 6 
months of screening] and concomitant medications [including other treatments for C3G] at study entry ) will be listed by [CONTACT_794165], and will also be summarized. 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 83 of 100  8.7.3. Prior and Concomitant Medications  
All medications will be coded using the World Health Organization Drug Dictionary (WHODD) . 
All prior (within 12 months of scre ening for C3G medications, and within 6 months of screening 
for all other medications ) and concomitant medications (including C3G medication) will be 
listed and summarized by [CONTACT_596829] (ATC)  classification  and 
preferred term . 
8.7.4. Study Drug Exposure and Compliance  
Patient  drug exposure will be calculated comparing  the study drug dispensing and return records, 
as well as avacopan  plasma concentrations over the course of the study. The study drug exposure 
(duration, total dose, and average daily dose) and compliance will be summarized for the double-
blind and active treatment periods separately. Individual patient  data listing will also be 
provided. 
8.7.5. Efficacy Analyses 
Summary statistics will be calculated for each of the efficacy endpoints. For categorical 
endpoints, numbers and percentages, and 95% confidence intervals will be calculated. For continuous variables, numbers, means, medians, minimum, maximum, standard deviations, and 
standard error of means, and 95% confidence intervals will be calculated. Geometric means will be calculated for U PCR and urinary MCP- 1:creatinine , and other data that are not normally 
distributed .  
Results will be presented by [CONTACT_1570]. Results will be presented by [CONTACT_794166] C3GN vs. DDD and renal trans plant vs. no renal transplant. Data will also be presented by [CONTACT_794167] ( North America  vs. Rest of World), sex , age group (including a separate analysis in 
12-17 year old patients ), race, and ethnicity for at least the primary endpoint. 
The overall  efficacy hypothesis in this study is that avacopan  treatment will be effective in 
treatment of patients with C3G based on improvement in renal histology (C3G histologic index of activity) .  
The primary efficacy endpoint is the percent change from  baseline to Week 26 in the C3G 
Histologic Index for disease activity . 
• The null hypothesis (H
0) is that the avacopan group is not different from  the placebo  group 
when comparing the percent change from baseline  to Week 26  in the C3G Histologic Index 
for disea se activity . 
• The alternative hypothesis (H 1) is that the avacopan group is superior to the placebo  group 
when comparing the percent change from baseline  to Week 26  in the C3G Histologic Index 
for disease activity . 
Avacopan and placebo groups will be compar ed by [CONTACT_794168] C3G Histologic Index for disease activity as covariate. A point estimate and corresponding 95% confidence interval will be estimated for the treatment main effect. The 
heterogeneity of the treatment effect across disease diagnoses and renal transplant strata will be 
investigated through subgroup analyses. If data are not normally distributed, in addition to the ANCOVA for the percent  change in C3G Histologic Index for disease activity and chronicity , 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 84 of 100  the Cochran -Mantel -Haenszel ( CMH ) test will be applied to the percent  change results and 
ANCOVA will be applied to the change in C3G Histologic Index disease activity and chronicity 
scores.  
The treatment effect based on the baseline complement profile of patients  will also be 
investigated.  
Data from patients  who are treatment failures, i.e., requiring treatment rescue measures such as 
high dose glucocorticoids during the treatment period, will be excluded from efficacy analysis after the point of rescue treatment.  
Since the placebo group will receive avacopan during the second [ADDRESS_1095165]. Point estimates and corresponding 95% confidence intervals will be estimated for the difference between the second 26 weeks (avacopan treatment) and the first 26 weeks (placebo treatment).  
The change from baseline to Week 52 in the C3G Histologic Index in the avacopan group will 
also be compared to the change from baseline to Week 26 in placebo control group using similar methodology as described for the primary efficacy endpoint. 
Continuous variables, including eGFR, UPCR, urinary MCP- 1:creatinine ratio, EQ -5D-5L, and 
SF-36 v2 will be analyzed using a mixed effects model for repeated measures (MMRM) with 
treatment group , visit,  and treatment -by-visit interaction as factors, and baseline as covariate. 
Patients  will be considered as repeated measure units over visits. The interaction term may be 
dropped if it is not significant at α  = 0.25 level. Point estimates and corresponding 95% 
confidence intervals will be estimated for the difference between the avacopan group and the 
control group at Week [ADDRESS_1095166].  Data from patients  who are treatment failures, i.e., require 
rescue medication, will be summarized.  
The primary efficacy analysis will be based on the intent- to-treat (ITT) po pulation, defined as all 
patients  who are randomized. 
8.7.6. Handling of Missing Data 
If data are missing after all efforts made to collect post-baseline C3G Histologic Index data, missing data will be imputed using the last observation carried forward (LOCF) met hod. This 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 85 of 100  method may impute Week 26 missing data with the baseline value if there are no unscheduled 
data from visits prior to the missing time point.  Multiple -imputation using Markov Chain Monte 
Carlo (MCMC) or other statistical method may also be performed.  
8.7.7. Covariates and Subgroups  
The analysis of the efficacy endpoints may be adjusted by [CONTACT_794169] , stratified analysis , and/or subgroup analysis: 
• Randomization stratification variables , i.e. C3GN or DDD and Having received a renal 
transplant or not 
• Sex 
• BMI  
• Age at diagnosis of C3G 
• Age at study entry; a subgroup analysis will be performed in 12 to 17 year -old patients , if 
feasible.  
• Duration of C3G 
• Patient ’s age, race,  and ethnicity (if plausible) 
• Baseline C3G His tologic Index for disease activity  
• Baseline C3G Histologic Index for disease chronic ity 
• Baseline eGFR  
• Baseline UPCR 
• Baseline urinary MCP -1:creatinine ratio  
• Baseline C5b-9, C5a, and C3a 
• Geographic distribution (North America vs. Rest of World) 
8.7.8. Safety Analys es 
All clinical safety and tolerability data will be listed by [CONTACT_794170].  
All reported adverse events will be coded using MedDRA and listed by [CONTACT_1196], preferred term, and verbatim term.  
Treatment -emergent adverse events will be listed and summarized by [CONTACT_794171] , by [CONTACT_182811] , by [CONTACT_794172].  
Serious adverse events and adverse events leading to study withdrawal will be summar ized by  
[CONTACT_1570]. This will include serious infections.  
Individual vital signs and change from baseline in vital signs will be listed by [CONTACT_1570], patient , and study visit, and summarized by [CONTACT_1570] . 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 86 of 100  Laboratory data (actual values and  change from baseline) will be listed by [CONTACT_1570], 
patient  and study visit. Abnormal laboratory values will be flagged. Laboratory data will also be 
summarized by [CONTACT_67486]. Shift tables will be generated for shifts in 
laborato ry parameters by [CONTACT_15449].  
8.7.9. Pharmacokinetic and Exploratory Pharmacodynamic Marker Analysis 
Individual plasma concentrations of avacopan  and its significant metabo lite CCX168- M1 will be 
listed, plotted, and summarized descriptively and graphically. When possible, the mean steady state trough concentrations and the terminal elimination half -life will be calculated.  PK 
parameters  such as C
max, Tmax, and AUC 0-6hr will be calculated in adolescents for avacopan and 
metabo lite CCX168-M1 based on plasma concentr ations for samples collected on Day 1 and on 
Day 183. 
Plasma and urinary PD markers will be summarized and may be analyzed using methods 
analogous to the efficacy parameters.  
The relationship between PK parameters and renal function based on eGFR will also be 
evaluated. The data may also be used to evaluate the PK/PD relationship of avacopan  treatment. 
To this end, the change  and/or percent change from baseline in C3G Histologic Index for disease 
activity, C3G Histologic Index for disease chronicity, eGFR, UPCR, urinary MCP- 1:creatinine 
ratio, or other biomarkers may be used as PD markers.  
8.8. Sample Size Justification  
A sample size of 22 patients  per treatment group (a vacopan and placebo , respectively) in each of 
the C5b- 9 level strata is based on the between -treatment difference of -35% in the C3G 
Histologic Index for activity  at Week [ADDRESS_1095167] deviation (SD) 34%, power 90%, and 2-sided 
α = 0.05. 
The sample size of 22 per group also provides approximately 90% power to detect a delta of -35% in the C3G Histol ogic Index for activity between the percent change from baseline in 
the first 26 weeks and in the second 26 weeks, assuming an SD of 34% for each change. 
The mean treatment effect size of 35% is considered reasonable based of the following: 
• Of the 5 patien ts with histologic data in the study by [CONTACT_794173]., 2012 with eculizumab, an 
anti-C5 antibody, 2 patients  had a 67% decrease (improvement) in histologic score, 1 had a 
43% decrease, and 2 had no change from baseline; the mean decrease for the 5 patient s was 
35%; 
• An improvement in the histologic score of at least 35% is considered clinically meaningful 
by [CONTACT_794174] ; 
• The SD for the percent change from baseline in C3G Histologic Index of activity was 34% in the Herlitz study; a change of 35% of greater will be above the observed variance for this parameter.  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 87 of 100  8.9. Interim Analysis  
Safety data from the study will be summarized for review by [CONTACT_596841] r the 
course of the study (see Section  7.6). The DMC charter will include details of the se review s. 
No Type I error adjustment will be made based on the DMC review of the data, since these 
reviews will focus on safety assessment . 
The earliest timepoint at which the primary analysis can be performed  is when all patients  in the 
primary population have completed at least the Week [ADDRESS_1095168] 
of significant protocol deviations on the safety and efficacy outcomes will be assessed by 
[CONTACT_794175]/or study visits with signif icant protocol 
deviations. This will be determined and documented before unblinding the study. 
The Sponsor will assess any protocol deviation and decide whether any of these should be 
reported to Competent Authorities (CAs) as a serious breach of GCP and the protocol. Protocol 
waivers are not acceptable.  
9. STUDY COMPLETION AND TERMINATION 
9.1. Study Completion  
A patient  has completed the study when s/he has completed the study procedures per protocol. 
9.2. Study Termination  
The end of study is defined as the last study visit of the last clinical trial patient. 
The study will be terminated early if there is an insurmountable safety concern. This will be 
determine d in conjunction with the DMC. In this case, the Investigators, CAs, and IRB/EC will 
be notified expeditiously and appropriate measures taken to safeguard the study patients.  
10. REGULATORY AND ADMINISTRATIVE REQUIREMENTS 
10.1. Investigator Responsibilities  
Prior to  trial initiation, the Investigator will provide the Sponsor with a fully executed and signed 
FDA Form 1572, a Financial Disclosure Form , and a curriculum vitae. Financial Disclosure 
Forms also will be completed for all Sub -Investigators listed on the Form 1572 who will be 
involved directly in the treatment or evaluation of research patients  in this trial.  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 88 of 100  The study will be conducted in accordance with the Declaration of Helsinki (amended by [CONTACT_941] 
59th World Medical Association General Assembly, October 2008) and Good Clinical Practices 
(GCP) according to International Conference on Harmonisation (ICH) guidelines. Specifically, 
the study is based on adequately performed laboratory and animal experimentation; the study 
will be conducted under a protocol reviewed by a properly constituted IRB/EC; the study will be 
conducted by [CONTACT_63043]; the benefits of the study are in proportion to the risks; the rights and welfare of the patients  will be respected; and each patient  
or his/her legal guardian will give his/her written Informed Consent /Assent  before any protocol-
specific tests or evaluations are performed.  
10.2. Institutional Review Board or Ethics Committee  
Prior to initiating the study, the Investigator will obtain written confirma tion from t he IRB/EC 
that the IRB/EC was properly constituted and met the definition of all [LOCATION_002] Code of Federal Regulations Title 21, Section 312.3(b) and Part 56, and/or the applicable local, regional or national Regulatory requirements. A copy of the con firmation will be provided to the Sponsor. 
The Principal Investigator [INVESTIGATOR_298293]/EC with all appropriate materials, including the protocol and Informed Consent /Assent  documents. The trial will not be initiated until IRB/EC 
approval of the protocol, the Informed Consent /Assent  document, and all recruiting materials are 
obtained in writing by [CONTACT_187641][INVESTIGATOR_596789]. Appropriate reports on the progress of the study will be made to the IRB/EC and the Sponsor by [CONTACT_079] [INVESTIGATOR_794118]. 
10.3. Informed Consent /Assent  
A properly executed, written, and appropriately explained Informed Consent Form, or As sent 
Form (where relevant), in compliance with the Declaratio n of Helsinki, ICH GCP, and US Code 
of Federal Regulations for Protection of Human Patients  (21 CFR 50.25[a,b], CFR 50.27, and 
CFR Part 46, Subpart A), will be signed by [CONTACT_794176]/her l egal guardian prior to 
entering the  trial. Either the Investigator or the Investigator’ s designee will obtain the consent of 
the study patient. The patient  will be provided as much time as necessary to review the 
document, to inquire about details of the trial, and to decide whether or not to participate in the study. The Informed Consent /Assent  will be signed and dated by [CONTACT_4694] /legal guardian  
and by [CONTACT_35884] I nformed Consent discussion. The Investigator will provide 
a copy o f the signed Informed Consent /Assent  Form to each patient  and will maintain the 
original in the patient ’s record file.  
10.4. Protocol Modifications  
Only the Sponsor may modify the protocol. The only exception is when the Investigator 
considers that a patient ’s safety would be comprom ised without immediate action. In this 
circumstance, immediate approval of the chairperson of the IRB/EC must be sought, and the 
Investigator should inform the Sponsor’s Medical Monitor and the full IRB/EC within five worki ng days  after the emergency occurred.  
All other amendments that have an impact on patient  risk or the study objectives, and/or that 
require revision of the Informed Consent /Assent  Form, must receive approval from the IRB/EC 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 89 of 100  prior to their implementation, except when the changes involve only logistical or admini strative 
aspects of the trial. The IRB/EC must be notified of changes that are made to study contact 
[CONTACT_6404], but IRB/EC review or approval of these changes is not required. If protocol amendments are substantial and are likely to have an impact on the safety of the trial patients  or 
to change the interpretation of the scientific documents in support of the conduct of the trial, or if they are otherwise significant, the sponsor shall notify the FDA and other CA s concerned of the 
reasons for, and content of, these amendments according to the European Directive “Detailed 
guidance on the request to the CAs  for authorization of a clinical trial on a medical products for 
human use, the notification of substantial amendments and the declaration of the end of trial 
(CT-1)(2010/C 82/01)” and other regulatory guidance. In case of a substantial amendment to the 
protocol, approval will be sought from CAs  before implementation.  
10.5. Regulatory Aspects  
Before the study is conducted, the protocol will be submitted to the country- specific 
CA/regulatory agency for review and approval. The study will not commence until written 
approval has been obtained from the CA. 
All regulatory documentation including regulatory submissions, [ADDRESS_1095169] of: 
1. 10 years according to national Swedish and EU regulations (LVFS 2003:3), or  
2. For [ADDRESS_1095170]. Otherwis e, all reports and communications 
relating to the study will identify participants by [CONTACT_396949] /or assigned number only. 
10.7. Record Retention  
The Investigator must retain all  study records required by [CONTACT_794177] a secure and safe facility. The Investigator must consult a Sponsor CRA before disposal of any study records, and must notify the Sponsor of any change in the location, dispositio n, or custody of the study files. Clinical trial related documents will be archived for the 
longe st of: 
1. 10 years according to national Swedish and EU regulations (LVFS 2003:3), or 
2. For 2 years following the date a full marketing application is approved, or 
3. For 2 years after the FDA is notified  that the IND is discontinued if th ere is no marketing 
application . 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 90 of 100  10.8. Case Report Form Completion  
Electronic Case Report Forms (CRFs) will be generated for each patient . The electronic data 
capture (EDC) system  will comply with CFR 21 Part 11. 
Participants will not be identified in the EDC  by [CONTACT_794178]. Only the 
Investigator or his/her designated representative will enter data into the EDC . It is the policy of 
the Sponsor that study data must be verifiable to the source data, which neces sitates access to all 
original recordings, laboratory reports, and patients’ recor ds. The Investigator must therefore 
agree to allow access to patients ’ records, and source data must be made available for all study 
data. Each  patient  (or their legal repres entative) must also allow access to their  medical records ; 
they will be informed of this requirement and will indicate their agreement when giving 
Informed Consent /Assent . Upon completion of the study, electronic copi[INVESTIGATOR_794119]/her study files and retained as per FDA or local regulations. 
10.9. Monitoring  
At intervals during the study, as well as after the completion of patient  enrollment at the study 
center , the study center will be monitored by a CRA for compliance, which will include ensuring 
that accurate and complete data are promptly recorded in EDC , and reviewing source 
documentation and drug accountability records. The study will be conducted according to the 
principles of GCP as accepted in the [LOCATION_002] and according to CPMP/ICH/135/95. 
10.10.  On-site Visits and Audits  
The Sponsor’s representatives will visit the study center prior to initiation of the study to review with the center personnel information regarding the investigational agent, protocol requirements, monitoring requirements, and reporting of serious adverse events. 
In certain circumstances, a secondary audit may be conducted by [CONTACT_365564] a Quality 
Assurance gr oup designated by [CONTACT_1034]. The Investigator will be informed if this is to take 
place and advised as to the nature of the audit. Representatives of the Food and Drug 
Administration (FDA) and/or representatives of other regulatory authorities may also conduct an 
audit of the study. If informed of such an audit, the Investigator should notify the Sponsor immediately.  
10.11.  Study Registration, Use of Information and Publication  
The study will be registered in clinicaltrials.gov and other country -specific registries, as required, 
prior to initiation.  
It is understood b y the Investigator that the information generated in this study will be used by 
[CONTACT_794179]. To allow for the use of information derived from the 
study, it is understood that the Investigator is obliged to provide the Sponsor with complete test results, all study data, and access to all study records.  
The Sponsor recognizes the importance of communicating study data and will disclose or publish the results in a suitable form regardless of outcome. The Sponsor will post the clinical trial 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095171] 
patients , and publish the results of this study in sc ientific journals, at seminars or conferences, 
and/or in other manner(s) it so chooses. Results from this study shall not be made available to 
any third party by [CONTACT_596845]. 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 92 of 100  11. REFERENCES  
1. Bekker P, et  al. Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a 
Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on 
Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS One. 2016; 11(10): 
e0164646.  
2. Bomback AS, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol. 2012; 7(5):748–756.  
3. Bomback AS, et al. C3 glomerulonephritis and dense deposit disease share a similar disease 
course in a large [LOCATION_002] cohort of patients with C3 glomerulopathy. Kidney Int. 2018.  
4. Food and Drug Administration (FDA), July 2009 Guidance for Industry.  Drug-induced liver 
injury: premarketing clinical evaluation.   
5. Herlitz LC, et al. Pathology after eculizumab in Dense Deposit Disease and C3 GN. J Am Soc Nephrol. 2012; 23(7):1229–1237.  
6. Hou J, et al. Toward a working definition of C3 glomerulopathy by [CONTACT_31122]. Kidney Int. 2014; 85(2):450–456.  
7. Jayne DRW, et al. Randomized Trial of C5a Receptor Inhibitor Avacopan i n ANCA-Associated 
Vasculitis. J Am Soc Nephrol. 2017; 28(9):2756–2767.  
8. Johnson TN, et al. Prediction of the clearance of eleven drugs and associated variability in 
neonates, infants and children. Clin Pharmacokinet. 2006; 45(9):931–956. 
9. Levey AS, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 
150(9):604–612. 
10. Momper JD, et al. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007. JAMA Pediatr. 2013; 167(10):926–932.  
11. Pi[INVESTIGATOR_221959], et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet. 2002; 31(4):424–428. 
12. Pi[INVESTIGATOR_221959], et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci [LOCATION_003]. 2006; 103(25):9649–
9654. 
13. Pi[INVESTIGATOR_221959], et al. C3 glomerulopathy: consensus report. Kidney Int. 2013; 84(6):1079–1089.  
14. Schwartz GJ, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009; 20(3):629–637.  
15. Selistre L, et al. Comparison of the Schwartz and CKD-EPI [INVESTIGATOR_794120], Adolescents, and Adults: A Retrospective Cross-Sectional Study 
PLoS Med. 2016; 13(3): e1001979.  
16. Sethi S, et al. Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic 
Classification, Diagnosis, and Reporting of GN. J Am Soc Nephrol. 2016; 27(5):1278–1287. 
17. Xiao H, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014; 25(2):225–231.
   
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 93 of 100  12. APPENDICES  
12.1. Statement of Obligations of Sponsor, Monitor, and Clinical 
Investigator  
Sponsor and Monitor 
If the Sponsor is not familiar with the s tudy s ite, the Sponsor or its designated representative, 
will: 
A. Conduct a pre-s tudy visit to: 
1. Establish the acceptability of the facility, the recruitment potential and the standard of patient  
care at this site, and record this in a written report.  
2. Discuss the proposed clinical trial with the Investigator, review the CRF requirements, and 
supply the Investigator ’s Brochure and the draft protocol for review and approval. 
3. Discuss with the Investigator FDA and other regulatory requirements with respect to Informed Consent /Assent , CA and IRB/ EC approval of the trial, the protocol, protocol 
amendments, and Informed Consent /Assent  changes.  
B. Conduct periodic site visits to: 
1. Assure adherence to the protocol.  
2. Review CRFs and medical records for accuracy and completeness of information. 
3. Examine pharmacy records for documentation of quantity and date of receipt of investigational supplies, dispensation and accountability data for administration to each patient , loss of materials, contamination, and unused supplies. 
4. Record and report observations on the progress of the trial and continued accepta bility of the 
facilities in a Site Visit Report.  
5. Review Investigator files for required documents, e.g., protocols, protocol amendments, CA and EC approvals (protocols, amendments, Informed Consent /Assent , etc.), EC charter and 
membership, and communica tions between the EC and the Investigator.  
Clinical Investigator  
A. EC 
The Investigator must assure the monitor that the EC: 
1. Meets FDA regulations as defined in 21 CFR Part 56 and other applicable ICH and GCP 
requirements.  
2. Has authority delegated by [CONTACT_794180]- laws, operation 
guidelines, or charter to approve or disapprove clinical trials and protocols, including Informed Consent /Assent  Forms and other documents (protocol amendments, information to 
be supplied to patients  concerning Informed Consent /Assent , etc.).  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 94 of 100  3. Complies with proper personnel makeup of an EC and maintains an active up- to-date roster 
of all EC members participating in the meetings.  
4. Convenes meetings using acceptable rules of order for making decisions, recording such 
decisions, and implementing them. 
5. Files contain (a) documentation of its decisions such as are found in EC minutes and correspondence, (b) written guidelines or by-laws governing EC functions, (c) protocols, (d) protocol information to be supplied to the patient , (e) correspondence between the EC and 
the Investigator (Informed Consent /Assent  Form changes, protocol amendments, etc.). 
B. Informed Consent /Assent  of Human Patients  
The Principal Investigator [INVESTIGATOR_794121] /Assent  Form:  
1. Meets FDA regulations as defined in 21 CFR Part 50 Informed Consent, and other applicable ICH and GCP requirements. 
2. Has been approved by [CONTACT_1383], including, when required, information to be given to the patient  regarding the trial in which s/he is enrolled.  
a. The Informed Consent /Assent  Form includes the Basic Elements and any Additional 
Elements necessary.  
b. The patient  and a study center representative sign the Informed Consent /Assent  Form and 
the patient  is given a copy.  
C. Storage and Dispensing of Study Supplies 
The Investigator (or pharmacist or pharmacy technician) must demonstrate to the Monitor that: 
1. Adequate and accurate written records show receipt and disposition of all study supplies, 
including dates, serial or lot numbers, quantities received, and each quantity dispensed, administered, or used, with identification of each patient . 
2. Purpose and reasons are given in written records for study material disposal, e.g., the amount contaminated, broken, or lost, and the quantity returned to the Sponsor. 
D. Case Report  Forms  
The Investigator must assure the Monitor that: 
1. Case report forms, when complete, accurately reflect the medical records on each patient . 
2. Case report forms and medical records will be accessible to the Monitor or FDA and oth er 
regulatory inspectors during site visits.  
E. Files and Records  
The Investigator must assure the quality, integrity, and content of his or her files that will be 
inspected by [CONTACT_794181]. The files must contain, at a minimum: 
1. Correspondence between the EC and the Investigator. 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 95 of 100  2. The following documents: 
a. EC-approved protocols. 
b. EC-approved protocol amendments. 
c. EC-approved Informed Consent /Assent  Form and information supplied to the patient . 
d. EC charter, membership, and qualifications. 
3. Clinical supplies:  
a. Record of receipt, date and quantity, and batch or lot number. 
b. Disposition dates and quantity administered to each patient . 
c. Inventory records. 
Clinical trial related documents will be archived for the longe st of: 
1. 10 years according to national Swedish and EU regulations (LVFS 2003:3), or 
2. For 2 years following the date a full marketing application is approved, or 
3. For 2 years after the FDA is notified that the IND is discontinued if th ere is no marketing 
application . 
12.2. Informed Consent/As sent Form  
In seeking Informed Consent /Assent , the following information shall be provided to each 
patient /legal guardian, where relevant : 
A statement that the study involves research, an explanation of the purposes of the research and 
the expected duration  of the patient 's participation, a description of the procedures to be 
followed, and identification of any procedures which are experimental. 
A description of any reasonably foreseeable risks or discomforts to the patient . 
A description of any benefits to the patient  or to others that may reasonably be expected from the 
research.  
A disclosure of appropriate alternative procedures or courses of treatment, if any, that might be 
advantageous to the patient. 
A statement describing the extent, if any, to which confidentiality of records identifying the 
patient  will be maintained and that notes the possibility that the Food and Drug Administration 
or other regulatory agency may inspect the records. 
For research involving more than minimal risk, an explanation as to whether any compensation 
and as to whether any medical treatments are available if injury occurs and, if so, what they consist of, or where further information may be obtained. 
An explanation of who to contact [CONTACT_794182] ' rights, and who to contact [CONTACT_44751] a research related injury to the 
patient . 
A statement that participation is voluntary, that refusal to participate will involve no penalty or loss of benefits to which the patient  is otherwise entitled, and that the patient  may discontinue 
participation at any time without penalty or loss of benefits to which the patient  is otherwise 
entitled.  
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 96 of 100  12.2.1. ADDITIONAL ELEMENTS OF INFORMED CONSENT  
1. A statement that the particular treatment or proce dure may involve risks to the patient  (or to 
the embryo or fetus if the patient  is or may become pregnant) which are currently 
unforeseeable.  
2. Anticipated circumstances under which the patient ’s participation may be terminated by [CONTACT_143507]’s consent.  
3. Any additional costs to the patient  that may result from participation in the research.  
4. The consequences of a patient ’s decision to withdraw from the research and procedures for 
orderly termination of participation by [CONTACT_102] . 
5. A statement that significant new findings developed during the course of the research which 
may relate to the patient ’s willingness to continue participation will be provided to the 
patient . 
6. The approximate number of patients  involved in the study. 
12.3. Benefit -Risk Assessment  
12.3.1. Nonclinical Evaluation  
Single  dose and repeat dose toxicology, safety pharmacology, and genotoxicity studies have been 
conducted with avacopan. General toxicity  studies of up to 26-week duration in rats and 44- week 
duration in cynomolgus monkeys have been conducted at avacopan  doses up to 200 and 
45 mg/kg/day, respectively, significantly higher than the highest human daily dose of 30 mg 
twice daily (BID) being tested in patients with C3G and other indications. 
Based on in vivo safety pharmacology studies, which included neuropharmacology, pulmonary, 
and renal safety studies in rats, and a cardiovascular safety study in conscious telemetered 
cynomolgus monkeys, there was no evidence of toxicity of avacopan . No evidence of 
electrocardiog raphic alterations was seen in the monkey 4-week, 20-week, or 44-week studies or 
in in vitro cardiovascular safety studies (IC 50 values for hERG inhibition was determined to be 
>2.3 µM for avacopan  and >3.0 µM for its metabolite avacopan -M1, the limit of s olubility for 
both compounds). A safety margin for avacopan  and its metabolite CCX168 -M1 of at least 
3,500-fold relative to expected steady state human unbound maximum plasma is  projected.  
Protein binding, red blood cell partitioning, hepatocyte metabolism, cytochrome P450 inhibition 
and induction, Caco-2 permeability and genotoxicity studies, including in vitro bacterial mutagenicity (Ames test) and in vitro mammalian cell mutagenicity (mouse lymphoma) studies, 
in vivo bone marrow rat micronucleus and in s ilico mutagenicity evaluation of starting materials, 
intermediates and chemical impurities utilized and formed during the synthesis of avacopan  were 
also conducted; none of these studies identif ied any safety concerns or significant potential for 
drug- drug interactions. In an acute toxicology study, single doses of avacopan  up to 100 mg/kg 
in rats produced no remarkable effects. No effects on IgG and IgM antibody production in rats or 
monkeys were noted following immunization with keyhole limpet hemocyanin antigen. 
Immunophenotypic analyses performed in the 44-week monkey study did not reveal any 
avacopan -related effects. No phototoxicity potential was observed for avacopan in the in vitro 
3T3 assay. 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095172] doses tested (200 mg/kg/day in rats and 45 mg/kg/day in 
cynomolgus monkeys). These doses provide an exposure margin of ~19-fold and ~6-fold, respectively, compared to the avacopan 30 mg twice daily therapeutic dose in humans. There 
were no significant toxicological findings of concern in these chronic studies or the preceding 
sub-chronic studies. Metabolite CCX168-M1 (which has been identified in humans) was present in samples collected in the rat 13 - and 26-week and the monkey 20- and 44- week studies at 
relatively high levels indicating that this metabolite has been qualified.  
No avacopan -related effects were observed upon pregnancy or embryo-fetal development in 
studies at doses up to 1000 mg/kg and 200 mg/kg in hamsters and rabbits, respectively. No 
evidence of histopathological alterations to the male or female reproductive system was seen in 
rats or monkeys in toxicology studies. 
In summary, no safety findings in toxicology studies in rats, cynomolgus monkeys, rabbits and 
hamsters have been observed that would preclude dosing to humans at the [ADDRESS_1095173] previously been c ompleted . A 
Phase 3 study in patients with AAV previously completed enrollment but follow up is ongoing 
and the study remain s blinded. A total of 182 healthy volunteers participated in the five Phase 1 
studies; 153 of these patients received avacopan at doses ranging from 1 mg up to 100 mg 
(CL001_168, CL004_168, CL007_168, CL008_168, and Japanese Phase 1 study CCX1101). 
Avacopan was generally well tolerated in these studies.  
The most frequently reported adverse events in patients  receiving avacopan  in Phase 1 clinical 
studies were headache ( 14.6% vs. 14.3% for placebo), diarrhea (6.7% vs. 7.1% for placebo), 
dizziness ( 4.5% vs. 0% for placebo), upper respi[INVESTIGATOR_1092] (4.5% vs. 0% for placebo), 
nausea (3.4% vs. 0% for placebo), oropharyngeal pain (3.4% vs. 7.1% for placebo), and 
decreased WBC count (3.4% vs. 0% for placebo). All other adverse events occurred at an 
incidence less than 3%.  
In addition, t wo Phase 2 clinical trials (CL002_168 and CL003_168) have been conducted in 
109 patients with AAV; [ADDRESS_1095174] common serious adverse event. The incidence of serious infections was similar in 
patients  receiving avacopan  compared to the control group. Vasculitis or renal vasculitis 
(worsening) was also reported at a similar incidence in the two groups.  
The most commonly reported treatment- emergent adverse events in patients  with AAV receiving 
avacopan  in studies CL002_168 and CL003_168 combined were hypertension (17.8% vs. 16.7% 
in the control group), nausea (17.8% vs. 19.4% in the control group), vomiting (13.7% vs. 0.0% 
in the control group), headache (11.0% vs. 11.1% in the control group), nasopharyngitis (11.0% 
vs. 8.3% in the control group), peripheral edema (9.6% vs. 11.1% in the control group), 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc. CONFIDENTIAL Page 98 of 100  arthralgia (8.2% vs. 2.8% in the control group), and diarrhea (8.2% vs. 2.8% in the control 
group). Grade [ADDRESS_1095175] 2 weeks of treatment, and was not progressive with 
continued treatment. 
Avacopan did not show evidence of pro-arrhyt hmic potential in an intensive ECG study 
(CL007_168). Caution should be exercised when avacopan is gi ven with potent CYP3A4 inhibitors such as 
itraconazole, since the avacopan plasma exposure may increase approximately two-fold. 
Avacopan has shown evidence of efficacy in Phase 2 study CL002_168 based on BVAS, quality 
of life measurements, renal response, urinary al buminuria, and urinary MC P-1:creatinine results. 
This efficacy was demonstrated across a num ber of relevant immunol ogical and clinical 
subgroups, i.e., patients with MPO ANCA-pos itive disease vs. PR3 ANCA-positive disease, 
newly diagnosed vs. relapsing patients, and in patients on cyclophosphamide vs. those on 
rituximab. Avacopan was able to sa fely replace the use of oral prednisone with the same or 
greater efficacy based on results from this study. 
It is of note that avacopan as a selective C5aR bl ocker does not appear to affect the formation of 
C5b and the membrane attack complex (MAC) or terminal complement complex (TCC) which is 
needed to protect against Neisseria  infections. Nevertheless, al l local and national vaccination 
protocols should be followed and  investigators should be vigilant in reporting all infections 
occurring during clinical trials and should atte mpt to identify the organisms involved in all 
infections.  
In an ongoing Phase 3 study of avacopan and background therapy of cyclophosphamide followed by [CONTACT_596806], or in combination with rituximab in patients with AAV (ADVOCATE, CL010_168), review of safety data by [CONTACT_794183] (DMC) for that study 
have commented on a potential risk of  and , and a potential risk of 
 after the  unblinded revi ew of safety data fr om enrolled patients. 
The Reference Safety Informa on section of the Investigator’s Brochure has been updated to 
include the potential risk of ,  and , and to state that general 
gastrointestinal adverse events (e g. nausea, diarrhea) as previousl observed in Phase [ADDRESS_1095176] been modified. These changes to the protocol were 
based on observations of  in th is blinded study in a patient 
with C3 glomerulopathy (CL011_168) and  in the ongoing and blinded Phase 3 
study of avacopan in patients with AAV (AD VOCATE  CL010_168). In all reported cases, 
patients were receiving mu ltiple immunosuppressants (e.g., cyclophosphamide, rituximab, 
mycophenolate mofetil, others) in addition to st udy medication. Therefore a causal relationship 
with study medication is not clear . 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.[ADDRESS_1095177] been included in clinical trials. There are no data currently available on the 
efficacy and safety of avacopan  in patients  younger than 18 years of age. However, avacopan  has 
been well tolerated at supra- therapeutic doses in young animals (rats and cynomolgus monkeys) 
in long term toxicology studies, and at doses up to [ADDRESS_1095178], e.g., formation of the terminal complement complex, C5b-9, C3a, C3b, or other parts of the immune system. It is not known at this time whether the efficacy and safety 
profile of avacopan  would be different in children compared to adults. However, it is anticipated 
that the mechanism of action of avacopan  would also apply to C3G in children. There is also no 
evidence from the animal toxicology studies in young gro wing animals that avacopan  affects 
growth and organ maturation. 
Avacopan  is orally administered, which makes it convenient for use in children. 
Avacopan  has shown evidence of efficacy in adults in Phase 2 studies in adults with AAV 
(CL002_168 and CL003_168) based on the BVAS , quality of life, and other markers such as 
albuminuria. 
The PK profile of avacopan  in children is not known. However, since avacopan  is cleared from 
the body primarily through hepatic metabolism mediated by [CONTACT_097]3A4, which is known to m ature 
in children well before the age of 12 ( Johnson et al., 2006), it can be scientifically justified to 
adjust the avacopan  dose for 12 to 17 year old children based on body weight. This methodology 
is proposed in this clinical trial. In a recent stud y of 126 unique products with pediatric studies 
by [CONTACT_794184] ( Momper et al ., 2013), allometric scaling using body weight was found to 
predict adolescent drug clearance well, with an overall mean absolute percentage error of 17.0%. 
By [CONTACT_762580], a 40 kg adolescent would need a 2/3 dose relative to a 70 kg adult to 
produce similar drug exposure. In this study (CL011_168), a conservative approach will be  
followed with an adolescent <40 kg by [CONTACT_64262]  a dose that is 1/3 of the adult dose (i.e., 
10 mg instead of 30 mg avacopan  twice daily ); the dose may be  adjusted based on the Day 1 
avacopan  plasma concentrations. Linear pharmacokinetics is assumed for this approach based on 
the approximate dose linearity in AUC observed between 10 mg and 30 m g in adult AAV 
patients  in study CL003_168 (153 ± 86.7 and 525 ± 276 ng•hr/mL for 10 mg and 30 mg 
avacopan, respectively).  
The level of discomfort and the risk threshold for adolescent participation in this study have been carefully considered, and measur es taken to monitor patients  closely during the study: 
CCX168 (avacopan)  Protocol CL011_168 
  Amendment 4.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 100 of 100  • Based on all available data, there is no evidence of a negative effect of avacopan  on growth 
and maturation of all relevant organ systems. 
• All patients  will be monitored closely over the course of the study by [CONTACT_794185], study monitors, as well as an external data monitoring comm ittee for any 
untoward effects.  
• The protocol provides stoppi[INVESTIGATOR_794122], such as hepati c 
enzyme elevations and WBC, neutrophil, and lymphocyte count decreases ( Section  4.4).  
• Patients  will be seen frequently over the course of the study, with a particularly high 
frequency in the first 4 weeks of treatment.  
• Adolescents will be kept for at least [ADDRESS_1095179] the dose of avacopan  if the plasma levels are too high or low 
(Section  3.3). 
In summary, there are a number of potential benefits of testing avacopan in adolescent patients with C3G in this study. For example, there are no currently approved medications for C3G in 
juveniles and it has been demonstrated that complement biology is involved in C3G. Further, as avacopan is an orally administered selective inhibitor of C5aR it carries potential safety and 
efficacy advantages of avacopan compared to other non-oral and/or non-approved therapi[INVESTIGATOR_794123]. Given the favorable safety profile that has been demonstrated with avacopan to date in conjunction with a prudent dose 
adjustment for adolescents based on plasma drug exposure these benefits outweigh the potential 
risk and would justify the testing in adolescent patients. 
12.3.4. Summary Benefit -Risk Statement  
Based on the nonclinical and clinical study results, the potential benefits of testing avacopan  in 
patients  with C3G outweigh the potential risks. 
Patients  participating in clinical trials must be closely monitored for any adverse events, and 
laboratory, physical examination, or vital signs abnormalities. WBC and differential  counts, and 
liver enzyme values  must be monitored over the course of the studies. 
As with all inve stigational compounds, the potential exists for unanticipated serious or life-
threatening toxicities or adverse events not predicted by [CONTACT_794186]. Investigators should exercise vigilance in the monitoring of patients  involved 
in this clinical trial with avacopan . 